TABLE OF CONTENTS

Welcome to Vancouver 3
Objectives 3
Bienvenue 4
Central Planning Committee (CPC) 5
Comité de planification 5
Scientific Planning Committee (SPC) 5
Comité scientifique 5
Collaborating Societies 5
AMMI Canada Council 6
CACMID Board 6
Are You a Member? 6
Abstract Review Committee 6
Educational Grants 7
Accreditation 7
General Information 8
Exhibit Hours 8
Vancouver, BC 9
CCM Workshop 10
Trainees’ Day 10
Association, Committee & Other Group Meetings 11
Integrated Symposia 11
Workshops 11
Merit and Association Awards Presentations 12
Poster and Research Awards Presentations 14
The AMMI Canada – CACMID Special Lecture 15
Closing Dinner 16
The Incubator 16
Program — Wednesday March 30 17
Thursday March 31 19
Friday April 1 22
Saturday April 2 28
Save The Date 31
Poster Presentations 32
Student Posters 37
Incubator Posters 40
Author Index 42
Conflict of Interest 46
Speaker Biographies 49
Exhibitor Overview 55
Exhibitor Directory 56
Floor Plans 62
Sponsors 64

WELCOME RECEPTION AND STAND UP DINNER

Date: Thursday March 31
Time: 1830 - 2030
Location: Exhibit Hall
Room: Grand Ballroom & Foyer

YOU ARE INVITED TO ATTEND THE 2016 ANNUAL CONFERENCE WELCOME RECEPTION AND DINNER

Whether you would like to share your experiences of the conference so far, discuss the day’s biggest debates or simply enjoy a drink and dinner, the welcome reception and dinner is the perfect place to make new acquaintances and catch up with old friends.

Join the conference planning committee, speakers, sponsors, exhibitors, and fellow delegates in a relaxed and informal atmosphere, while enjoying culinary delights in a stand up style dinner.
The AMMI Canada - CACMID Annual Conference provides an interactive venue where experts in the fields of diagnostic microbiology, antimicrobial stewardship, infectious diseases, infection prevention and control, and public health meet. The conference attracts attendees from across Canada and internationally. As in previous years, the 2016 conference will provide updates on a variety of topics to a diverse audience of clinicians, microbiologists, laboratory technologists, public health professionals, infection prevention and control practitioners, students and residents.

In addition to the pre-meeting workshops, the program will offer plenary sessions, state of the art clinical lectures, a special lecture, integrated symposia, short oral presentations, poster presentations, workshops and interactive clinical vignettes. The Innovation Academy has undergone some changes to make it even more engaging. At the 2016 meeting, we are pleased to introduce “The Incubator” - a forum where novel approaches to common challenges will be showcased. The 2016 meeting will be a chance for attendees to showcase their research as well as get up to speed with the latest in the areas of microbiology, adult and paediatric infectious diseases and related subjects. Dynamic expert speakers will be invited from across Canada and internationally to ensure another exciting meeting.

In addition to the scientific component, the meeting will provide ample opportunity for attendees to network, exchange ideas, and reconnect with colleagues.

The 2016 meeting will address topics including:

• Global Health
• Non HIV Immunodeficiency
• What’s Hot in Adult and Paediatric Infectious Diseases and Diagnostic Microbiology
• Tuberculosis Update
• Debate on Whether Healthcare Workers Should be Going Bare Below the Elbows

And a whole lot more!
BIENVENUE

Au nom de l’Association pour la microbiologie médicale et l’inféctiologie Canada et de l’Association canadienne de microbiologie clinique et des maladies infectieuses, nous vous souhaitons la bienvenue à Vancouver, C.-B., pour notre 11e conférence annuelle conjointe sur la prévention, le diagnostic et le traitement des maladies infectieuses. Cette année, nous nous déplaçons sur la côte opposée pour vous offrir, nous l’espérons, une occasion de partager des projets, d’acquérir de nouvelles connaissances et de forger de nouvelles collaborations avec des collègues de partout au pays.

Les comités de planification générale et scientifique ont consacré d’innombrables heures à la mise au point d’un programme exceptionnel à l’intention des participants. Comme prévu, il y aura une variété de présentations orales et d’affiches sur la recherche menée par nos étudiants, résidents, fellows et collègues. Des prix seront d’ailleurs remis pour les meilleurs résumés présentés dans le cadre de la conférence. Cette année marque aussi l’introduction d’un atelier sur la gestion des antibiotiques dans l’ensemble de la chaîne alimentaire humaine. La Journée des stagiaires offrira pour sa part aux résidents et au personnel junior un après-midi rempli de perspicacité et d’information. De plus, nous espérons que vous pourrez participer à la deuxième course amicale annuelle de la Fondation canadienne pour les maladies infectieuses, samedi, matin.

Notre conférence annuelle est rendue possible grâce à la contribution continue de nos commanditaires. Nous tenons à les remercier de leur généreux soutien. Assurez-vous de visiter la Salle des exposants pour voir ce que les commanditaires de notre industrie ont à offrir pour nous aider à dispenser des soins aux patients atteints d’infections. Ce lieu offre aux participants la possibilité unique de se retrouver dans un seul endroit pour mettre en contraste et comparer les produits et services offerts sur le marché.

Comme par les années passées, il y aura une réception et un souper de bienvenue jeudi soir. C’est là une excellente occasion de renouer avec vos amis et de rencontrer des collègues. Et, encore plus important, vous pourrez y rencontrer de nouveaux collègues et de possibles collaborateurs pour de futurs projets. Le souper de fermeture aura lieu à l’hôtel et prendra la forme d’un événement de camions de cuisine de rue. Vous aurez alors l’occasion de vous mélanger à vos collègues tout en essayant une variété de saveurs dans le cadre d’une expérience culinaire. Si vous souhaitez y assister, assurez-vous d’acheter vos billets le plus tôt possible.

Notre conférence annuelle est le fruit du travail acharné et de l’engagement de nombreuses personnes qui souhaitent offrir aux participants une rencontre de haute qualité. Ces personnes comprennent les organisateurs bénévoles, les personnes qui ont présenté des résumés et qui font des présentations et nos délégués. Nous souhaitons tous vous remercier pour vos efforts et votre participation; notre réussite se poursuit grâce à votre contribution. Certaines réunions des plus mémorables ont eu lieu dans la ville de Vancouver et dans le cadre de la conférence.

Nous sommes certains que la conférence de cette année continuera à tirer profit notre réussite commune. Nous avons hâte de vivre une autre excellente expérience éducative et d’avoir l’occasion de rencontrer collègues et amis.

Daniel B. Gregson
Le président de l’AMMI Canada

March 30, 2016
Dear convention delegates,

On behalf of Tourism Vancouver and our community, we would like to extend a warm West Coast welcome to all attendees of the AMMI Canada – CACMID Annual Conference 2016. Vancouver is extremely proud and excited to be the host city for this prestigious conference.

We hope that during your free time from conference sessions that you’ll be able to take a moment or two to enjoy what Vancouver has to offer. We are surrounded by some of the most stunning natural beauty in the world: Mountains, Ocean, Rainforest and Parks. This is a city like no other! With endless options for cuisine, activities, sights and attractions, Vancouver is a city to explore and you won’t want to miss a thing. It doesn’t matter what time of day or what time of season you visit.

Sincerely,

Ty Speer
President & CEO
CENTRAL PLANNING COMMITTEE (CPC)
COMITÉ DE PLANIFICATION

AMMI Canada
- Daniel B. Gregson, President
- Central Planning Committee Co-Chair
- Caroline Quach, President Elect
- A. Mark Joffe, Past President
- Isabelle Chiu, Scientific Planning Committee Co-Chair
- Shariq Haider, Sponsorship Committee Co-Chair
- Mel Krajden, Co-Treasurer

CACMID
- Jeff Fuller, President
- Central Planning Committee Co-Chair
- Jessica Minion, Vice-President
- Scientific Planning Committee Co-Chair
- Heather Adam, Past President
- Carmen Charlton, Sponsorship Committee Co-Chair
- Matthew W. Gilmour, Co-Treasurer
- Paul N. Levett, Meeting Secretary, Abstract Chair

COLLABORATING SOCIETIES

AMMI Canada
- Daniel B. Gregson, President
- Central Planning Committee Co-Chair
- Caroline Quach, President Elect
- A. Mark Joffe, Past President
- Isabelle Chiu, Scientific Planning Committee Co-Chair
- Shariq Haider, Sponsorship Committee Co-Chair
- Mel Krajden, Co-Treasurer

CACMID
- Jeff Fuller, President
- Central Planning Committee Co-Chair
- Jessica Minion, Vice-President
- Scientific Planning Committee Co-Chair
- Heather Adam, Past President
- Carmen Charlton, Sponsorship Committee Co-Chair
- Matthew W. Gilmour, Co-Treasurer
- Paul N. Levett, Meeting Secretary, Abstract Chair

SCIENTIFIC PLANNING COMMITTEE (SPC)
COMITÉ SCIENTIFIQUE

AMMI Canada
- Isabelle Chiu, Co-Chair
- Edith Blondel-Hill
- Peter Daley
- Gerald Evans
- Sarah Forgie
- Todd Hatchette
- Shazia Masud
- Matthew Oughton
- David Patrick
- Susan Poutanen
- Duncan Webster
- Titus Wong

CACMID
- Jessica Minion, Co-Chair
- Vanessa Allen
- Meghan Dey
- Gregory German
- Matthew W. Gilmour
- Paul N. Levett
- Doris Poole
- Christine Turenne
- Titus Wong

COLLABORATING SOCIETIES

- Canadian Society for Medical Laboratory Science (CSML)
- Société canadienne de science de laboratoire médical (SCSLM)
- Pan American Society for Clinical Virology (PACV)
- Canadian Association for HIV Research (CAHR)
- Canadian College of Microbiologists (CCM)
- Canadian Microbiological Society (CMS)
- Canadian Foundation for Infectious Diseases (CFID)
- STHORACIC SOCIETY CANADIENNE DE THORACOLOGIE
- Infectious Diseases Society of America (IDSA)
- Infection Prevention and Control Canada (IPAC)
- SHEA: The Society for Healthcare Epidemiology of America (SHEA)
**AMMI Canada Council**

Daniel B. Gregson (Calgary, AB)  
**President**

Caroline Quach (Montréal, QC)  
**President-Elect**

A. Mark Joffe (Edmonton, AB)  
**Past President**

Mel Krajden (Vancouver, BC)  
**Treasurer**

Deborah Yamamura (Hamilton, ON)  
**Secretary**

Tony Mazzulli (Toronto, ON)  
**Medical Microbiology Section Chair**

Michael Libman (Montréal, QC)  
**Infectious Disease Section Chair**

**Members of Council**

Steven J. Drews (Edmonton, AB)  
Christian Lavallée (Montréal, QC)  
Andrew Morris (Toronto, ON)  
Romina Reyes (Vancouver, BC)  
Daniel Smyth (Moncton, NB)  
Mark Tyndall (Vancouver, BC)

**Ex-Officio Members**

Shazia Masud (Vancouver, BC)  
**Associate Committee Chair**

Don Sheppard (Montréal, QC)  
**Grants and Awards Committee Chair**

Isabelle Chiu (Edmonton, AB)  
**Program Planning Committee Chair**

---

**CACMID Board**

Jeff Fuller (Edmonton, AB)  
**President**

Jessica Minion (Regina, SK)  
**Vice-President**

Heather Adam (Winnipeg, MB)  
**Past President**

Matthew W. Gilmour (Winnipeg, MB)  
**Secretary Treasurer**

Paul N. Levett (Regina, SK)  
**Meeting Secretary**

**Councilors**

Vanessa Allen (Toronto, ON)  
Carmen Charlton (Edmonton, AB)  
Meghan Dey (Ottawa, ON)  
Gregory German (Charlottetown, PE)  
Doris Poole (Charlottetown, PE)  
Christine Turenne (Regina, SK)  
Titus Wong (Vancouver, BC)

**Abstract Review Committee**

Paul N. Levett (Regina, SK)  
**Chair**

Heather Adam (Winnipeg, MB)  
Vanessa Allen (Toronto, ON)  
Andrée-Anne Boisvert (Montréal, QC)  
Julie Carson (Calgary, AB)  
Carmen Charlton (Edmonton, AB)  
Vikas Chauhey (Kelowna, BC)  
Jasmine Chong (Montréal, QC)  
Peter Daley (St John's, NL)  
Meghan Dey (Ottawa, ON)  
Margaret Doll (Montréal, QC)  
Steven J. Drews (Edmonton, AB)  
Margaret Fearon (Toronto, ON)  
David Fisman (Toronto, ON)  
Jeff Fuller (Emonton, AB)  
Matthew W. Gilmour (Winnipeg, MB)  
Jennifer Grant (Vancouver, BC)  
Todd Hatchette (Halifax, NS)  
Linda Hoang (Vancouver, BC)  
Charles Hui (Montréal, QC)  
Philippe Lagacé-Wiens (Winnipeg, MB)  
Christian Lavallée (Montréal, QC)  
Lynne (Ying) Li (Montréal, QC)  
Tony Mazzulli (Toronto, ON)  
Joanna Merckx (Montréal, QC)  
Jessica Minion (Regina, SK)  
Andrew Morris (Toronto, ON)  
Shauna O’Donnell (Montréal, QC)  
Romina Reyes (Burnaby, BC)  
Daniel Smyth (Moncton, NB)  
Yoko Schrieber (Ottawa, ON)  
Anu Wadhwa (Toronto, ON)  
Bing Wang (Kelowna, BC)  
Deborah Yamamura (Hamilton, ON)  

**ARE YOU A MEMBER?**

TO JOIN AMMI CANADA  
PLEASE CONTACT:

Deborah Yamamura  
Secretary, AMMI Canada  
c/o AMMI Canada Secretariat  
192 Bank Street, Ottawa ON K2P 1W8  
Toll-free: 1(866)467-1215  
Tel.: (613)260-3233 ext. 103  
Fax: (613)260-3235  
info@ammi.ca

For more information on AMMI Canada visit: [www.ammi.ca](http://www.ammi.ca)

**TO JOIN CACMID  
PLEASE CONTACT:**

Matthew W. Gilmour  
Secretary Treasurer, CACMID  
c/o National Microbiology Laboratory  
1015 Arlington Street, Winnipeg MB R3E 3R2  
Tel.: (204)789-2070  
Fax: (204)789-2097  
matthew.gilmour@cacmid.ca

For more information on CACMID visit: [www.cacmid.ca](http://www.cacmid.ca)
EDUCATIONAL GRANTS

AMMI CANADA
For ASSOCIATE Members ONLY

Eligibility
The applicant must be an AMMI Canada associate member in good standing. To be eligible the applicant must register for the AMMI Canada – CACMID Annual Conference 2016 and pay the full student conference registration fee. One-day registrants are not eligible.

Application
An education grant application form will be available at the registration desk during the conference or can be downloaded from the AMMI Canada website – annual conference section (www.ammi.ca). This form can be completed during the conference and handed in at the registration desk, or be completed after the conference and sent to info@ammi.ca or faxed to 613-260-3235.

- $250 for Associates attending from British Columbia and Washington State
- $500 for Associates attending from Alberta and Saskatchewan
- $750 for Associates attending from Manitoba, Ontario, Quebec, Nova Scotia, PEI, Newfoundland and Labrador, New Brunswick, NWT, Yukon, Nunavut and International

N.B: Associate members attending from the city of Vancouver or the Lower Mainland are ineligible for grants.

CACMID
For Technical Staff and Clinical Microbiology Fellows

Eligibility
Applicants must be microbiology laboratory technologists or technicians, or clinical microbiology fellows registered in a Canadian training program, and all must be active members of CACMID. Each applicant is eligible for only one grant.

Application
An education grant application form will be available at the registration desk during the conference or can be downloaded from the Vancouver 2016 web page on the CACMID website (www.cacmid.ca). This form can be completed during the conference and handed in at the registration desk, or be completed after the conference and mailed to the CACMID Secretary Treasurer (www.cacmid.ca/contact-us/).

- $250 for Technical staff attending from British Columbia and Washington State
- $500 for Technical staff attending from Alberta and Saskatchewan
- $750 for Technical staff attending from Manitoba, Ontario and Quebec
- $1,000 for Technical staff attending from Nova Scotia, PEI, Newfoundland and Labrador, New Brunswick, NWT, Yukon, Nunavut, and International

N.B: Clinical microbiology fellows (all must be Canadian residents) may submit itemized expenses with receipts to a maximum of $1,000.

ACCREDITATION

Maximum credits possible: 29.75 hours
A. For specialists certified with the Royal College of Physicians and Surgeons of Canada (RCPSC): This educational event is approved as an Accredited Learning Activity, (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

MAINPORT - Transfer of Hours
The Royal College of Physicians and Surgeons of Canada allows for attendance data of Section 1, Group Learning activities, to be transferred directly into participants’ MAINPORT Transfer of Hours.

Please indicate your RCPSC ID Number when registering.

B. For specialists certified with the American Medical Association (AMA):
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Please indicate your AMA ID Number when registering.

C. For Fellows and Specialists of the Canadian College of Microbiologists and Diplomats of the American Board of Medical Microbiology: The Canadian College of Microbiologists (CCM) accredits the AMMI Canada – CACMID Annual Conference for CE credits. Certificates of continuing education activity are available through the CCM for documentation of attendance and maintenance of certification. A one-hour educational activity is equivalent to one CE credit. Program evaluation forms and record of CE activity can be obtained and returned, once completed, at the conference registration desk or by email to the FCCM co-chair (hadam@dsmanitoba.ca) following the conference.
GENERAL INFORMATION

Conference Evaluations
The conference uses an online evaluation system.
Conference Attendees: Please click on the links below to access the 2016 conference evaluation and the 2016 program evaluations by day:

- Wednesday, March 30, 2016
- Wednesday, March 30, 2016 - Trainees' Day
- Thursday, March 31, 2016
- Friday, April 1, 2016
- Saturday, April 2, 2016
- 2016 Conference Evaluation

All evaluations will be made available online on the event's mobile app, the AMMI Canada (www.ammi.ca) or CACMID (www.cacmid.ca) websites. They are also available as a supplement in JAMMI, the official journal of the Association of Medical Microbiology and Infectious Disease Canada (www.pulsus.com).

Abstracts
There will be NO printed version of the abstracts. All abstracts can be found online in the conference sections of the AMMI Canada (www.ammi.ca) or CACMID (www.cacmid.ca) websites. They are also available as a supplement in JAMMI, the official journal of the Association of Medical Microbiology and Infectious Disease Canada (www.pulsus.com).

Disclaimer
The Central Planning and Scientific Planning Committees will make every effort to present the program as published and printed. However, the Central Planning and Scientific Planning Committees, AMMI Canada, CACMID or their agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the annual conference, for any cause beyond their reasonable control. The above-mentioned are not liable for any loss or inconvenience caused as a result of such alteration. In the event of cancellation of the annual conference, all pre-paid fees will be refunded, however the Central Planning and Scientific Planning Committees, AMMI Canada, CACMID or their agents are not liable for any loss or inconvenience caused as a result of such cancellation, and delegates are therefore advised to take out their own travel insurance and extend their policy for personal possessions as the annual conference does not cover individuals against cancellations of bookings or theft or damage of belongings.

Notice
Satellite symposia, receptions, and meals provided by Industry Representatives surrounding or during the conference that are not in the official program are not sanctioned or approved by the annual conference, AMMI Canada, or CACMID. Conference attendees should be cognizant of perceived or real conflicts of interests, and their ethical obligations as health care workers when making decisions on participating in such events.

Handouts
Handouts will NOT be available at the conference. Following conference, presentations approved by speakers for posting will be uploaded to both the AMMI Canada (www.ammi.ca) and CACMID (www.cacmid.ca) websites.

Lost and Found
Please go to the Registration Desk for lost or found items.

Messages and Conference Updates
A message board will be available by the Registration Desk for posting messages for other delegates.

Registration Desk
Room: Junior Ballroom Foyer

EXHIBIT HOURS
Room: Grand Ballroom & Foyer

Thursday March 31
1215 – 1400
1545 – 1700
1830 – 2030 Welcome Reception and Stand Up Dinner

Friday April 1
1215 – 1400

The AMMI Canada – CACMID Annual Conference has received tremendous support from our exhibiting companies. We encourage you to visit the exhibit hall to discover the leading edge of business and research in the fields of medical microbiology, infectious diseases, medicine, pharmaceuticals and diagnostics.

Lunch will be served in the exhibit hall on Thursday and Friday.

Don’t miss the opportunity to network with colleagues and friends during the Thursday evening welcome reception and stand up dinner!
Tourism Whistler, invites you to visit Whistler, before or after the annual conference.

Whistler offers endless opportunities for all kinds of unique experiences and adventures. Play hard, rest easy, wine and dine, attend an event, explore the arts, shop non-stop, commune with nature, or find the ultimate adrenaline rush. The big question is where do you want to start?

Begin the Journey.
We Are What We Eat: Our Shared Obligations to Promote Animal, Ecosystem and Public Health from Microbes to Muscles

Date: Wednesday March 30
Time: 0800 – 1300
Room: Junior Ballroom CD
Cost: $80 plus 5% tax

One Health - Sharing Our Obligations for Food Safety and Security in the 21st Century

date: Bonnie Buntain, Professor Emerita, Public Health and Food Safety, University of Calgary; Diplomate of the American College of Veterinary Preventive Medicine

canadian Aquaculture: Sustainable Fish Production or Microbe Factories?

Speaker: Kyle Garver, Head Virology Research Program, Aquatic Animal Health Section, Government of Canada

A Shared Crisis: The Impact of Avian Influenza (AI) Outbreaks on Agriculture, Public Health, Food Security and the Economy

Speaker: Victoria Bowes, Avian Pathologist, BC Ministry of Agriculture and Lands

The Sad Side of Happy Chickens: Salmonella enterica Enteritidis (SE) and ‘Backyard’ Poultry Production

Speaker: Clayton Botkin, Industry Specialist, Livestock Health Management and Regulatory Unit, BC Ministry of Agriculture and Lands

Meeting Our Shared Obligations: Tools to Get There and Added Value

Speaker: Bonnie Buntain, Professor Emerita, Public Health and Food Safety, University of Calgary; Diplomate of the American College of Veterinary Preventive Medicine

Our Shared Policy Obligations: The Mug’s Game of Governing Antimicrobial Use Without Measurable Objectives

Speaker: Brian Radke, Public Health Veterinarian, Livestock Health Management and Regulatory Unit, BC Ministry of Agriculture and Lands

Is Antibiotic-Free a Good Place to Be: Antibiotic Stewardship Strategies in the Poultry Industry and Their Impact on Poultry and Public Health

Speakers: Lindsay Kehler, Poultry Veterinarian, Canadian Poultry Consultants, Ltd.

Stewart Ritchie, Poultry Veterinarian, Canadian Poultry Consultants, Ltd.

Surviving and Thriving After Residency

Speaker: Melanie Murray (Vancouver, BC)

Beyond “Staff” aureus – Getting the Most out of Residency

Speakers: Philippe Martin (Sherbrooke, QC)

Zain Chagla (Hamilton, ON)

Trainees’ Day is an afternoon of interactive sessions for trainees in adult and paediatric infectious disease and clinical and medical microbiology, held at the AMMI Canada – CACMID Annual Conference 2016. Sessions provide a chance to hear from experts in the field about topics outside of the conventional medical curriculum, with a focus on professional development and employment options. It’s also a great opportunity to meet peers and future colleagues from around the country.

Attendance is free of charge for all trainees, but for planning purposes we ask that you please register only if you are able to attend, and to notify the conference secretariat should your plans change for food and beverage planning purposes.

Trainees’ Day Reception

Room: Junior Ballroom Foyer

Mingle with fellow trainees, speakers, and the executive boards of AMMI Canada and CACMID over light snacks and beverages on Wednesday, March 30, from 1700 - 1800, in the Junior Ballroom Foyer.
### ASSOCIATION, COMMITTEE & OTHER GROUP MEETINGS

#### Wednesday March 30

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800 – 1630</td>
<td>AMMI Canada Council Meeting</td>
<td>Parksville</td>
<td>Daniel B. Gregson</td>
</tr>
<tr>
<td>1400 – 1600</td>
<td>CCM Board Meeting</td>
<td>Beluga</td>
<td>Steven J. Drews</td>
</tr>
<tr>
<td>1800 – 2030</td>
<td>CACMID Board Meeting</td>
<td>Parksville</td>
<td>Jeff Fuller</td>
</tr>
<tr>
<td>1800 – 2100</td>
<td>CFID Board Meeting</td>
<td>Beluga</td>
<td>Susan Richardson</td>
</tr>
</tbody>
</table>

#### Thursday March 31

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 – 0845</td>
<td>AMMI Canada AGM and Sections Meetings</td>
<td>Junior Ballroom CD</td>
<td>Daniel B. Gregson</td>
</tr>
<tr>
<td>1215 – 1415</td>
<td>Royal College ID Specialty Committee Meeting</td>
<td>Parksville</td>
<td>Andrew Morris</td>
</tr>
<tr>
<td>1230 – 1400</td>
<td>CCM AGM</td>
<td>Junior Ballroom AB</td>
<td>Steven J. Drews</td>
</tr>
</tbody>
</table>

### Friday April 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 – 0830</td>
<td>AMMI Canada Education / Continuing Professional Development Committee Meeting</td>
<td>Parksville</td>
<td>Sarah Forgie</td>
</tr>
<tr>
<td>0700 – 0845</td>
<td>CACMID AGM</td>
<td>Junior Ballroom CD</td>
<td>Gerald Evans</td>
</tr>
<tr>
<td>1215 – 1415</td>
<td>Royal College MM Specialty Committee Meeting</td>
<td>Parksville</td>
<td>Tony Mazzulli</td>
</tr>
<tr>
<td>1230 – 1445</td>
<td>MALDI-TOF Users Group Meeting</td>
<td>Junior Ballroom AB</td>
<td>Kathryn Bernard and Philippe Legacé-Wiens</td>
</tr>
<tr>
<td>1230 – 1430</td>
<td>AMMI Canada Guidelines Committee Meeting</td>
<td>Parksville</td>
<td>Gerald Evans</td>
</tr>
</tbody>
</table>

### Saturday April 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>1230 – 1430</td>
<td>Choosing Wisely Canada Campaign Meeting</td>
<td>Junior Ballroom CD</td>
<td>Wayne Gold and Jerome Leis</td>
</tr>
<tr>
<td>1230 – 1430</td>
<td>JAMMI Editorial Board Meeting</td>
<td>Parksville</td>
<td>John Conly</td>
</tr>
</tbody>
</table>

### INTEGRATED SYMPOSIA

#### Wednesday March 30

- **C. difficile**: Both Sides of the Story
  - **Date**: Thursday March 31
  - **Time**: 1230 – 1430
  - **Room**: Junior Ballroom CD

- **STIs on the Fringe**: What we Know and Don’t Know about Trichomonas vaginalis and Mycoplasma genitalium in Canada
  - **Date**: Thursday March 31
  - **Time**: 0700 – 0830
  - **Room**: Junior Ballroom AB

#### Thursday March 31

- **Antimicrobial Susceptibility Challenges and Opportunities in the Treatment of Patients with Bloodstream Infections**
  - **Date**: Friday April 1
  - **Time**: 1730 – 1900
  - **Room**: Junior Ballroom AB

#### Friday April 1

- **Back to the Patient: Refocusing Antimicrobial Stewardship**
  - **Date**: Friday April 1
  - **Time**: 1230 – 1430
  - **Room**: Junior Ballroom CD

#### Saturday April 2

- **Debate: Single versus Combination Antibiotic Therapy for Serious Gram-Positive Infections**
  - **Date**: Saturday April 2
  - **Time**: 0700 – 0830
  - **Room**: Junior Ballroom AB
2015 AMMI Canada Lifetime Achievement Award
Dr. Mark Wainberg is the recipient of the AMMI Canada Lifetime Achievement Award, in recognition of his outstanding and distinguished career. His research and collaboration on AIDS and HIV are acknowledged as having saved millions of lives around the world. Dr. Wainberg played a lead role in the discovery and development of lamivudine (3TC), as an antiviral drug, now one of the most widely used drugs in the treatment of HIV. While President of the International AIDS Society, he brought unprecedented international attention to the lack of access to anti-HIV drugs in developing countries. Most recently, Dr. Wainberg has turned his attention to achieving a cure for HIV infection.

Presenting the award:
Daniel B. Gregson,
President AMMI Canada

2016 AMMI Canada – bioMérieux Post Residency Fellowship in Microbial Diagnostics
The AMMI Canada – bioMérieux Post Residency Fellowship in Microbial Diagnostics is a one year fellowship, presented to a research project aimed to advance or improve microbial diagnostics within the areas of antimicrobial susceptibility testing, microbial detection and identification or biomarkers.

Presenting the award:
Daniel B. Gregson,
President AMMI Canada
and
Xavier Nouvelot,
Head of Canada Subsidiary bioMérieux

2015 Royal College of Physicians and Surgeons of Canada Innovation Award
The AMMI Canada Education and Continuous Professional Development Committee received the 2015 Royal College Accredited CPD Provider Innovation Award for their CPD Educational Needs Assessment – “A Novel Approach to Determine Unperceived Educational Needs”.

Accepting the award: Dr Sarah Forgie, outgoing Chair of the AMMI Canada EdCPD Committee.

Presenting the award:
Jennifer Gordon,
Associate Director,
Continuing Professional Development,
Royal College of Physicians and Surgeons of Canada

Date: Thursday March 31
Time: 1700 – 1730
Room: Pavilion Ballroom

Masters of Ceremony:
Caroline Quach (Montréal, QC)
Jessica Minion (Regina, SK)

2015 AMMI Canada Distinguished Service Award
Dr. Fred Aoki is the recipient of the AMMI Canada Distinguished Service Award for his longstanding professional achievements and dedicated service to AMMI Canada. Since 1988, Dr Aoki has been a Professor in the Departments of Medicine, Medical Microbiology and Pharmacology and Therapeutics at the University of Manitoba. He has been associated with AMMI Canada and its predecessor, the Canadian Infectious Disease Society (CIDS) for 20 years, is active on the Guidelines Committee and served as a former Associate Editor of the Canadian Journal of Infectious Diseases.

Presenting the award:
Daniel B. Gregson,
President AMMI Canada
John G. FitzGerald – CACMID Outstanding Microbiologist Award
Dr. Greg Horsman is the recipient of the 2016 John G. FitzGerald – CACMID Award. Greg has been the medical director of the Saskatchewan provincial laboratory (now Saskatchewan Disease Control Laboratory) since 1987. Throughout his career Greg has played a major role in developing and supporting public health laboratory science in its broadest sense. From appearing before the Krever Commission (1986) and North Battleford Enquiry (2001), he became an advocate for partnerships between public health laboratories, working with colleagues to organize the Canadian Public Health Laboratory Network and served as the first provincial CPHLN Co-Chair in 2000. His research has been focused on a range of communicable diseases, with an emphasis on diagnosis of sexually transmitted infections, leading to over 60 publications. In 2012 he received the Deputy Minister’s Award for Excellence from Health Canada for work with the team that established HIV point-of-care testing in rural Saskatchewan.

Presenting the award:
Jeff Fuller,
President CACMID

Canadian College of Microbiologists (CCM) Distinguished Microbiologist Award
The Canadian College of Microbiologists (CCM) Distinguished Microbiologist Award is given to members of the Canadian College of Microbiologists in recognition of outstanding professional contributions to the field of microbiology in Canada in the areas of research, teaching and involvement in the Canadian College of Microbiologists. The recipient of the award this year is Kathryn Bernard, Head of the Special Bacteriology Unit, National Microbiology Laboratory.

Presenting the award:
Steven J. Drews,
President CCM

Canadian Foundation for Infectious Diseases (CFID) Dr. John M. Embil Mentorship Award in Infectious Diseases
Dr. Caroline Quach (McGill University) is the recipient of the 2016 award. This award celebrates the commitment of a member of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada to inspiring interest and excitement in the field of infectious diseases. The award recognizes clinical specialists in infectious diseases who have performed extraordinary service as role models and mentors to junior clinicians, faculty, fellows, and students involved in the field of infectious diseases. Her nominators and supporters unanimously note her unstinting devotion to her clinical and research trainees, her open door and her interest in furthering and supporting all aspects of their personal and professional lives. Dr. Quach serves as an important role model for those she mentors, modelling excellence in clinical infectious diseases, teaching and research, building collaborative and dynamic partnerships, and taking on important professional roles on the regional, national and international stages. Dr. Quach remains a loyal supporter, friend and touchstone to her many mentees during the course of their careers. We are fortunate to benefit from these admirable qualities as she takes on the role of AMMI Canada President.

Presenting the award:
Susan Richardson,
President CFID

Canadian Foundation for Infectious Diseases (CFID) Dr. Juan A. Embil Award for Excellence in Infectious Disease Research
Dr. Allison Mah (UBC) is the recipient of the 2016 award for her manuscript entitled “Systematic review of factors associated with antibiotic prescribing for respiratory tract infections”, supervised by Dr. David Patrick. This award is given to an infectious diseases trainee in recognition of research excellence in infectious diseases as demonstrated through a published or submitted manuscript.

Presenting the award:
Susan Richardson,
President CFID

Dr. Lindsay E. Nicolle Editorial Award
This award is given annually in honour of Dr. Lindsay E. Nicolle, the Founding Editor-in-Chief of The Canadian Journal of Infectious Diseases & Medical Microbiology. This award is given to an individual who has made a significant contribution to infectious diseases and medical microbiology as demonstrated by the impact of their original research published in The Canadian Journal of Infectious Diseases & Medical Microbiology.

Presenting the award:
Ann LeBlanc,
Vice-President Pulsus Group
POSTER AND RESEARCH AWARDS PRESENTATIONS

Date: Saturday April 2
Time: 1545 – 1615
Room: Pavilion Ballroom

Masters of Ceremony:
Caroline Quach (Montréal, QC)
Jessica Minion (Regina, SK)

Canadian Foundation for Infectious Diseases (CFID) Summer Student Research Award
The CFID Summer Student Research Awards were established to attract bright young minds with outstanding academic records to the field of infectious diseases, microbiology, and infection control; and to fulfill the CFID mission of supporting research in infectious diseases.
Kate Miller (Dalhousie University) for her project entitled "Understanding poor vaccine responses: transcriptomics of vaccine failure" under the supervision of Dr. Lisa Barrett.
Presenting the award: Susan Richardson, President CFID

AMMI Canada Medical Student Research Award
The goal of this award is to provide support for medical students who are interested in research in infectious diseases and microbiology who are supervised by an AMMI Canada member.
Charlie Tan (University of Toronto and McMaster University) for his project entitled "Variability in antibiotic use across Ontario acute care hospitals" under the supervision of Dr. Nick Daneman.
Jeremy Soo (University of Alberta) for his project entitled "Biomarkers of inflammation and endothelial activation in vertically HIV-1 infected children" under the supervision of Dr. Michael Hawkes.
Presenting the award: Susan Richardson, President CFID

Canadian Journal of Infectious Diseases and Medical Microbiology (CJIDMM) Trainee Review Article Award
Dr. Philip Lam is the recipient of the 2015 CJIDMM Trainee Review Article Award for his article, "Pasteurella multocida non-native joint infection after a dog lick: A case report describing a complicated two-stage revision and a comprehensive review of the literature".
Presenting the award: John Conly, Past Editor-in-Chief, CJIDMM Editor-in-Chief, JAMMI

AMMI Canada Trainee Research Award
This award is given annually to a trainee to promote scholarship and scientific excellence among trainees. It is awarded for excellence in a primary research article on a topic within the disciplines of infectious diseases or medical microbiology. The recipient of the 2015 AMMI Canada Trainee Research Award is Dr. Ilan Schwartz, for his manuscript entitled "Clinical characteristics, diagnosis, management and outcomes of disseminated emmonsiosis: a retrospective case series".
Presenting the award: Daniel B. Gregson, President AMMI Canada

AMMI Canada Young Investigator Award
Dr. Donald Vinh is the recipient of the 2015 AMMI Canada Young Investigator Award, in recognition of his contributions to research in the fields of Infectious Diseases and Medical Microbiology.
Presenting the award: Daniel B. Gregson, President AMMI Canada

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Student Oral Presentation Award
Presenting the award: Jeff Fuller, President CACMID

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Poster Award
Presenting the award: Jeff Fuller, President CACMID

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Technologist Poster Award
Presenting the award: Steven J. Drews, CCM President

Canadian College of Microbiologists (CCM) Poster Award
Presenting the award: Steven J. Drews, CCM President

Canadian College of Microbiologists (CCM) Dr. Kenneth Rozee Memorial Poster Award
Presenting the award: Steven J. Drews, CCM President

The following award consists of $500 and an engraved plaque:

Dr. Susan King Paediatric Abstract Award
This award is given annually to the best abstract by a trainee on a paediatric topic. It is presented in honour of Dr. Susan King. Funds for this award are generously provided by the PICNIC team and the Hospital for Sick Children (Division of Infectious Diseases).
Presenting the award: Joan Robinson, Chair PICNIC
Existing tests in microbiology fail to diagnose many life-threatening infections - encephalitis, meningitis, sepsis, and pneumonia - in a clinically relevant timeframe, resulting in excessive healthcare costs and increased morbidity and mortality. Metagenomic next-generation sequencing (mNGS) is an emerging genomics tool to comprehensively detect all pathogens -- viruses, bacteria, fungi, and parasites, in a single assay. At UCSF, we have proven the utility of this approach in multiple clinical scenarios, including its use to save the life of a 14 year-old boy with a critical case of undiagnosed neuroleptospirosis (Wilson, et al., 2015, New England Journal of Medicine). This technology has been enabled by the vast increases in sequencing capacity over the past several years and the availability of rapid computational pipelines such as SURPI (“Sequence-based Ultra-Rapid Pathogen Identification”) for analysis of NGS data. Critical to the utility of mNGS approach for infectious disease diagnosis will be clinical validation of the test in a CLIA-certified laboratory and eventual FDA regulatory approval. Key challenges that will thus need to be addressed include (1) generation of accurate reference materials and controls, (2) customization of research-based computational pipelines for clinical use, (3) development of user-friendly graphical interfaces for data analysis, (4) data storage and HIPAA compliance issues, (5) generation of interpretative clinical reports, and (6) integration of sequence data into the patient electronic medical record (EMR). As a “proof-of-principle” demonstration project, we will launch in March of 2016 a new multi-center, prospective study of mNGS for precision diagnosis of acute infectious diseases across 3 medical centers: University of California, San Francisco (UCSF), UCLA, and UC Davis. CLIA laboratory results will be used clinically to guide patient care and management. A dedicated precision medicine consult team will evaluate the impact of mNGS on health care costs, diagnostic yield, and patient outcomes. The eventual goal is to incorporate mNGS and other emerging technologies, such as nanopore sequencing and transcriptome profiling of human host gene expression, into a precision medicine framework for improved clinical diagnosis of infectious diseases.

Charles Chiu, M.D./Ph.D. is Associate Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. He is a board-certified consulting infectious diseases physician at UCSF, and his practice is in both infectious diseases and clinical microbiology. Dr. Chiu received an MD and PhD in biophysics from UCLA and subsequently completed an internal medicine residency, infectious diseases fellowship, and postdoctoral research at UCSF. He heads a translational research laboratory focused on clinical diagnostic next-generation sequencing assay development for infectious diseases and genomic analyses of emerging pathogens, including Borrelia burgdorferi, Ebola virus, and enterovirus D68. His work is supported by research grants from the NIH, Bay Area Lyme Disease Foundation, Global Lyme Alliance, USAID PREDICT program, UC Center for Accelerated Innovation, Sandler / Bowes Foundation, and the California Initiative to Advance Precision Medicine. Dr. Chiu has authored more than 50 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory board for Karius Dx and Rubicon Genomics.
THE INCUBATOR
(formerly The Innovation Academy)

Poster Presentations:
Date: Thursday March 31
Time: 1545 – 1700
Room: Grand Ballroom

Oral Pitch:
Date: Friday April 1
Time: 1445 – 1545
Room: Pavilion Ballroom

The new and creative approaches will first be presented in poster format on Thursday March 31st for initial review and judging. Presenters will be at their posters between 1545 – 1700 to answer questions, and be judged. After judging, selected posters will move on to the oral “pitch”. The “pitch” will convey the nature of the presenter’s project in an informative and energetic manner.

Presentations will be adjudicated based on originality, creativity, applicability, and ease of duplication, sustainability and overall significance. An audience response system will be used.

PREVIOUS WINNERS

MRSAid Photodisinfection Project
Titus Wong presented the innovation at the 2012 annual conference.

The Automated Antimicrobial Prescription Surveillance System (APPS)
Vincent Nault presented the innovation at the 2013 annual conference.

CLOSING DINNER
Vancouver Street Eats
Date: Saturday April 2
Time: 1900 - 2200
Location: Grand Ballroom, Sheraton Vancouver Wall Centre

Enjoy the sights, sounds, and flavours of Vancouver with an outdoor street festival – INDOORS! Guests will be treated to an evening of fun activities, unique buskers, and delicious eats served from food truck-styled stations.

Registration for the Closing Dinner is easy — just use the same online registration system as used for the Annual Conference and select the extra sessions you wish to attend. For more information, visit the Annual Conference sections of either the AMMI Canada (www.ammi.ca) or CACMID (www.cacmid.ca) websites.
PROGRAM — Wednesday March 30

0800 – 1630
AMMI Canada Council Meeting
Room: Parksville

0800 – 1300
CCM Workshop: We Are What We Eat: Our Shared Obligations to Promote Animal, Ecosystem and Public Health from Microbes to Muscles (5 hours)
Room: Junior Ballroom CD
Moderator: Bonnie Buntain (Calgary, AB)
0805 – 0825
One Health - Sharing Our Obligations for Food Safety and Security in the 21st Century
Speaker: Bonnie Buntain (Calgary, AB)
0825 – 0900
Canadian Aquaculture: Sustainable Fish Production or Microbe Factories?
Speaker: Kyle Garver (Nanaimo, BC)
Objectives:
By the end of this session participants should be able to:
- Understand the economic scale of aquaculture in Canada and its role in food security
- Discuss salmon farming in British Columbia and its evolution to its current state
- Understand microbial impact to the BC salmon aquaculture industry from an economic and societal perspective
- Describe the development of tools to investigate microbial exchange in aquaculture

0935 – 1010
The Sad Side of Happy Chickens: Salmonella enterica Enteritidis (SE) and ‘Backyard’ Poultry Production
Speaker: Clayton Botkin (Abbotsford, BC)
Objectives:
By the end of this session participants should be able to:
- Understand why people engage in backyard farming
- Describe the differences between regulated and unregulated poultry production systems in terms of human and animal disease risk, product distribution, and food security
- Discuss how animal and human health experts may need to work together to deal with a backyard SE outbreak

1010 – 1045
Our Shared Policy Obligations: The Mug’s Game of Governing Antimicrobial Use Without Measurable Objectives
Speaker: Brian Radke (Abbotsford, BC)
Objectives:
By the end of this session participants should be able to:
- Review the existing Canadian antimicrobial use (AMU) and antimicrobial resistance (AMR) objectives
- Illustrate the inadequacy of these objectives using reaction to the recent global discovery of the MCR-1 gene
- Discuss how a lack of measurable objectives poses difficulty for AMU and AMR governance, including policy selection and guidance for prescribers
- Review potential AMU and AMR objectives including those of other countries

1045 – 1135
Is Antibiotic-Free a Good Place to Be: Antibiotic Stewardship Strategies in the Poultry Industry and Their Impact on Poultry and Public Health
Speakers: Lindsay Kehler (Abbotsford, BC)
Stewart Ritchie (Abbotsford, BC)
Objectives:
By the end of this session participants should be able to:
- Understand which antibiotics are currently used in intensive poultry production systems in Canada
- Discuss how the poultry industry can best provide continuing education and transparent opportunities for the consumer to evaluate and critique current intensive rearing practices
- Identify key educational themes that should be communicated to the consumer e.g., animal welfare, food safety, environmental stewardship, and value

1135 – 1220
Meeting Our Shared Obligations: Tools to Get There and Added Value
Speaker: Bonnie Buntain (Calgary, AB)
Objectives:
By the end of this session participants should be able to:
- Describe the future of one health and its impact on human health
- List options for better service delivery in both human and animal health
- Discuss improved surveillance in animals and its impact on human health
- Consider how we link research and add value to our efforts and resources

1220 – 1225
Wrap Up
Speakers: Steven J. Drews (Edmonton, AB)
Chelsea Himsworth (Abbotsford, BC)
PROGTRAM — Wednesday March 30

1230 – 1700
Trainees’ Day (3.75 hours)
Room: Junior Ballroom AB
Moderator: Shazia Masud (Vancouver, BC)

1230 – 1300
Lunch & Registration

1300 – 1345
Breaking Open the Royal College Oyster: Pearls for Success on the Board Exam
Speaker: Troy Grennan (Vancouver, BC)
Objectives:
By the end of this session, participants should be able to:
• Present an overview of key concepts covered on the infectious diseases and medical microbiology examinations
• Provide practical strategies on board exam study techniques
• Review illustrative case examples of common exam topics

1345 – 1445
Oh, the Places You’ll Go!
Speaker: Miguel Imperial (Vancouver, BC)
Melanie Murray (Vancouver, BC)
Objectives:
By the end of this session, participants should be able to:
• Identify strategies and common mistakes when marketing oneself
• Explore different career paths from academic to alternative practice settings and how they can be customized for one’s career goals

1445 – 1500
Break

1500 – 1600
Surviving and Thriving After Residency
Speaker: Melanie Murray (Vancouver, BC)
Objectives:
By the end of this session, participants should be able to:
• Describe tips to becoming self-reliant
• Discuss strategies to face the challenges in setting up a practice
• Understand how to stay up to date with the literature: CME
• Identify an approach to Finances - incorporating, paying off debts, billing
• Understand the importance of balancing work and family

1600 – 1700
Beyond “Staff” aureus – Getting the Most out of Residency
Speaker: Philippe Martin (Sherbrooke, QC)
Objectives:
By the end of this session, participants should be able to:
• Name some of the best Infectious Diseases and Medical Microbiology references I wish I knew about earlier
• Describe a few pearls on the preparation for the Royal College Exams I wish I knew earlier
• Describe a strategy to deal with complex/rare Infectious Diseases and Medical Microbiology situations

1700 – 1800
Trainees’ Day Reception
Room: Junior Ballroom Foyer

1800 – 2030
CACMID Board Meeting
Room: Parksville

1800 – 2100
CFID Board Meeting
Room: Beluga

WE’RE GOING MOBILE!

Get the conference on the go!
Head over to http://bit.ly/AMMIapp on an iPhone, iPad or Android device (not a desktop or laptop) or scan the QR code. You will be taken to your device’s app store to download the app. Please note that the URL is case sensitive.

The mobile app provides access to conference information, including schedules, floor plans, abstracts, and much more – all at your fingertips!

1400 – 1600
CCM Board Meeting
Room: Beluga

1700 – 1800
Trainees’ Day Reception
Room: Junior Ballroom Foyer

1800 – 2030
CACMID Board Meeting
Room: Parksville

1800 – 2100
CFID Board Meeting
Room: Beluga
**0700 – 0845**
AMMI Canada AGM and Sections Meetings
Room: Junior Ballroom CD

**0845 – 0900**
Break
Room: Pavilion Ballroom Foyer

**0900 – 1100**
Plenary: Global Health (2 hours)
Room: Pavilion Ballroom

**Moderators:**
Peter Daley (St. John’s, NL)
Titus Wong (Vancouver, BC)

**0900 – 0940**
A World of Microbes at our Doorstep
**Speaker:**
Matthew W. Gilmour (Winnipeg, MB)

**Objectives:**
- List pathogens that are endemic in other areas of the world, but through travel, Canadians are increasingly returning home with
- Describe pathogens that, while not encountered in Canada, are large enough threats in other parts of the world that they are driving planning and preparatory efforts for Canadian hospitals, laboratories and public health institutes
- Explain ecological and anthropogenic drivers that are influencing pathogen niche and transmission

**0940 – 1020**
Diagnostics Arsenal for Diagnosing Emerging Infectious Diseases
**Speaker:**
Niaz Banaei (Palo Alto, CA)

**Objectives:**
By the end of this session, participants should be able to:
- Discuss laboratory diagnosis of emerging infectious diseases
- Describe role of clinical microbiology laboratory in health system
- Explain laboratory diagnosis of carbapenem-resistant enterobacteriaceae

**1020 – 1100**
Keeping Microbes at our Doorstep
**Speaker:**
Mark Loeb (Hamilton, ON)

**Objectives:**
- Discuss laboratory diagnosis of emerging infectious diseases
- Describe role of clinical microbiology laboratory in health system
- Explain laboratory diagnosis of carbapenem-resistant enterobacteriaceae

**1100 – 1115**
Break
Room: Oral Presentation Foyers

**1115 – 1215**
Oral Presentations (1 hour)
Session A
**Room:** Fort McNeill

**Moderator:**
Philippe Lagacé-Wiens (Winnipeg, MB)

---

**19**

**0700 – 0830**
Workshop (1 hour)
co-developed by AMMI Canada and Hologic, Inc.
**STIs on the fringe: what we know and don’t know about Trichomonas vaginalis and Mycoplasma genitalium in Canada**

**Room:** Junior Ballroom AB

**Moderator:**
Ameeta Singh (Edmonton, AB)

**Introductions and overview of STI testing/screening guideline for Mycoplasma genitalium and Trichomonas vaginalis**

**Speaker:**
Ameeta Singh (Edmonton, AB)

**Objectives:**
- Describe clinical manifestations and epidemiology for Mycoplasma genitalium and Trichomonas vaginalis
- Provide an overview of treatment regimens and drug resistance for Mycoplasma genitalium and Trichomonas vaginalis
- Review current updates to STI screening and testing guideline in Canada for Mycoplasma genitalium and Trichomonas vaginalis

---

**0700 – 0830**
Workshop (1 hour)
**STIs on the fringe: what we know and don’t know about Trichomonas vaginalis and Mycoplasma genitalium in Canada**

**Room:** Junior Ballroom AB

**Moderator:**
Ameeta Singh (Edmonton, AB)

**Introductions and overview of STI testing/screening guideline for Mycoplasma genitalium and Trichomonas vaginalis**

**Speaker:**
Ameeta Singh (Edmonton, AB)

**Objectives:**
- Describe clinical manifestations and epidemiology for Mycoplasma genitalium and Trichomonas vaginalis
- Provide an overview of treatment regimens and drug resistance for Mycoplasma genitalium and Trichomonas vaginalis
- Review current updates to STI screening and testing guideline in Canada for Mycoplasma genitalium and Trichomonas vaginalis

**1020 – 1100**
Keeping Microbes at our Doorstep
**Speaker:**
Mark Loeb (Hamilton, ON)

**Objectives:**
By the end of this session, by using the recent Ebola outbreak as well as others as examples, participants should be able to:
- Provide an overview of best available evidence to inform Infection Control practice
- Highlight the discrepancy between existing evidence and what could be considered optimal
- Discuss measurement of risk assessment

**1100 – 1115**
Break
Room: Oral Presentation Foyers

**1115 – 1215**
Oral Presentations (1 hour)
Session A
**Room:** Fort McNeill

**Moderator:**
Philippe Lagacé-Wiens (Winnipeg, MB)

---

**0700 – 0830**
Workshop (1 hour)
co-developed by AMMI Canada and Hologic, Inc.
**STIs on the fringe: what we know and don’t know about Trichomonas vaginalis and Mycoplasma genitalium in Canada**

**Room:** Junior Ballroom AB

**Moderator:**
Ameeta Singh (Edmonton, AB)

**Introductions and overview of STI testing/screening guideline for Mycoplasma genitalium and Trichomonas vaginalis**

**Speaker:**
Ameeta Singh (Edmonton, AB)

**Objectives:**
- Describe clinical manifestations and epidemiology for Mycoplasma genitalium and Trichomonas vaginalis
- Provide an overview of treatment regimens and drug resistance for Mycoplasma genitalium and Trichomonas vaginalis
- Review current updates to STI screening and testing guideline in Canada for Mycoplasma genitalium and Trichomonas vaginalis

---

**1020 – 1100**
Keeping Microbes at our Doorstep
**Speaker:**
Mark Loeb (Hamilton, ON)

**Objectives:**
By the end of this session, by using the recent Ebola outbreak as well as others as examples, participants should be able to:
- Provide an overview of best available evidence to inform Infection Control practice
- Highlight the discrepancy between existing evidence and what could be considered optimal
- Discuss measurement of risk assessment

**1100 – 1115**
Break
Room: Oral Presentation Foyers

**1115 – 1215**
Oral Presentations (1 hour)
Session A
**Room:** Fort McNeill

**Moderator:**
Philippe Lagacé-Wiens (Winnipeg, MB)

---

**0700 – 0830**
Workshop (1 hour)
co-developed by AMMI Canada and Hologic, Inc.
**STIs on the fringe: what we know and don’t know about Trichomonas vaginalis and Mycoplasma genitalium in Canada**

**Room:** Junior Ballroom AB

**Moderator:**
Ameeta Singh (Edmonton, AB)

**Introductions and overview of STI testing/screening guideline for Mycoplasma genitalium and Trichomonas vaginalis**

**Speaker:**
Ameeta Singh (Edmonton, AB)

**Objectives:**
- Describe clinical manifestations and epidemiology for Mycoplasma genitalium and Trichomonas vaginalis
- Provide an overview of treatment regimens and drug resistance for Mycoplasma genitalium and Trichomonas vaginalis
- Review current updates to STI screening and testing guideline in Canada for Mycoplasma genitalium and Trichomonas vaginalis

---

**1020 – 1100**
Keeping Microbes at our Doorstep
**Speaker:**
Mark Loeb (Hamilton, ON)

**Objectives:**
By the end of this session, by using the recent Ebola outbreak as well as others as examples, participants should be able to:
- Provide an overview of best available evidence to inform Infection Control practice
- Highlight the discrepancy between existing evidence and what could be considered optimal
- Discuss measurement of risk assessment

**1100 – 1115**
Break
Room: Oral Presentation Foyers

**1115 – 1215**
Oral Presentations (1 hour)
Session A
**Room:** Fort McNeill

**Moderator:**
Philippe Lagacé-Wiens (Winnipeg, MB)
PROGRAM — Thursday March 31

A03 1145 - 1200
Quaking Induced Conversion for CJD Diagnosis
R Vendrameelli, A Sloan, K Cheng, J D Knox
1Public Health Agency of Canada, 2University of Manitoba, Winnipeg, MB

A04 1200 - 1215
Early Identification and Susceptibility Testing of Positive Blood Cultures using the WASP™/WASPLab™ Automation System and MALDI-TOF VitekMS™ and Vitek2 Susceptibility Instrument
M Gaskin, D Johnson, J Korver, D Yamamura
1Provincial Laboratory, Alberta Health Services, Hamilton, ON, 2McMaster University, Hamilton, ON

A01 1115 - 1130
Oral Presentations (1 hour)
Session B
Room: Port Alberni
Moderator: Romina Reyes (Kelowna, BC)

B01 1115 - 1130
Antifungal Susceptibility of Invasive Candida Isolates from Canadian Hospitals: Results of the CANWARD 2015 Study
J Fuller, S Shokoples, L Turnbull, RP Rennie, HJ Adams, M Baxter, DJ Hoban, GG Zhanell
1Provincial Laboratory, Alberta Health Services, University of Alberta, Edmonton, AB, 2Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3Diagnostic Services of Manitoba, Winnipeg, MB

B02 1130 - 1145
Diagnosis of Cryptococcus gattii Infection in BC, 1999-2007
P Phillips, L MacDougall, M Chong, LH Hoang, M Morshed, D Thompson
1Division of Infectious Diseases, St Paul’s Hospital, Vancouver, BC, 2University of British Columbia, Vancouver, BC, 3BC Centre for Disease Control, Vancouver, BC, 4EMMES Canada, Simon Fraser University, Burnaby, BC

B03 1145 - 1200
Evaluation of the IMMY Cryptococcal Lateral Flow Assay Compared to the Meridian CALAS™ Latex Agglutination and the IMMY Latex Agglutination in Immunocompromised Patients at Hamilton Health Sciences and St. Joseph Healthcare Hamilton
J Dalle Vedove, J Todd, R Marsh, D Yamamura
1Hamilton Regional Laboratory Medicine Program, Hamilton, ON, 2McMaster University, Hamilton, ON

B04 1200 - 1215
Antifungal Susceptibility of Respiratory Aspergillus Isolates from Canadian Hospitals: Results of the CANWARD 2015 Study
J Fuller, S Shokoples, L Turnbull, RP Rennie, HJ Adams, M Baxter, DJ Hoban, GG Zhanell
1Provincial Laboratory, Alberta Health Services, University of Alberta, Edmonton, AB, 2Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3Diagnostic Services of Manitoba, Winnipeg, MB

C01 1115 - 1130
Trends in Antibiotic Utilization for Urinary Tract Infections in the Province of British Columbia, Canada
DM Patrick, D George, M Chong, E Blondel-Hill, F Marrara
1University of British Columbia, Vancouver, BC, 2BC Centre for Disease Control, Vancouver, BC, 3Interior Health Authority, Kelowna, BC

C02 1130 - 1145
Antimicrobial Stewardship Programs Reduce Daily Prescribing Variability in Academic ICUs
L Dresser, J Hughes, M McIntyre, S Nelson, N Ferguson, S Lapinsky, N Lazar, S Mehta, L Burry, J Singh, C Bell, AM Morris
1University Health Network, Toronto, ON, 2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON, 4York University, Toronto, ON, 5Faculty of Medicine, University of Toronto, Toronto, ON

C03 1145 - 1200
Strobilid and Darunavir Evaluation (STRIDE): A New Standard in Salvage Therapy
S Vafadary, S Hakobyan, T Raycraft, G Kiani, S Sharma, B Conway
Vancouver Infectious Diseases Centre, Vancouver, BC

C04 1200 - 1215
Lessons Learned from a National Antibiotic Awareness Pilot Campaign in Canada
C Soon, L Smylie, J Arthur
Public Health Agency of Canada, Ottawa, ON

D01 1115 - 1130
Genomic Analysis of Wetland Sediment as a Tool for Avian Influenza Virus Surveillance in Wild Waterfowl
C Himsworth, M Coombe, W Baticados, A Jassem, N Prystajecky, P Tang, W Hsiao
1BC Ministry of Agriculture, Abbotsford, BC, 2BC Centre for Disease Control, Vancouver, BC, 3University of British Columbia, Vancouver, BC, 4Sidra Medical and Research Centre, Doha, Qatar

D02 1130 - 1145
Mining for Avian Influenza Virus RNA in Wetland Soil Sediments
W Baticados, A Jassem, C Himsworth, M Coombe, N Prystajecky, P Tang, W Hsiao
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, 2British Columbia Centre for Disease Control Public Health Laboratory, Provincial Health Services Authority, Vancouver, BC, 3Animal Health Centre, British Columbia Ministry of Agriculture, Vancouver, BC, 4School of Population and Public Health, University of British Columbia, Vancouver, BC, 5Sidra Medical and Research Centre, Doha, Qatar
PROGRAM — Thursday March 31

D03 1145 – 1200
Serologic Follow-up of Healthcare Workers (HCWs) Exposed to Influenza A H5N1
RA HARRISON1,2, D HINSHAW1,2, S TSEKREKOS1, G TIPPLES1, K FONSECA1, Y LI1, M LAVOIE1, G PREDY2, AM JOFFE1,2
1University of Alberta, Edmonton; 2Alberta Health Services, AB; 3Provincial Laboratory for Public Health, Alberta Health Services, Calgary, Edmonton, AB; 4National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 5Alberta Health, AB

D03 1230 – 1430
Integrated Symposium (1.5 hours) co-developed by AMMI Canada and Merck Canada Inc.
C. difficile: Both Sides of the Story
ROOM: Junior Ballroom CD
MODERATOR: Ted Steiner (Vancouver, BC)
CDI Challenging Cases - the Physician’s Perspective
SPEAKER: Ted Steiner (Vancouver, BC)
OBJECTIVE: By the end of this session, participants should be able to:
• Describe an approach to complicated or refractory cases of recurrent CDI
CDI - the Patient’s Perspective
SPEAKER: Gail Attara (Vancouver, BC)
OBJECTIVE: By the end of this session, participants should be able to:
• Highlight patient group initiatives such as patient survey and educational video regarding Clostridium difficile infections
CDI Treatment - Has the Direction Changed Since the Last Guidelines?
SPEAKER: Stuart Johnson (Hines, IL)
OBJECTIVES: By the end of this session, participants should be able to:
• Describe the relative efficacy of metronidazole and vancomycin in the treatment of CDI
• Understand the limitations of standard treatments in patients with multiple CDI recurrences
• Describe the 5 major alternative strategies for managing recurrent CDI

D04 1200 – 1215
Seroprevalence of Jamestown Canyon Virus in Nova Scotia
G PATRIQUIN1, E SCHLEIAHAUF2, BL JOHNSTON1,3, K DIMITROVA4, A MASK1, M TRAYKOVA-ANDONOVA4,5, D HALDANE1,4, M DREBOT4,5, T COLE4,5, R LINDSAY4,5, TF HATCHETTE1,3
1Dalhousie University, Halifax, NS; 2Public Health Agency of Canada, Ottawa, ON; 3Nova Scotia Health Authority, Halifax, NS; 4National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB; 5Nova Scotia Department of Health and Wellness, Halifax, NS

D04 1215 – 1400
Poster Viewing
ROOM: Grand Ballroom

D04 1445 – 1545
State of the Art Clinical Lecture (1 hour) co-developed by the Canadian Foundation for Infectious Diseases (CFID)
Tuberculosis in Canada: from Sea to Sea to Sea
ROOM: Pavilion Ballroom
MODERATOR: Susan Richardson (Toronto, ON)
SPEAKER: Marcel Behr (Montréal, QC)
OBJECTIVES: By the end of this session, participants should be able to:
• Describe whole genome sequencing as it pertains to TB epidemiology
• Describe whole genome sequencing as it pertains to TB diagnostics
• Discuss issues related specifically to MDR-TB

D04 1545 – 1700
Student and Incubator Poster Judging (presenters at posters)
ROOM: Grand Ballroom

D04 1700 – 1730
AMMI Canada – CACMID Special Lecture: Next Generation Sequencing for the Diagnosis of Infections (1 hour)
ROOM: Pavilion Ballroom
MODERATORS: Jeff Fuller (Edmonton, AB) Daniel B. Gregson (Calgary, AB)
SPEAKER: Charles Chiu (San Francisco, CA)
OBJECTIVES: By the end of this session, participants should be able to:
• Understand the concepts behind metagenomic next-generation sequencing for diagnosis of clinical infections
• Learn about California efforts to implement next-generation sequencing-based diagnosis in critically ill hospitalized patients (California Initiative to Advance Precision Medicine)
• Learn new technologies including nanopore sequencing and transcriptome profiling for diagnosis of infections

1830 – 2030
Welcome Reception and Stand Up Dinner in Exhibit Hall
Posters available for viewing
ROOM: Grand Ballroom & Foyer
PROGRAM — Friday April 1

0700 – 0845  CACMID AGM
Room: Junior Ballroom CD

0700 – 0830  AMMI Canada Education / Continuing Professional Development Committee Meeting
Room: Parksville

0845 – 0900  Break
Room: Pavilion Ballroom Foyer

0900 – 1100  Plenary: Non HIV Immunodeficiency (2 hours)
Room: Pavilion Ballroom
Moderators: Gerald Evans (Kingston, ON) Todd Hatchette (Halifax, NS)
0900 – 0940  The Intersection of ID and PIDD: A Primer on Primary Immune Deficiency Diseases from an Infectious Diseases Perspective
Speaker: Sarah Forgie (Edmonton, AB)
Objectives: By the end of this session, participants should be able to:
• Create a classification scheme for Primary Immune Deficiency Diseases (PIDD)
• Recognize the characteristic clinical and microbiological findings of PIDD in children and adults
• Design an infection prevention plan for patients with PIDD
• Locate online resources for PIDD

1040 – 1020  Dropping our Defenses: Infections in the Setting of Immunosuppressive Therapy
Speaker: Alissa Wright (Vancouver, BC)
Objectives: By the end of this session, participants should be able to:
• Describe the expected infectious complications of steroid & anti-TNF therapy
• Work-up a patient for latent infection before initiating immunosuppression
• Recommend the appropriate vaccines before initiating immunosuppression

0940 – 1100  Dropping our Defenses: Infections in the Setting of Immunosuppressive Therapy
Speaker: Alissa Wright (Vancouver, BC)
Objectives: By the end of this session, participants should be able to:
• Describe the expected infectious complications of steroid & anti-TNF therapy
• Work-up a patient for latent infection before initiating immunosuppression
• Recommend the appropriate vaccines before initiating immunosuppression

1020 – 1100  Lab Diagnosis of Immune Defects: Why Blood is thicker than Water
Speaker: Donald Vinh (Montreal, QC)
Objectives: By the end of this session, participants should be able to:
• Describe an overview of host defenses and relevant immunological diagnostic tests
• Discuss diagnostic strategies and tailoring Immunology tests to Infectious Disease syndromes
• Discuss genetic testing of the Microbe: Targeted vs. Agnostic approaches… and why should we even care

1100 – 1115  Break
Room: Oral Presentation Foyers

1115 – 1215  Oral Presentations (1 hour)
Session E
Room: Port McNeill
Moderator: Carmen Charlton (Edmonton, AB)

E01  1115 - 1130  Validation of the Fast-Track Diagnostics Bacterial Gastroenteritis Real-Time PCR Assay
P Lagacé-Wiens, P Dégagné, K Nichol, HJ Adam, P Pieroni, J Karlowsky
Diagnostic Services Manitoba, Winnipeg, MB

E02  1130 - 1145  Zika Virus: A Canadian Perspective
K Dimitrova, on behalf of the national microbiology laboratory’s zika virus team
Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada

E03  1145 - 1200  Prevalence of Genital C. trachomatis, N. gonorrhoeae and T. vaginalis among Young Adults in Québec: Results from the 2013-2014 PIXEL Study
G Lambert1, S Mathieu2,3, F Coutlée2, A-C Labbé2,3, P Goggin1, É Maurois1
1Institut national de santé publique du Québec, Montréal, QC, 2Université de Montréal, Montréal, QC

1200 - 1215  Comparison of Two Digital PCR Platforms and Development of an HIV-2 Quantitative Assay
S Lavoie, F Cholette, D Ng, J Kim
Public Health Agency of Canada, Winnipeg, MB

1115 – 1215  Oral Presentations (1 hour)
Session F
Room: Port Alberni
Moderator: Daniel B. Gregson (Calgary, AB)

F01  1115 - 1130  Retrospective Evaluation of Bio-Rad’s CARBA assay for Detection of a Diverse Range of Carbenemase-producing Organisms (CPO)
BM Willey4, X Trim1, R Iaboni1, S Rajadurai1, DN Grohn5, G Ricci1, DA Boyd6, P Lo7, T Mazzulli7,8, SM Poutanen7,8
1Mount Sinai Hospital, Toronto, ON, 2University Health Network, Toronto, ON, 3University of Toronto, Toronto, ON, 4Michener Institute, Toronto, ON, 5William Osler Health Sciences Centre, Brampton, ON, 6National Microbiology Laboratory, Winnipeg, MB

1200 - 1215  Comparison of Two Digital PCR Platforms and Development of an HIV-2 Quantitative Assay
S Lavoie, F Cholette, D Ng, J Kim
Public Health Agency of Canada, Winnipeg, MB
PROGRAM — Friday April 1

**F02 1130 - 1145**
Detection of Carbapenemase-Producing Enterobacteriaceae in TIBDN Laboratories, 2014

A CARRERA1, J ARMSTRONG2, BL COLEMAN1-3, A FAHEEM1, K GREEN1, J JOHNSTONE1-3, KC KATZ1-4, P KOHLER1, R MELANO1, M MULLER1,2, S PATEL5, SM POUTANEN1,2, A REBBAPRAGADA6, D RICHARDSON7, A SARAIBA8, S SHAFINAZ2, AE SIMOR4,5, AJ MCGEER1,3
1University of Toronto; 2Toronto Public Health (Toronto); 3Mount Sinai Hospital; 4St Joseph’s Health Centre; 5Public Health Ontario; 6North York General Hospital; 7St Michael's Hospital, Toronto, ON; 8Dynacare Laboratories; 9William Osler Health System, Brampton; 10Trillium Health Partners, Mississauga; 11Sunnybrook Health Sciences Centre, Toronto, ON

**F03 1145 - 1200**
A Cross-Sectional Point Prevalence Survey (PPS) of the Antiseptic Resistance Genes qacA/B and smr in Clinical Isolates of *Staphylococcus* spp. from across Alberta

O LARIOS1-2, K ZHANG1,3, J MCCONCHY1,2, JZ DELONGCHAMPA1,2, S SPARKSMAN3, V BORAS1, RP RENNIE1,2, L CONLY4
1Alberta Health Services, Calgary, AB; 2University of Calgary, Calgary, AB; 3University of Alberta, Edmonton, AB

**F04 1200 - 1215**
Retrospective Evaluation of bioMérieux’s chromID CARBA-SMART Agar (C-S) Bi-Plate for Detection of a Diverse Range of Carbapenemase-Producing Organisms (CPO)

BM WILLEY1,2, X TRIMI1, R IABONI1, DA BOYD1, G RICCI1, DN GROHN2, A MAZZULLI1, D TERENZI1, MR MULVEY1, P LO1,2, T MAZZULLI1,2, SM POUTANEN1,2
1Mount Sinai Hospital, Toronto, ON, 2University Health Network, Toronto, ON

**GO1 1115 - 1230**
Session G

**Otal Oral Presentations (1 hour)**

**Session G**

**Room:** Finback

**Moderator:** Shazia Masud (Vancouver, BC)

**G01 1115 - 1130**
A Randomized Controlled Trial of Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent *Clostridium difficile* Infection

S HOTA1,2,3, V SALES1,4, G TOMLINSON1,2, MJ SALPETER1, AJ MCGEER1,2,3, DE LOW1,2,3, SM POUTANEN1,2,3
1University Health Network, Toronto, ON, 2University of Toronto, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON, 4Markham-Stouffville Hospital, Markham, ON

**G02 1130 - 1145**
Use of Ceftaroline in Patients with Methicillin Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis Despite Adequate Source Control

Z CHAGLA1,2, N IRFAN1, A SHROFF1,3
1McMaster University, Hamilton, ON; 2St. Joseph’s Healthcare, Hamilton, ON; 3Hamilton Health Sciences, Hamilton, ON

**G03 1145 - 1200**
Risk Factors for Mortality in Patients with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Bloodstream Infections: A Multi-Centre, Cohort Study

NF DEWHURST1,2, SM POUTANEN1,2,3,4, B HAMANDI2,4, LW GONEAU2,4, M PITRE5, AYC LIN5, MD MISTRY6, L GRAHAM4, DO LOWE4
1St. Michael’s Hospital, Toronto, ON, 2University of Toronto, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON, 4University Health Network, Toronto, ON, 5London Health Sciences Centre, London, ON, 6Kingston General Hospital, Kingston, ON

**G04 1200 - 1215**
C-EDGE CO-STAR: Efficacy of Elbasvir and Grazoprevir in Persons Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

B CONWAY1, G DORE2, F ALTICE3, AH LITWIN4, O DALGARD5, EJ GANE6, O SHIBOLET7, A LUETKEMEYER8, R NAHASS9, C-Y PENG10, J GREBELY11, AY HOWE11, B-Y NGUYEN11, J WAHL11, E BARR12, M ROBERTSON13, HL PLATT14
1Vancouver Infectious Diseases Centre, Vancouver, BC; 2The Kirby Institute, Sydney, Australia; 3Yale School of Medicine, New Haven, CT, USA; 4Montefiore Medical Center, Bronx, NY, USA; 5Institute of Clinical Medicine, Oslo, Norway; 6Auckland Clinical Studies, Auckland, New Zealand; 7Tel Aviv Medical Center, Tel Aviv, Israel; 8University of California, San Francisco, San Francisco, CA, USA; 9ID Care, Hillsborough, NJ, USA; 10China Medical University Hospital, Taichung, Taiwan; 11Merck & Co., Inc., Kenilworth, NJ, USA
PROGRAM — Friday April 1

1115 – 1215 Oral Presentations (1 hour)
Session H
Room: Orca
Moderator: Jessica Minion (Regina, SK)

H01 1115 - 1130 Cumulative Antibiogram for the Empirical Treatment of Uncomplicated Urinary Tract Infections in Women: Should we Really Care about which Isolates to Include?
G DELISLE1, C LAV ALLEE2, M-C DOMINGO3, AA BOUDREAULT4, M GOURDEAU4, H BERNATCHEZ5, C QUACH1,6
1Research Institute, McGill University Health Centre, McGill University, Montréal, QC, 2CIUSSS de l’Est-de-l’Île-de-Montréal, Université de Montréal, Montréal, QC, 3Institut national de santé publique du Québec, Montréal, QC, 4CHU de Québec, Université Laval, Montréal, QC, 5Centre intégré de santé et de services sociaux de l’Est-du-Québec, Université de Montréal, Montréal, QC, 6Epidemiology, Biostatistics & Occupational Health, McGill University, Montréal, QC

H02 1130 - 1145 A Laboratory Workflow Algorithm Using Urinary Nitrite and Leukocyte Dipstick Results in Conjunction with a Urinary Tract Infection Management Bundle
C ELLIS1, K YOUNG1, D SMYTH1,2, T MACLAGGAN3, Z HUSSAIN1
1The Moncton Hospital, Moncton, NB, 2Department of Medicine, Dalhousie University, Halifax, NS, 3Horizon Health Network, Moncton, NB

H03 1145 - 1200 Antimicrobial Resistance for First Line Agents on Urine Isolate Staphylococcus saprophyticus
P PIERONI1,2, K BEHEYT1
1DSM, Westman Laboratory, Brandon, MB, 2Brandon University, Brandon, MB

H04 1200 - 1215 Urinary E. coli Antimicrobial Susceptibility Profile Isolated from Adult Women in the Province of Québec, 2010-2015
G DELISLE1, C LAV ALLEE2, M-C DOMINGO3, AA BOUDREAULT4, M GOURDEAU4, H BERNATCHEZ5, C QUACH1,6
1Research Institute, McGill University Health Centre, McGill University, Montréal, QC, 2CIUSSS de l’Est-de-l’Île-de-Montréal, Université de Montréal, Montréal, QC, 3Institut national de santé publique du Québec, Montréal, QC, 4CHU de Québec, Université Laval, Montréal, QC, 5Centre intégré de santé et de services sociaux de l’Est-du-Québec, Université de Montréal, Montréal, QC, 6Epidemiology, Biostatistics & Occupational Health, McGill University, Montréal, QC

1215 – 1400 Poster Viewing (presenters at posters)
Room: Grand Ballroom

1215 – 1400 Exhibit Hall Open
Room: Grand Ballroom & Foyer

1215 - 1445 MALDI-TOF Users Group Meeting
Room: Junior Ballroom AB

1215 – 1415 Royal College MM Specialty Committee Meeting
Room: Parksville

1230 – 1330 Lunch (In Exhibit Hall)

1230 – 1430 AMMI Canada Guidelines Committee Meeting
Room: Port Hardy

1230 – 1430 Integrated Symposium (1.5 hours) co-developed by AMMI Canada and Merck Canada Inc.
Back to the Patient: Refocusing Antimicrobial Stewardship
Moderator: Andrew Simor (Toronto, ON)
Speaker: Andrew Simor (Toronto, ON)
Objectives:
• Review the basic elements and requirements for an effective hospital-based antimicrobial stewardship program
• Consider various strategies and methods for conducting antimicrobial stewardship in hospital settings
• Assess the evidence for effectiveness of antimicrobial stewardship

Outcomes in Stewardship
Speaker: Victor Leung (Vancouver, BC)
Objectives:
• Assess stewardship effectiveness using conventional outcomes (drug use, cost, guideline compliance)
• Consider developing patient-oriented outcomes (mortality, nosocomial infection rate, length of stay, resistance index) as a new method of assessing effectiveness
• Propose standardized outcomes to allow comparison between stewardship interventions

The Future of Stewardship
Speaker: Jennifer Grant (Vancouver, BC)
Objectives:
• Be aware of application of advanced stewardship software for drug use measurement, drug appropriateness measurement and decision support
• Understand the impact of rapid lab techniques on antimicrobial stewardship
• Consider the impact of mathematical modelling on antimicrobial stewardship
• Describe novel stewardship ideas in development
PROGRAM — Friday April 1

1445 – 1545  The Incubator: “The Pitch”
   ROOM: Pavilion Ballroom

1545 – 1600  Break
   ROOM: Oral Presentation Foyers

1600 – 1700  Oral Presentations (1 hour)
Session I
   ROOM: Orca
   MODERATOR: Matthew W. Gimlour (Winnipeg, MB)

IO1  1600 - 1615
   Genome Sequencing of Salmonella Javiana in British Columbia: Gaining Perspective on Rare Serotypes in a Clinical Genomics Workflow
   KA MACDONALD1, MA CROXEN1, M TAYLOR1, M WALKER1, A PACCAGNELLA1, A REIMER2, E GALANIS1,4, L HOANG1,5
   1British Columbia Centre for Disease Control (BCCDC), Vancouver, BC, 2National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 3Surrey Memorial Hospital, Fraser Health Authority, Surrey; 4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver; 5Public Health Agency of Canada, Winnipeg, MB

IO2  1615 - 1630
   Rebuilding of a Laboratory Surveillance System
   A REIMER1, L TSCHEITER1,2, A KEARNEY1,2, J RUMORE2,3, C SIEFFERT1, C PETERSON1, M WALKER1, A PETKAU1, C BERRY3, M GRAHAM3, PNC STEERING COMMITTEE3, C NADON1,2
   1PHAC, Winnipeg, MB, 2PulseNet Canada, (multiple cities), Canada

1600 – 1715  Oral Presentations (1.25 hours)
Session J
   ROOM: Port Alberni
   MODERATOR: Susan Poutanen (Toronto, ON)

J01  1600 - 1615
   Decreased Rates of Hospital-Associated MRSA and VRE with Daily Chlorhexidine Gluconate Bathing for Medical Inpatients
   C LOWE1,2, E LLOYD-SMITH1, B SIDHU1,2, A SHARMA1, D RICHARDS1, T KIND1, V LEUNG1,2, M ROMNEY1,2
   1Providence Health Care, Vancouver, BC, 2British Columbia Centre for Disease Control, Public Health Laboratory, Vancouver, BC

J02  1615 - 1630
   VRE Positive Blood Culture Rates before and after Discontinuation of VRE Screening: A Quasi-Experimental Study of VRE Rates in Ontario Canada from January 2009 to June 2015
   J JOHNSTONE1,2, M POLICARPIO1, F LAM1, K ADOMAKO1, C PREMATUNGE1, E NADOLNY1, L LI1, K BROWN1,2, E KERR1, G GARBER1,2
   1Public Health Ontario, Toronto, ON, 2University of Toronto, Toronto, ON

J03  1630 - 1645
   Prevention of Post-Operative Catheter-Associated Urinary Tract Infection on Surgical Wards Following Implementation of a Multi-Faceted Intervention
   J A LEIS1,2, M SADEGHI1, C CORPS1, A WATAMANIUK1, M AVANESS1, F JINNA1, G HART1, D MACKAY1, B CATT1, S GALLERY1, M VEARNCOMBE1,2, A NATHENS1,2
   1Sunnybrook Health Sciences Centre, Toronto, ON, 2University of Toronto, Toronto, ON

J04  1645 - 1700
   Assessment of the Development of Chlorhexidine Gluconate Resistance in Staphylococcus aureus on Medical Inpatient Units
   C LOWE1,2, G RITCHIE1,2, B SIDHU1,2, A SHARMA1, W JANG1, A WONG1, J BILAWKA1, S CHAMPAGNE1,2, V LEUNG1,2, E LLOYD-SMITH1, M ROMNEY1
   1Providence Health Care, Vancouver, BC, 2British Columbia Centre for Disease Control, Public Health Laboratory, Vancouver, BC
PROGRAM — Friday April 1

**J05  1700 - 1715**

**Provincial Surveillance for Carbapenemase-producing Organisms in British Columbia: 2014-15**

G HAN¹, L FORRESTER¹,², T DONOVAN¹,³, JC COLLET⁴, A LEAMON¹,³, E LLIOYD-SMITH¹,², J MORIE¹,², D HEMBROFF¹,³, B GAMAGE¹, E BRYCE¹,², L HOANG¹,⁹

¹Provincial Infection Control Network, Provincial Health Services Authority; ²Infection Prevention and Control, Vancouver General Hospital, Vancouver; ³Infection Prevention and Control, Fraser Health Authority, Surrey; ⁴Infection Prevention and Control, BC Children’s Hospital, Vancouver; ⁵Infection Prevention and Control, Island Health Authority, Victoria; ⁶Infection Prevention and Control, Providence Healthcare, Vancouver; ⁷Infection Prevention and Control, Interior Health Authority, Kelowna; ⁸Infection Prevention and Control, Northern Health Authority, Penticton; ⁹BC Centre for Disease Control Public Health Laboratory, Vancouver, BC

**K02  1615 - 1630**

**Antimicrobial Susceptibility Profile of Helicobacter pylori Isolates from 2009-15, at St-Paul’s Hospital, Vancouver, B.C.**

M PAYNE¹,², S CHAMPAGNE¹,²

¹Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC; ²Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

**K03  1630 - 1645**

**Self-stool Banking as a Source for Fecal Transplantation: A Pilot Study**

S RAYBARDHAN¹, W NG¹, J TOMASSI¹, KC KATZ¹,²

¹North York General Hospital, Toronto, ON; ²University of Toronto, Toronto, ON

**K04  1645 - 1700**

**Use of Whole Genome Sequencing to Ascertain that Brevibacterium massiliense (Roux, Raoult 2009) is a Later Heterotypic Synonym of Brevibacterium ravenspurgense (Mages 2008)**

K BERNARD¹,², T BURDŹ¹, C HUYNH¹, AL PACHECO¹, D WIEBE¹, C BONNER¹, G GERMAN³, A-M BERNIER¹

¹National Microbiology Laboratory, Winnipeg, MB; ²University of Manitoba, Department of Medical Microbiology, Winnipeg, MB; ³Queen Elizabeth Hospital, Charlottetown, PE; ⁴Université Saint Boniface, Winnipeg, MB

**K05  1700 - 1715**

**Oral Presentations (1 hour)**

**Session K**

**Room:** Finback

**Moderator:** David Patrick (Vancouver, BC)

**L01  1600 - 1615**

**Factors Associated with 30-day Survival in Infections Caused by Streptococcus pneumoniae**

MP CHENG¹, TC LEE¹,²

¹McGill University Health Centre, Montréal, QC; ²University of Toronto, Toronto, ON

**L02  1615 - 1630**

**Systematic Review of Factors Associated with Antibiotic Prescribing for Respiratory Tract Infections**

A MAH¹,², R MCKAY¹, M LAW², K MCGRAIL², DM PATRICK¹,²

¹Division of Infectious Diseases, University of British Columbia, Vancouver, BC; ²School of Population and Public Health, University of British Columbia, Vancouver, BC

**L03  1630 - 1645**

**Of Mice and Men in Uniform – A Cluster of Hantavirus Pulmonary Syndrome Amongst Canadian Military Personnel**

LO PARKES¹, TT NGUYEN¹, J LONGTIN²,³, MC BEAUDOIN¹, J BESTMAN-SMITH¹, DC VINH¹, G BOIVIN³, VG LOO¹

¹McGill University Health Centre, Montréal, QC; ²Infectious Diseases Research Center and Université Laval, Québec, QC; ³Laboratoire de Santé Publique du Québec, Québec, QC; ⁴CHU de Québec and Université Laval, Québec, QC

**L04  1645 - 1700**

**Characteristics of Antimicrobial Stewardship Programs at Paediatric Centres Across Canada**

J WONG¹,², K TIMBERLAKE³, S BOODHAN³, M BARTON⁴, S FANELLA⁵, S READ¹,², M SCIENCE¹,²

¹Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON; ²Department of Paediatrics, University of Toronto, Toronto, ON; ³Department of Pharmacy, The Hospital for Sick Children, Toronto, ON; ⁴Department of Paediatrics, Western University, London, ON; ⁵Departments of Pediatrics and Child Health and Medical Microbiology, University of Manitoba, Winnipeg, MB

**L05 - 1700 - 1715**

**Transmission Rate of HIV from Infected Healthcare Workers to Patients, a Meta-analysis**

S PARAMALINGAM¹, T OGUHREM², K DEFAŁCO¹, P PELUDE¹, K DUNN²

¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON; ²Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON

**L07  1700 - 1715**

**STUDENT Oral Competition (1.25 hours)**

**Session L**

**Room:** Port McNeill

**Moderator:** Peter Daley (St. John’s, NL)

**L01  1600 - 1615**

**Factors Associated with 30-day Survival in Infections Caused by Streptococcus pneumoniae**

MP CHENG¹, TC LEE¹,²

¹McGill University Health Centre, Montréal, QC; ²University of Toronto, Toronto, ON

**L02  1615 - 1630**

**Systematic Review of Factors Associated with Antibiotic Prescribing for Respiratory Tract Infections**

A MAH¹,², R MCKAY¹, M LAW², K MCGRAIL², DM PATRICK¹,²

¹Division of Infectious Diseases, University of British Columbia, Vancouver, BC; ²School of Population and Public Health, University of British Columbia, Vancouver, BC

**L03  1630 - 1645**

**Of Mice and Men in Uniform – A Cluster of Hantavirus Pulmonary Syndrome Amongst Canadian Military Personnel**

LO PARKES¹, TT NGUYEN¹, J LONGTIN²,³, MC BEAUDOIN¹, J BESTMAN-SMITH¹, DC VINH¹, G BOIVIN³, VG LOO¹

¹McGill University Health Centre, Montréal, QC; ²Infectious Diseases Research Center and Université Laval, Québec, QC; ³Laboratoire de Santé Publique du Québec, Québec, QC; ⁴CHU de Québec and Université Laval, Québec, QC

**L04  1645 - 1700**

**Characteristics of Antimicrobial Stewardship Programs at Paediatric Centres Across Canada**

J WONG¹,², K TIMBERLAKE³, S BOODHAN³, M BARTON⁴, S FANELLA⁵, S READ¹,², M SCIENCE¹,²

¹Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON; ²Department of Paediatrics, University of Toronto, Toronto, ON; ³Department of Pharmacy, The Hospital for Sick Children, Toronto, ON; ⁴Department of Paediatrics, Western University, London, ON; ⁵Departments of Pediatrics and Child Health and Medical Microbiology, University of Manitoba, Winnipeg, MB

**L05 - 1700 - 1715**

**Transmission Rate of HIV from Infected Healthcare Workers to Patients, a Meta-analysis**

S PARAMALINGAM¹, T OGUHREM², K DEFAŁCO¹, P PELUDE¹, K DUNN²

¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON; ²Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON
PROGRAM — Friday April 1

1730-1900
Workshop (1 hour)
co-developed by AMMI Canada and Accelerate Diagnostics
Antimicrobial Susceptibility Challenges and Opportunities in the Treatment of Patients with Bloodstream Infections
ROOM: Junior Ballroom AB
MODERATOR: Susan Poutanen (Toronto, ON)
What Should Laboratories Do After the Blood Culture Bottle Turns Positive: Technology is Giving Us More Options
SPEAKER: Susan Poutanen (Toronto, ON)
OBJECTIVES:
• Review available microbiology technologies regarding rapid identification and susceptibility profiles of blood pathogens
• Investigate the challenges in microbiology test implementation / interpretation when there is not a particular gold standard as it relates to blood pathogens

New Concepts in Susceptibility Testing
SPEAKER: Jennifer Dien Bard (Los Angeles, CA)
OBJECTIVE:
• Explore novel and emerging techniques that provide rapid susceptibility, or rapid identification profiles of blood pathogens

Antimicrobial Stewardship: How to Optimize the utility of Susceptibility Results
SPEAKER: Daniel Thirion (Montréal, QC)
OBJECTIVES:
• Expand on the increasingly important role that MIC reporting has for antimicrobial drug selection and dose optimization. Illustrate with example of patients with serious infections including bloodstream infections
• Describe the effect of time to appropriate therapy on outcomes of patients with bacteremia and examine the evidence for utilization of pharmacokinetic principles to reduce the potential to harm of inappropriate antimicrobial therapy

1730 - 1900  AMMI Canada Antimicrobial Stewardship and Resistance (ASR) Committee Meeting
ROOM: Granville
0700 – 0830  CFID Bug Run  
0700 – 0830  Workshop (1 hour)  
co-developed by AMMI Canada and Sunovion Pharmaceuticals Canada  
Debate: Single versus Combination Antibiotic Therapy for Serious Gram-Positive Infections  
ROOM: Junior Ballroom AB  
MODERATOR: Matthew Oughton (Montréal, QC)  
DEBATES:  
PRO COMBINATION THERAPY: George Sakoulas (La Jolla, CA)  
PRO MONOTHERAPY: Gerald Evans (Kingston, ON)  
OBJECTIVES:  
• To understand the potential role(s) of combination antibiotic therapy in serious Gram-positive infections  
• To analyze the in vivo effectiveness of antibiotics used to treat gram positive infections with attention to interactions at the cell wall or the immune system  
• To explore the details between clinical effectiveness versus microbiological effectiveness in considering combination therapy  
• To understand the possible limitations of combination therapy including added toxicity, cost, and antagonism  
0845 – 0900  Break  
ROOM: Pavilion Ballroom Foyer  
0900 – 1100  Plenary: What’s Hot? (2 hours)  
ROOM: Pavilion Ballroom  
MODERATORS:  
David Patrick (Vancouver, BC)  
Susan Poutanen (Toronto, ON)  
0900 – 0940  What’s Hot in Paediatric Infectious Diseases  
SPEAKER: Soren Gantt (Vancouver, BC)  
OBJECTIVES:  
By the end of this session, participants should be able to discuss recent findings regarding:  
• Azithromycin to prevent progression of upper into lower respiratory tract infection  
• Risk-benefit ratio of low-dose gentamicin for enterococcal bacteremia  
• Use of probiotics to prevent necrotizing enterocolitis  
• Vaccine resistant malaria  
• Congenital Zika virus infection  
0940 – 1020  What’s Hot in Adult Infectious Diseases  
SPEAKER: Victor Leung (Vancouver, BC)  
OBJECTIVES:  
By the end of this session, participants should be able to:  
• Describe a selection of interesting literature in adult infectious diseases from the last year  
• Consider how these developments may influence clinical practice  
1020 – 1100  What’s Hot in Diagnostic Microbiology: Transformation  
SPEAKER: Deirdre Church (Calgary, AB)  
OBJECTIVES:  
By the end of this session, participants should be able to:  
• Describe the transformative change taking place in your laboratory  
• Outline current and upcoming technology changes  
• Discuss the impact of new information generation for your practice  
1100 – 1115  Break  
ROOM: Oral Presentation Foyers  
0700 – 0830  CFID Bug Run  
0700 – 0830  Workshop (1 hour)  
co-developed by AMMI Canada and Sunovion Pharmaceuticals Canada  
Debate: Single versus Combination Antibiotic Therapy for Serious Gram-Positive Infections  
ROOM: Junior Ballroom AB  
MODERATOR: Matthew Oughton (Montréal, QC)  
DEBATES:  
PRO COMBINATION THERAPY: George Sakoulas (La Jolla, CA)  
PRO MONOTHERAPY: Gerald Evans (Kingston, ON)  
OBJECTIVES:  
• To understand the potential role(s) of combination antibiotic therapy in serious Gram-positive infections  
• To analyze the in vivo effectiveness of antibiotics used to treat gram positive infections with attention to interactions at the cell wall or the immune system  
• To explore the details between clinical effectiveness versus microbiological effectiveness in considering combination therapy  
• To understand the possible limitations of combination therapy including added toxicity, cost, and antagonism  
0845 – 0900  Break  
ROOM: Pavilion Ballroom Foyer  
0900 – 1100  Plenary: What’s Hot? (2 hours)  
ROOM: Pavilion Ballroom  
MODERATORS:  
David Patrick (Vancouver, BC)  
Susan Poutanen (Toronto, ON)  
0900 – 0940  What’s Hot in Paediatric Infectious Diseases  
SPEAKER: Soren Gantt (Vancouver, BC)  
OBJECTIVES:  
By the end of this session, participants should be able to discuss recent findings regarding:  
• Azithromycin to prevent progression of upper into lower respiratory tract infection  
• Risk-benefit ratio of low-dose gentamicin for enterococcal bacteremia  
• Use of probiotics to prevent necrotizing enterocolitis  
• Vaccine resistant malaria  
• Congenital Zika virus infection  
0940 – 1020  What’s Hot in Adult Infectious Diseases  
SPEAKER: Victor Leung (Vancouver, BC)  
OBJECTIVES:  
By the end of this session, participants should be able to:  
• Describe a selection of interesting literature in adult infectious diseases from the last year  
• Consider how these developments may influence clinical practice  
1020 – 1100  What’s Hot in Diagnostic Microbiology: Transformation  
SPEAKER: Deirdre Church (Calgary, AB)  
OBJECTIVES:  
By the end of this session, participants should be able to:  
• Describe the transformative change taking place in your laboratory  
• Outline current and upcoming technology changes  
• Discuss the impact of new information generation for your practice  
1100 – 1115  Break  
ROOM: Oral Presentation Foyers
PROGRAM — Saturday April 2

1115 – 1215
Oral Presentations (1 hour)
Session M
Room: Port McNeill
Moderator: Meghan Dey (Ottawa, ON)

M01 1115 – 1130
Determination of the Ability of the Carbapenemase Inhibition Method (CIM) to Accurately Identify Carbapenemase-Producing Organisms (CPO) and the Impact of Decreasing Carbapenem Inactivation Times (CIT)
BM WILLEY1,2, S RAJADURAI1, DN GROHN4, R IABONI1, X TRIMI1, G RICCI5, P LO1,2, T MAZZULLI1,2,3, SM POUTANEN1,2,3
1Mount Sinai Hospital, Toronto, ON, 2University Health Network, Toronto, ON, 3University of Toronto, Toronto, ON, 4Michener Institute, Toronto, ON, 5William Oder Health Sciences Centre, Brampton, ON, 6National Microbiology Laboratory, Winnipeg, MB

M02 1130 – 1215
Carbapenemase-Producing Organisms (CPO) Isolated from Environmental Water Samples (EWS) Collected in the Greater Toronto Area (GTA), Ontario, Canada
AI MCGEER1, BM WILLEY2,3, DA BOYD4, L MATASEJE4, V PORTER5, K FAKHARUDDIN6, MR MULVEY7, T EDGE8
1Mount Sinai Hospital, Toronto, ON, 2University of Toronto, Toronto, ON, 3University Health Network, Toronto, ON, 4Toronto Public Health, Toronto, ON, 5Sunnybrook Health Sciences Centre, Toronto, ON, 6National Microbiology Laboratory, Winnipeg, MB, 7Sunnybrook Health Sciences Centre, Toronto, ON, 8Environment & Climate Change Canada Water Science & Technology Directorate Aquatic Contaminants Research Division, Burlington, ON

M03 1145 – 1200
Rapid Enzymatic Detection of Clinically-Relevant Class D-Type Carbapenemases in Carbapenemase-Producing Organisms (CPO) using Coris BioConcept’s OXA48 K-Set Assay
BM WILLEY2, R IABONI1, X TRIMI1, DN GROHN1, G RICCI1, DA BOYD8, T MAZZULLI1,2,3, SM POUTANEN1,2,3
1Mount Sinai Hospital, Toronto, ON, 2University Health Network, Toronto, ON, 3University of Toronto, Toronto, ON, 4Michener Institute, Toronto, ON, 5William Oder Health Sciences Centre, Brampton, ON, 6National Microbiology Laboratory, Winnipeg, MB

M04 1200 – 1215
Molecular and Epidemiological Features of Carbapenemase Producing Enterobacteriaceae and Actinobacter in Alberta 2013-2015
A RUSK1,2, K BUSH1, J FULLER2, K SIMMONDS3, G TAYLOR1,3, FAKHARUDDIN4, MR MULVEY5, EA HENDERSON1,2
1Alberta Health Services Infection Prevention and Control Surveillance Program, Calgary, AB, 2Community Health Sciences, University of Calgary, Calgary, AB, 3Provincial Laboratory for Public Health, Edmonton, AB, 4Alberta Health, Edmonton, AB, 5National Microbiology Laboratory, University of Alberta, Edmonton, AB, 6National Microbiology Laboratory, Winnipeg, MB

1115 – 1215
Oral Presentations (1 hour)
Session N
Room: Port Alberni
Moderator: A. Mark Joffe (Edmonton, AB)

N01 11150 – 1130
Cerebral Phaeohyphomycosis Caused by Fonsecaea
W STOKES1, V MEIER-STEPHENSON1, J FULLER2, B MEATHERALL1, L REMINGTON2
1University of Calgary, Calgary, AB, 2University of Alberta, Edmonton, AB

N02 1130 – 1145
Report of 2 Cases of Prosthetic Joint Infections Due to Neisseria skkuensis, a Novel Neisseria Species
M PAYNE1, W HSIAO1, A STEFANOVIC1, R TSANG2, L HOANG1
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, 2National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

N03 1145 – 1200
Morbilliform Rash Associated with Coronavirus Detection during an Outbreak of Measles in Manitoba
J BULLARD1,2, K DUST1,2, R COLE1,4, P VAN CAESEEM1,2,3
1Cadham Provincial Laboratory, Winnipeg, MB, 2Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, MB, 4Public Health Agency of Canada/National Microbiology Laboratory, Winnipeg, MB

1115 – 1215
Tick-tock, the Curious Case of an ID Time Bomb – Pulmonary Melioidosis in Québec, Canada
LO PARKES2, MP CHENG1, GJ ZAHARATOS2,3
1McGill University Health Centre, Montréal, QC, 2McGill University, Montréal, QC

1115 – 1215
Oral Presentations (1 hour)
Session O
Room: Finback
Moderator: Caroline Quach (Montréal, QC)

O01 1115 – 1130
Hepatitis C Virus (HCV) Mortality Patterns in the British Columbia Hepatitis Testers Cohort (BC-HTC)
M KRAJDEN2, A YU1, D COOK2, M KUO3, M ALVAREZ2, M TYNDALL1,2, N JANJUA1,3
1BC Centre for Disease Control, Vancouver, BC, 2University of British Columbia, Vancouver, BC, 3University of British Columbia, Vancouver, BC

O02 1130 – 1145
Mapping the Gaps and Opportunities for Improved Knowledge Translation and Exchange Concerning Tuberculosis among Priority Populations in Canada
G BOILY-LAROUCHE, S BALAKUMAR
National Collaborating Center for Infectious Diseases, University of Manitoba, Winnipeg, MB
PROGRAM — Saturday April 2

O03 1145 - 1200
Analyzing Your Sequence Data
MA CROXEN1, KA MACDONALD1,3, L HOANG1,2
1British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, 2Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, 3National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

O04 1200 - 1215
Hospital Pandemic Preparedness: Are We Ready? A Simulation-Based Assessment
N BELZILE, A LONERGAN, V BRUNETTE, C CLOUTIER, M MELLOUK, L LEBLANC
Hôpital du Sacré-Cœur de Montréal, Montréal, QC

1115 – 1215
Oral Presentations (1 hour)
Session P
Room: Orca
Moderator: Sarah Forgie (Edmonton, AB)

P01 1115 - 1130
A Learner-Centered Antimicrobial Stewardship Educational Curriculum: Results of the Needs Assessment Pilot Study
C CONSTANTINESCU1,2, M LEMAY1,2, A KASSAM1, D DERSCH-MILLS1, T WU1,2, C TSANG1, S PARSONS1,2, L DAVIES1,2, J VAYALUMKAL1,2
1University of Calgary, Calgary, AB, 2Alberta Health Services, Calgary, AB

P02 1130 - 1145
An Apparent Increase in Defined Daily Doses per Prescription can be Explained by a Change in the Age Distribution of Antibiotic Use
DM PATRICK1,2, D GEORGE1, M CHONG1, F MARRA1
1University of British Columbia, Vancouver, BC, 2BC Centre for Disease Control, Vancouver, BC

P03 1145 - 1200
A Point-Prevalence Survey of Antimicrobial Utilization within New Brunswick Hospitals to Focus Antimicrobial Stewardship Efforts
D BRIDEAU-LAUGHLIN1, G GIROUARD2, M LEVESQUE1, T MACLAGGAN1, J MURRAY1, J SALMON2
1Horizon Health Network, NB, 2Reseau de Santé Vitalité, NB

P04 1200 - 1215
The Impact of Reported Beta-Lactam Allergy on Inpatient Outcomes: A Prospective Multicenter Observational Study
D MACFADDEN, A LADELEA, J LEEN, W GOLD, N DANEMAN, E WEBER, I AL-BUSAIDI, D PETRESCU, I SALTZMAN, M DEVLIN, N ANDANY, JA LEIS
University of Toronto, Toronto, ON

1230 – 1430
Delegate Lunch
Room: Grand Ballroom

1230 – 1430
Choosing Wisely Canada Campaign Meeting
Room: Junior Ballroom CD

JAMMI Editorial Board Meeting
Room: Parksville

1445 – 1545
State of the Art Clinical Lecture (1 hour) Debate: Baring It All – or Not
Moderator: Titus Wong (Vancouver, BC)
For: Lynn Johnston (Halifax, NS)
Against: Mary Vearncombe (Toronto, ON)

Debaters:

Resolution:
Be it resolved that healthcare workers should be encouraged to remain bare below the elbows and avoid the use of personal items in the patient care setting which may act as fomites and promote the spread of potential pathogens.

Objective:
• Argue for and against whether healthcare workers should be going bare below the elbows.

1545 – 1615
Poster and Research Awards Presentations
Room: Pavilion Ballroom

1615 – 1800
Clinical Vignettes (1.75 hours)
Room: Pavilion Ballroom
Chairs: Michael Libman (Montréal, QC) Caroline Quach (Montréal, QC)
Discussants: Matthew Cheng (Montréal, QC) Jennifer Grant (Vancouver, BC) Jeffrey Pernica (Hamilton, ON)

The audience, using an audience response system, along with discussants, will work through the cases to try and solve them.

1900 – 2200
Closing Dinner – Vancouver Street Eats
Grand Ballroom, Sheraton Vancouver Wall Centre
SAVE THE DATE

AMMI Canada CACMID
Annual Conference Conférence annuelle

TORONTO 2017
May 3–6 mai
Sheraton Centre Toronto
**Thursday March 31**

**Room:** Grand Ballroom

**Poster Viewing:**
Student and Incubator Poster Judging: Welcome Reception and Stand Up Dinner

Student Poster Presentations
Incubator Poster Presentations
Poster Presentations

**Poster Viewing:**
1215 – 1400 (Presenters at Posters)
1545 – 1700 (Presenters at Posters)
1830 – 2030

**Student and Incubator Poster Judging:**
1215 – 1400
1545 – 1700

**Welcome Reception and Stand Up Dinner:**
1830 – 2030

**Student Poster Presentations**
(SP01 – SP33)
(IP01 – IP22)
(P01 – P09)

**Incubator Poster Presentations**
(IP10 – IP19)

**Poster Presentations**
(P10 – P33)

**Friday April 1**

**Room:** Grand Ballroom

**Poster Viewing:**
1215 – 1400 (Presenters at Posters)

**Poster Presentations**
(P10 – P33)

**EXHIBIT HALL – GRAND BALLROOM**

---

**P01**

Dynamics of Serum Quantitative Hepatitis B Surface Antigen Testing in Assessing Nucleos/tide Analog Treatment Response and Disease Phenotype in Chronic Hepatitis B Patients in Canada

CR O'NEIL1, SE CONGLY1, SS LEE1, MA BORMAN1, CL CHARLTON2, C OSIOWY3, MG SWAIN1, KW BURAK1, CS COFFIN1

1University of Calgary, Calgary, AB, 2University of Alberta, Edmonton, AB, 3National Microbiology Laboratory, Winnipeg, MB

---

**P02**

Not Such a Lonely Planet: Travelers with Hand, Foot, and Mouth Disease Affecting Limbs, Trunk, and Face

J OSOWICKI1,2, M BADAWI1,2, M AL-RAWAHI1, WE REHMUS3, L SAUVÉ1, A GWEE2,3

1Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, University of British Columbia, BC Children's Hospital, Vancouver, BC, 2Infectious Diseases Unit, The Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia, 3Murdoch Childrens Research Institute, Parkville, Victoria, Australia

---

**P03**

Time to Reporting of Positive Blood Cultures for Pediatric Patients Assessed at a Children's Hospital Emergency Department

A WALKTY1, J KARLOWSKY1,2, J BULLARD1,2

1University of Manitoba, Winnipeg, MB, 2Diagnostic Services Manitoba, Winnipeg, MB, 3Cadham Provincial Laboratory, Winnipeg, MB

---

**P04**

Detection of Viral RNA Fragmentation as a Surrogate Measure of Virus Viability for Environmental Surveillance Projects

G POLIQUIN1,2, A GROLLA1, A LEUNG1, S JONES1, J STRONG1,2

1Public Health Agency of Canada, Winnipeg, MB, 2University of Manitoba, Winnipeg, MB
P05
Trends of Antimicrobial Resistance of Neisseria gonorrhoeae Strains in Québec from 2010 to 2014: Emergence of Sequence Type, ST-10567 Associated with Azithromycin Resistance
B LEFEBVRE1, A-C LABBE2, S VENNE1,2,3, I MARTIN1, P SAWATZKY1,2, C FORTIN1, A TRUDELLE1, G LAMBERT1, K BLOUIN1, F DOUALLA-BELL1, J LONGTIN2
1Institut national de santé publique du Québec, QC, 2National Microbiology Laboratory, Public Health Agency of Canada, MB, 3Ministère de la santé et des services sociaux du Québec, QC, Montréal, Montréal, QC
P06
Using Signal-to-Cutoff Ratios to Improve Reverse Sequence Algorithm for Phylogenies
C FORTIN1,2, A-C LABBE2, C TREMBLAY1,2, A TRUDELLE1, F DOUALLA-BELL1, G LAMBERT1, B SERHIR1
1Institut national de santé publique du Québec, Montréal, QC, 2Département de microbiologie, infectiologie et immunologie de l’Université de Montréal, QC
P07
Enhanced Selectivity for Targeted Killing of Streptococcus mutans by A Pheromone-Guided Antimicrobial Peptide
Y-H LI, X-L TIAN, K CYR, G DON, C CHEN, H SALIM
Dalhousie University, Halifax, NS
P08
WITHDRAWN
P09
The Performance of Direct Disk Diffusion for Community-acquired Bacteremia due to Gram-negative Bacilli, and its Impact on Physician Treatment Decisions
A COMERFORD, P DALEY, J UMALI, C PENNEY
Faculty of Medicine, Memorial University of Newfoundland and Labrador, St. John’s, NL
P10
Comparison of Two Chromogenic Media and an Enhanced Blood Plate Method for the Purpose of GBS Detection from Broth Enriched Vaginal/Rectal Samples
P KORNHERR, N RUNDLE, M MICHELIN, K DELCORDE
DynaCare, Ottawa, ON
P11
The Use of Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI ToF MS) to Determine Susceptibility of Candida glabrata to Caspofungin
L MCTAGGART1, R KARIYAWASAM1, R POOPALARAJAH1, IV KUS1
1Public Health Ontario, Toronto, ON, 2University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON
P12
Hiding in Plain Sight: How Do Prescription Practices and Clinical Outcomes Differ Between Known and Potential Extended-Spectrum Beta-Lactamase Producing Organisms?
M CHENG1, A CHENG2, S DE L’ETOILE-MOREL1, E MCDONALD1, T LEE1,2
1McGill University, Montréal, QC, 2University of Montréal, Montréal, QC
P13
Direct MALDI TOF identification and Vitek® 2 Antibiotic Susceptibility Testing of Enteric Gram Negative Bacilli from Blood Cultures
N HILLMER1,2, H JEWSBURY1,2, V HADWELL1,2, B WANG1,2, S WHITEHEAD1,3, E BLONDEL-HILL1,2, A WILMER1,2
1Kelowna General Hospital, Kelowna, BC, 2University of British Columbia, Vancouver, BC, 3Interior Health Authority, BC
P14
Outbreak of a Variant Strain of CMRSA-5 in a Neonatal Intensive Care Unit
N SANT1,2, J GORN1, N BRUCE1, K SUH1,2, M DESJARDINS1,2,3
1Eastern Ontario Regional Laboratories, Ottawa, ON, 2The Ottawa Hospital, Ottawa, ON, 3The University of Ottawa, Ottawa, ON
P15
Management of Malaria in [Large Canadian City]: A Multi-Faceted Quality Assurance Project Reviewing 2010-2013
V MEIER-STEPHENSON1, D SABUDA2, D PILLAI1,2, B MEATHERALL1
1Department of Medicine, Section of Infectious Diseases, Alberta Health Services and University of Calgary, Calgary, AB, 2Department of Pharmacy, Alberta Health Services, Calgary, AB, 3Departments of Microbiology, Immunology & infectious Diseases and Pathology & Laboratory Medicine, Calgary, AB
P16
Comparison of Four Different Serological Assays for Diagnosis of Hepatitis C Virus Infection
S GEIER1, J FENTON1, CL CHARLTON1,2
1University of Alberta, Edmonton, AB, 2Provincial Laboratory for Public Health, Edmonton, AB
P17
Alere i Influenza A&B Isothermal Molecular Assay Performance in Direct Fluorescent Antibody Indeterminate and False Negative Samples in a Pediatric Setting
L BOOK1, N WATSON1, V YOUNG1, G AL-RAWAH1,2, P TILLEY1,2, D GOLDFARB1,2
1Microbiology Laboratory BC Children’s Hospital Lower Mainland Pathology and Laboratory Medicine, Vancouver, BC, 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC
P18
Facility Characteristics Incorporation in Standardized Incidence Ratios for Central-Line Associated Bloodstream Infections (CLABSI)
L LI1, E FORTIN1, M NGENADA-MUADI1, C TREMBLAY1,2, C QUACH1
1Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, QC, 2Institut National de Santé Publique du Québec, Montréal, QC, 3Centre Hospitalier Universitaire de Québec, Québec, QC, 4Department of Medical Microbiology and Infectious Diseases, McGill University Health Center, Montréal, QC, 5Department of Pediatrics, The Montreal Children’s Hospital, Montréal, QC
P19
Effects of Storage Time and Temperature on the Ability of Hologic’s Aptima HPV Assay to Detect HPV in Cervical Samples Collected in Surepath Preservative
K DUST1, A HEDLEY1, P VAN CAESEEL1,2
1Cadham Provincial Lab, Winnipeg, MB, 2University of Manitoba, Department of Medical Microbiology, Winnipeg, MB
POSTER PRESENTATIONS

P20
A New Brunswick Case of California Serogroup Virus Infection Associated with Probable Encephalitis and Cognitive Impairment
K DIMITROVA1, K HOLLOWAY1, K MAKOWSKI1, D SAFRONETZ2, D DREBOT1, D WEBSTER1
1Public Health Agency of Canada, Winnipeg, MB, 2Horizon Health Network, Saint John's, NB

P21
Continuing Hospital Exposure Despite Active Surveillance for Influenza
BL COLEMAN2,3, W NG1, V MAHESH1, AJ MCGEER2,3, KC KATZ1,3
1North York General Hospital, Toronto, ON, 2Mount Sinai Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto, ON

P22
What Impact Does Plasma Storage Temperature have on HIV-1 Viral Load Quantification?
K KADIVAR1, S LAVOIE, J KIM
Public Health Agency of Canada, Winnipeg, MB

P23
Qualitative and Quantitative Assessment of Whole Genome Amplification kits for Next Generation Sequencing of Scarc DNA
K ANTONATION1, I CUNNINGHAM1, P MABON1, C CORBETT1,2
1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 2Department of Medical Microbiology, University of Manitoba, Winnipeg, MB

P24
Withdrawn

P25
A 63-year-old Man with an Unusual Aetiology of Cough
LO PARKES, MP CHENG, M LIBMAN
McGill University Health Centre, Montréal, QC

P26
Withdrawn

P27
Rapid Identification of Bacteria Recovered Directly from Positive Blood Cultures using the MALDI-TOF mass spectrometer (Vitek®-MS, bioMérieux)
K HEGGLIN1, J MINION1,2, K MALEJCZYK1,2
1Regina Qu’Appelle Health Region, Department of Laboratory Medicine, Regina, SK, 2University of Saskatchewan, College of Medicine, Department of Pathology and Lab Medicine, Regina, SK

P28
Increased Parvovirus B19 Activity in Newfoundland and Labrador (NL), Canada in 2015
A ANDONOV1, L GILBERT2, C LAYNE1, R NEEDLE2, S RATNAM2
1Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, MB, 2Department of Public Health Laboratory, St. John’s, NL

P29
Implementation of Centralized IGRA testing in British Columbia Partnering with Laboratories across British Columbia
Y SIMPSON1, Q WONG1, M ROMNEY2, P KIBSEY1, E BLONDEL-HILL3, R DUMONT3, B MACK5, V COOK7, M MORSHEDE4
1British Columbia Public Health Laboratory (BC PHL); 2St Paul’s Hospital, Vancouver; 3Royal Jubilee Hospital, Victoria; 4Kelowna General Hospital, Kelowna; 5University Hospital of Northern BC, Prince George; 6Surrey Memorial Hospital, Surrey; 7BC Centre for Disease Control TB Services; 8Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

P30
Evaluation of a New Zeus VlsE-1/pepC10 IgG/IgM Lyme ELISA on the Dynex DS2 Automated Platform
Y SIMPSON1, R WADA1, M KWOK1, I WONG1, Q WONG1, M MORSHEDE1,2,4
1British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

P31
Clinical Features of Influenza- and Respiratory Syncytial Virus-Positive Adult Cases during the 2014-2015 Winter Season: A Retrospective Cohort Study from a Tertiary Medical Centre in Québec
E GAUDREAUT1, J-F ROUSSY, G BOIVIN
Centre Hospitalier Universitaire de Québec, Université Laval, Québec, QC

P32
Quality of Design and Reporting of Studies of Commercial Point-of-Care Diagnostic Tests
JM HUGHES1, P DALEY1,2
1Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, 2Eastern Health, St. John’s, NL

P33
Descriptive Epidemiology of HIV Point-of-Care Testing (POCT) in Manitoba from 2011 to 2014
J JOHNSTON1, J WYLIE2,3, J REIMER2,4, J BULLARD2,5
1College of Medicine, University of Manitoba, Winnipeg, MB, 2Manitoba Health and Healthy Living and Seniors, Winnipeg, MB, 3Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 4Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, 5Department of Pediatrics and Child Health, Winnipeg, MB

P34
Evaluation of the Luminex® MAGPIX® NxTAG™ Respiratory Pathogen Panel
A JASSEM1,2, R CHOW1, R AZANA1, K GUNADASA1, A PACCAGNELLA1, A MCNABB1, L HOANG1,2, M KRAJDEN1,2
1British Columbia Centre for Disease Control Public Health Laboratory, Provincial Health Services Authority, Vancouver, BC, 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC
POSTER PRESENTATIONS

P35
Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae are Not Associated with Decreased Survival in Patients with Bloodstream Infections
NF DEWHURST, SM POUTANEN, B HAMANDI, LW GONEAU, L DRESSER, M PITRE, AYC LIN, MD MISTRY, L GRAHAM, E CHUNG, DO LOWE
1St. Michael's Hospital, Toronto, ON, 2University of Toronto, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON, 4University Health Network, Toronto, ON, 5London Health Sciences Centre, London, ON, 6Kingston General Hospital, Kingston, ON, 7The Hospital for Sick Children, Toronto, ON

P36
Decreasing Time to Antimicrobial Susceptibility Testing Results Using a Novel Lysis Centrifugation Method Directly from Positive Blood Cultures
LW GONEAU, A CAMPIGOTTO, R FATTOUH, J NADARAJAH, LM MATUKAS
1University of Toronto, Toronto, ON, 2St. Michael's Hospital, Toronto, ON

P37
Blinded Comparison of Performance and Cost Effectiveness of Chromogenic and Direct Latex Methods for Detection of Group B Streptococcus, with In-House PCR and LAMP as Reference Standards
C PENNEY, J UMALI, R NEEDLE, P JAYARATNE, F JANES, E TAH, P DALEY
1Memorial University of Newfoundland, St. John's, NL, 2Newfoundland and Labrador Public Health Laboratory, St. John's, NL, 3McMaster University, Hamilton, ON, 4Eastern Health, St. John's, NL

P38
Comparison of Monoplex and Duplex RT-PCR Assays for the Detection of Measles Virus
K BINKHAMIS, J HIEBERT, L MENDOZA, JD LAFRENIERE, TF HATCHETTE, JJ LEBLANC
1Nova Scotia Health Authority (NSHA) and Dalhousie University, Halifax, NS, 2Viral Exanthemata and STDs, National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, MB

P39
Pneumonia in the ICU: Comparing Criteria for Pneumonia Diagnosis and Treatment in ICU Patients at Hamilton Health Sciences
N SZABOLCS, N IRFAN, A BROOKS, D MERTZ
1Hamilton Health Sciences, Hamilton, ON, 2University of Waterloo, Waterloo, ON, 3McMaster University, Hamilton, ON

P40
Comparison of Two Automated Instruments for Epstein Barr virus (EBV) Serology Testing
H AL SIDAIRI, C JACKSON, C HEINSTEIN, R NEEDLE, TF HATCHETTE, JJ LEBLANC
1Nova Scotia Health Authority (NSHA) and Dalhousie University, Halifax, NS, 2Public Health Laboratory & Microbiology, Eastern Health, St. John's, NL

P41
Impact of a Urinary Tract Infection Management Bundle on Microbiology Laboratory Workload
C ELLIS, D SMYTH, T MACLAGGAN, T WILCOX-CARRIER, Z HUSSAIN
1The Moncton Hospital, Moncton, NB, 2Department of Medicine, Dalhousie University, Halifax, NS, 3Horizon Health Network, Moncton, NB

P42
Susceptibility Results of Urinary Strains of E. coli isolated from Four Distinct Outpatient Groups
C ELLIS, G DOW, K YOUNG, Z HUSSAIN
The Moncton Hospital, Moncton, NB

P43
Evaluation Of CHROMagar TM Campylobacter (CAC)
L FORSBERG, C BARTH, K MALEJCZYK, J MINION
Regina Qu’Appelle Health Region, Regina, SK

P44
Exploring the Next Generation Sequence Analysis Pipeline for Lyme Disease Causing Agent
M-K LEE, W HSIAO, Q WONG, M MCCABE, M MORSHED
1BC Centre for Disease Control - Public Health Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC

P45
Impact of a Urinary Tract Infection Management Bundle on Microbiology Laboratory Workload
C ELLIS, D SMYTH, T MACLAGGAN, T WILCOX-CARRIER, Z HUSSAIN
1The Moncton Hospital, Moncton, NB, 2Department of Medicine, Dalhousie University, Halifax, NS, 3Horizon Health Network, Moncton, NB

P46
Susceptibility Results of Urinary Strains of E. coli isolated from Four Distinct Outpatient Groups
C ELLIS, G DOW, K YOUNG, Z HUSSAIN
The Moncton Hospital, Moncton, NB

P47
Exploring the Next Generation Sequence Analysis Pipeline for Lyme Disease Causing Agent
M-K LEE, W HSIAO, Q WONG, M MCCABE, M MORSHED
1BC Centre for Disease Control - Public Health Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC

P47
医师和药剂师对使用协同路径的抗生素管理程序（ASP）的看法
C NOTT, R ZYONAR, T LLOYD, J SQUIRES, V ROTH, K SUH
1The Ottawa Hospital Research Institute, Ottawa, ON, 2Department of Medicine, University of Ottawa, Ottawa, ON, 3Ottawa Hospital Research Institute, Ottawa, ON

P48
PCR is Useful as a Supplemental Test in the Reference Laboratory to Assist with Diagnosis of Amoebiasis in Liver Samples
T LO, Q WONG, M MORSHED, M-K LEE
1BCDC Public Health Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC

P49
Pan-Hospital Participation within a Single Metropolitan Region in the Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (GLOBAL-PPS) – A Tool for Identification of Targets for Quality Improvement (QI) in Antimicrobial Stewardship (AS)
D SABUDA, N RAJAPAKSE, D GRAVEL TROPPER, O LARIO, J KIM, J VAYALUMKAL, B MISSAGHI, D WERRY, A VERSPORTEN, H GOOSSENS, J CONLY
1Alberta Health Services, Calgary, AB, 2University of Calgary, Calgary, AB, 3Public Health Agency of Canada, Ottawa, ON, 4University of Antwerp, Antwerp, Belgium
P48  Confirmation of Neisseria gonorrhoeae Positive NAAT Results: Are Preservation and Transport Media Compatible Across Assays for Validation Purposes?

D Murphy1, C Fortin1,2, J Longtin1,4, I Tetrault1,3, C Tremblay1,3, B Lefebvre1, B Filatrault2, S Gourd3, A-C Labbe4,5

1InstitutnationaldedesantépubliqueduQuébec,Montréal,2Centrehospitalierdel’universitédeMontréal,Montréal,3CHUdeQuébec,Québec,4CIUSSdel’est-de-l’île-de-Montréal,Montréal,5CISscoreS

P49  A Retrospective Observational Cohort Study of HCV Re-Infection in High-Risk People Who Inject Drugs

S Hakobyany, S Vafadary, T Raycraft, G Kiani, S Sharma, B Conway

Vancouver Infectious Diseases Centre, Vancouver, BC

P50  Surveillance of Invasive Streptococcus pyogenes in Southwestern Manitoba

P Pieroni

1DSM, Westman Laboratory, Brandon, MB, 2Brandon University, Brandon, MB

P51  Challenges in Developing a Real-Time PCR Assay for Hepatitis C Virus Genotyping

T Lee1, A Olmstead2, A McNabb1, M Krajden1,3, A Jassem1,2

1British Columbia Centre for Disease Control Public Health Laboratory, Provincial Health Services Authority, Vancouver, BC, 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

P52  Development of a Fast Triplex Real-time RT-PCR for the Detection of Norovirus Genotypes I and II in RNA Extracts from Stool and Vomitus Specimens

D Eisler1, A McNabb1, T Hirid1, F Tsang1, B Auk1, L Hoang1,2

1British Columbia Centre for Disease Control Public Health Laboratory, Provincial Health Services Authority, Vancouver, BC, 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

P53  Development of a Fast Multiplex Real-time PCR for the Detection of Chlamydiaphila pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in DNA Extracts from Atypical Pneumonia Specimens

D Eisler1, A McNabb1, L Janz1, A Paccagnella1, N Prystajecky1,2, P Tang1, L Hoang1,2

1British Columbia Centre for Disease Control Public Health Laboratory, Provincial Health Services Authority, Vancouver, BC, 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

P54  WITHDRAWN

P55  Use of Genome Sequencing to Inform Diagnostic Assay Development for Streptococcus pneumoniae and S. pseudopneumoniae

MA Croxen1, T Lee1, L Hoang1,2

1British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, 2Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC

P56  Comparison of Four Assays for Detection of Clostridium difficile Toxin

N Watson, B Shkurattoff, M Margach, E Browne, P Tilley, G Al-Rawahi

BC Children’s and Women’s Hospital Microbiology Laboratory, Vancouver, BC

P57  Implementing the BD BACTEC™ FX in the ER Department – a Lakeridge Health Lean Initiative

GR Johnson4, G Johnson1, L Galama2

1Lakeridge Health Care, Oshawa, ON, 2BD Canada, Mississauga, ON

P58  Development of Antimicrobial Stewardship Online Resources by Public Health Ontario

R Zvonar3, C Johanson1,2, A Hogg1,3, S Raybardhan1,4, J Cook1,5,7, GA Evans6,8, G Didiodato9,4, G Garber1,9,10

1Public Health Ontario, Toronto/Ottawa ON, 2The Ottawa Hospital, Ottawa ON, 3Markham Stouffville Hospital, Markham ON, 4North York General Hospital, Toronto ON, 5Grey Bruce Health Services, Owen Sound ON, 6Kingston General Hospital, Kingston ON, 7Queens University, Kingston ON, 8Royal Victoria Regional Health Centre, Barrie ON, 9Ottawa Hospital Research Institute, Ottawa ON, Canada, 10University of Ottawa/University of Toronto, Ottawa/Toronto ON

P59  A Survey of Current Practice for Detection of Gastrointestinal Pathogens in Canadian Microbiology Laboratories

E Feria1,2, A Petrich1

1The Hospital for Sick Children, Toronto, ON, 2Markham Stouffville Hospital, Markham, ON

P60  Genetic Characterization of the Infrequent Clindamycin-Resistant/Erythromycin-Susceptible (CR/ES) Phenotype in Gram-positive Coccici

A Cabrera5, M Kissou2, BM Willey4, SM Poutanen3

1Clinical Microbiology Program, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, 2Microbiology Department, Mount Sinai Hospital, Toronto, ON

P61  Prospective Evaluation of bioMérieux’s chromID CARBA-SMART (C-S) Agar Bi-Plate used with bioMérieux’s RAPIDEC CARBA-NP (RC) Assay for Rapid Phenotypic Detection of Carbapenemase-Producing Organisms (CPO) from Surveillance eSwabs (SS)

BM Willey2, G Ricci4, A Magaloni2, E Villena4,5, DA Boyd4, L Mataseje3, Pauline LO1,2, MR Mulvey3, T Mazzulli3,2, SM Poutanen1,2

1Mount Sinai Hospital, Toronto, ON, University Health Network, Toronto, ON, 2University of Toronto, Toronto, ON, 3William Osler Health Sciences Centre, Brampton, ON, 4National Microbiology Laboratory, Winnipeg, MB
Prospective Evaluation of Bio-Rad's BCARBA (BC) Assay Tested from Various Agars for Rapid Phenotypic Detection of Diverse Carbapenemase-Producing Organisms (CPO)

BM WILLEY1,2, DA BOYD3, L MATASEJE3, G RICCI4, P LO5, MR MULVEY3, T MAZZULLI1,2, SM POUTANEN1,2,5
1Mount Sinai Hospital; 2University Health Network; 3National Microbiology Laboratory, Winnipeg, MB; 4University of Manitoba, Winnipeg, MB; 5University of Toronto, Toronto, ON

Antibiotic Decision-Making: Perceived Competencies and Needs of Paediatric Residents at a Tertiary Centre

M BARTON, D BOCK, J GRIMMER, M SALVADORI
University of Western Ontario, London, ON

Histoplasma capsulatum var. duboisi isolates from a patient over 5 years post exposure

S MASUD1, I SEKIROV1, S BORDER3, B WANG4, A CHURG5, A FERRIS6, M MORSHED1,2, L HOANG1,5
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; 2Mount Sinai Hospital, Toronto, ON; 3British Columbia Centre for Disease Control, Vancouver, BC

Impact of Hospital-Acquired Viral Respiratory Tract Infections (HA-VRTIs) in Children Admitted to a Tertiary Care Hospital in Montreal, Quebec between 2009-2014

J KEEN1, C PERPETE1, L MOISAN2, C QUACH1,2,3
1Department of Infectious Diseases and Medical Microbiology, McGill University, Montréal, QC; 2Division of Infection Prevention and Control, Fraser Health Authority, Surrey, BC; 3Division of Medical Microbiology and Infection Control, Vancouver Coastal Health, Vancouver, BC

A Novel Mutation D404N in the Connection Subdomain of Reverse Transcriptase of HIV-1 CRF08_BC Subtype Confers Cross-Resistance to NNRTIs

XM ZHANG, BL ZHENG
Department of Microbiology, The University of Hong Kong, Hong Kong, Hong Kong

Viral Respiratory Tract Infections (VRTIs) in the Intensive Care Unit (ICU): Clinical Definitions, Findings and Outcomes

S KASSIM1,2, E CUDEK2,3, T MAZZULLI1,2, AJ MCGEE4
1University of Manitoba, Winnipeg, MB; 2Division of Infection Prevention and Control, Fraser Health Authority, Surrey, BC; 3Division of Medical Microbiology and Infection Control, Vancouver Coastal Health, Vancouver, BC; 4British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC

Detection of Group B Streptococci (GBS) by Isothermal Amplification: An Affordable, and Rapid Point-of-Care Alternative to Expensive Commercial Molecular Diagnostic Tests

F ALMUTAWA1,2, P JAYARATNE3,4
1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON; 2Saudi Ministry of Education, Riyadh, Saudi Arabia; 3Hamilton Health Science, Hamilton, ON; 4St. Joseph's Healthcare, Hamilton, ON

Student Posters

Infectious Diseases Consultation at Academic Tertiary Centres in Toronto, Ontario

A VAISMAN1,2, K GOUGH3,4, AE SIMOR1,4, W GOLD1,2,4
1University Health Network, Toronto, ON; 2St. Michael's Hospital, Toronto, ON; 3Sunnybrook Health Sciences Centre, Toronto, ON; 4Division of Infectious Diseases, University of Toronto, Toronto, ON

Enterovirus as an Emerging Respiratory Pathogen: the NL Paediatric Experience

A COMERFORD, N BRIDGER
Faculty of Medicine, Memorial University of Newfoundland and Labrador, St. John's, NL

Detection of Group B Streptococci (GBS) by Isothermal Amplification: An Affordable, and Rapid Point-of-Care Alternative to Expensive Commercial Molecular Diagnostic Tests

F ALMUTAWA1,2, P JAYARATNE3,4
1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON; 2Saudi Ministry of Education, Riyadh, Saudi Arabia; 3Hamilton Health Science, Hamilton, ON; 4St. Joseph's Healthcare, Hamilton, ON
POSTER PRESENTATIONS

**SP05**
Verification of the Alere™ Influenza A & B Test for the Rapid Detection of Influenza A/B from Nasopharyngeal Swabs and Aspirates

N ZELVAS1, S SHOKOPLES3, L DROGERS1, D LEEDELL1, R LUNDERBERG1, S J DREWS1,3
1Alberta Provincial Laboratory for Public Health, Edmonton, AB, 2Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, 3Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB

**SP06**
12 weeks of Sofosbuvir-Ledapavir versus Sofosbuvir-Ledapavir-Ribavirin in Chronic Hepatitis C, genotype 1: A Systematic Review and Meta-Analysis

W STOKES, C FENTON, F CLEMENT, K TANG
University of Calgary, Calgary, AB

**SP07**
A Case of Subacute Native-Valve Infective Endocarditis Caused by Cardiobacterium hominis

L VASANTHAMOHAN, C HOU, N KRONFLI, A PREBTANI, A SHROFF
McMaster University, Hamilton, ON

**SP08**
Characteristics of Pneumonia Admissions in HIV Positive Individuals: A Single Centre 10 Year Cross-sectional Retrospective Analysis

S VAN GAALEN1, Z RUEDA1, L ARROYAVE2, K KASPER1, Y KEYNAN1,2
1University of Manitoba, Winnipeg, MB, 2Health Sciences Centre, Winnipeg, MB, 3Universidad de Antioquia, Medellín, Colombia, 4Universidad Pontificia Bolivariana, Medellín, Colombia

**SP09**
First Reported Human Case of Cryptococcus gattii Meningoencephalitis with Local Acquisition in Eastern Canada

J ST PIERRE1, P DUFRESNE2, J DÉSEILLET3, J LONGTN2, L LEBLANC2
1Hôpital Sacré-Cœur de Montréal, Montréal, QC, 2Laboratoire de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC, 3Direction de Santé Publique du CISS Lanaudière, Joliette, QC

**SP10**
Frequency and Types of Positive Blood Culture Gram Stain Interpretation Errors – Association with Technologists’ Experience

C ELLIS1,2, D MEDJUCK3, L ROY3, B TOYE1,2,3
1The Ottawa Hospital, Ottawa, ON, 2University of Ottawa, Ottawa, ON, 3Eastern Ontario Regional Laboratory Association, Ottawa, ON

**SP11**
In Vitro Susceptibility to Fosfomycin of Escherichia coli and Enterococcus Urinary Isolates from a Canadian Tertiary Care Hospital

TT NGUYEN, DC VINH, TC LEE, VG LOO
McGill University Health Centre, Montréal, QC

**SP12**
Binoculars to Bird Flu: Using Citizen Science to Study the Ecology of Avian Influenza in Wild Waterfowl

M COOMBE1,2, C HIMSWORTH1,2, G GADSDEN1, P TANG1,2, N PRYSTAJECKY1,2, W BATICADOS1, W HSIAO1,2, A JASSEM1
1University of British Columbia, Vancouver, BC, 2BC Centre for Disease Control, Vancouver, BC, 3Ministry of Agriculture, Abbotsford, BC, Canada, 4Fraser Valley Birding, Abbotsford, BC

**SP13**
Group B Streptococcal Sternotomy Sepsis: A Case Report and Review

D WHELLMANS1, P EL-HELOU2,3
1McMaster University, Hamilton, ON, Canada, 2St Joseph’s Healthcare, Hamilton, ON

**SP14**
The Indirect Effects of Childhood Pneumococcal Conjugate Vaccine (PCV) and Community Acquired Pneumonia (CAP) in Adults: A Systematic Review

H KRAICER-MELAMED1,2, S O’DONNELL1,2, C QUACH1,2,3,4
1Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montréal, QC, 2MUHC Vaccine Study Centre – Research Institute, McGill University Health Centre, Montréal, QC, 3Department of Pediatrics, Division of Infectious Diseases, McGill University, Montréal, QC, 4Institut national de santé publique du Québec, Montréal, QC

**SP15**
The α-Hemolysin (Hla) Gene Knockout (KO) in MRSA USA300 Alters the Local Host Cytokine/Chemokine Profile to Levels of MRSA Non-Dermonecrosis Strains in a Murine Dermonecrosis Model

J ZHANG1, J CONLY1,2,3, K WU1, M HARDING1, JZ DELONGCHAMP2, M COOMBE1,3, C HIMSWORTH1,3, M VEARNCOMBE1,2, AE SIMOR1,2
1University of Toronto, Toronto, ON, 2Sunnybrook Health Sciences Centre, Toronto, ON, 3Institute for Clinical Evaluative Sciences, Toronto, ON

**SP16**
Determination of the Volume of Distribution for Pyrazinamide and Ethambutol using Serum Drug Levels in the Treatment of Mycobacterium tuberculosis

J CHEN, D KUNIMOTO
University of Alberta, Edmonton, AB

**SP17**
Close Encounters: Using Sociometric Devices to Map and Measure Network Interactions and Bacteria in a Pediatric Emergency Department

R WHITESIDE, R HAGTVEDT, B WRIGHT, S FORGIE
University of Alberta, Edmonton, AB

**SP18**
Hidden Resistance: Treatment Implications of a Possible Inducible Beta-Lactamase in Pantoea agglomerans

N MATIC1,2, S MUBAREKA1,2, M VEARCOMBE1,2, AE SIMOR1,2
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, 2Department of Microbiology, Sunnybrook Health Sciences Centre, Toronto, ON

**SP19**
Incidence and Risk Factors of Infection Following Transcatheter Aortic Valve Implantation (TAVI)

Y SHIH1, HC WIJEYSUNDERA1,2, S FREMES1,2, AE SIMOR1,2
1University of Toronto, Toronto, ON, 2Sunnybrook Health Sciences Centre, Toronto, ON, 3Institute for Clinical Evaluative Sciences, Toronto, ON
POSTER PRESENTATIONS

SP20 Fatal Case of Aspergillus fumigatus Empyema Necessitans in a Patient with Cystic Fibrosis Post Double-Lung Transplant – a Case Report and Review of Literature

G YU, H RABIN, M PARKINS
University of Calgary, Calgary, AB

SP21 Microbiology Laboratory Technologist Clinical Review Program

M REHAN1, B ALBARADI2, D JOHNSON3, D MERTZ4, C MAIN5,6
1McMaster University, Hamilton, ON, 2Hamilton Regional Laboratory Medicine Program, Hamilton, ON

SP22 The Utility of BACTEC MYCO/F and BacT/ALERT MB Fungal Blood Culture Bottles for the Detection of Invasive Fungal Infections: A 5-year Review at the McGill University Health Centre (MUHC) in Montréal, QC

J KEEN, M PLANTE, DC SHEPPARD
Division of Infectious Diseases and Department of Medical Microbiology, McGill University Health Centre, Montréal, QC

SP23 Direct Cefoxitin Disk Diffusion Testing from Blood Cultures with Gram Positive Cocci in Clusters for Rapid Identification of Methicillin Susceptibility for Staphylococcus aureus

S MASUD1, S CHAMPAGNE1,2
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, 2Department of Microbiology, Saint Paul Hospital, Vancouver, BC

SP24 Exploiting Peptide Mimetics as Novel Therapeutics for Respiratory Syncytial Virus

C CHIANG1,2, J NELSON1,2, D BULIR1,2, S LIANG1,2, K MWAWASI1,2, S MIHALCO1,2, Z SCI NOCCA1,2, J MAHONY1,2
1McMaster University, Hamilton, ON, 2Father Sean O’Sullivan Research Centre, St. Joseph’s Healthcare, Hamilton, ON

SP25 Developing a Dengue Antiviral Drug via Computational-Aided Screening

V MEIER-STEPHENSION1, A CHAMBERLAIN2, S NOSKOV1, B METHERALL1, A NARENDRA1, R TELLIER1, M TRAYKOVA-ADONOVA1, M DREBOT1

SP26 Does Molecular Testing for Influenza and Clostridium difficile toxin B Improve Patient Flow in the Emergency Department (ED)?

A CABRERA1,2, A NOORANI1, C MOORE3, J SO4, E CUDEK1, J NG5, L LAW6, T MAZZULLI1,2, SM POUTANEN1,2, A MC GEER1,2
1University of Toronto, Toronto, ON, 2Mount Sinai Hospital, Toronto, ON

SP27 A Simple Educational Intervention Aimed at Junior Residents During a General Internal Medicine Rotation improves Hand Hygiene Compliance

A SONPAR, N KASSAM, A TAPARDEL, S SMITH
University of Alberta, Edmonton, AB

SP28 Review of Human Parechovirus (HPeV)-Associated Central Nervous System (CNS) Infections in Infants Admitted to a Canadian Pediatric Tertiary Hospital

I SEKIROV1, M HASAN1,2, G AL-RAWAH1,2, E THOMAS1,2, R TAN1,2, P TILLEY1,2
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, 2Division of Microbiology, Virology and Infection Control, Department of Pathology, Children's and Women's Health Centre of BC, Vancouver, BC, 3Department of Pathology, Sidra Medical & Research Center, Doha, Qatar

SP29 Central Line Association Bloodstream Infections in Québec Intensive Care Units: Results from the Provincial Healthcare-Associated Infections Surveillance Program (SPIN)

L LI, E FORTIN2, M NGENDA-MUADI1, C TREMBLAY1-3, C QUACH1
1Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, QC, 2Institut National de Santé Publique du Québec, Québec and Montréal, QC, 3Centre Hospitalier Universitaire de Québec - Pavillon Hôtel-Dieu de Québec, Québec, QC

SP30 A Study of Clinical Staphylococcus pseudintermedius Isolated from 24 Patients

R PRIYANTHA1, R SOMAYAJI1, D CHURCH1,2, J RUBIN1
1Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK, 2Department of Pathology & Laboratory Medicine and Medicine, University of Calgary, Calgary, AB, 3Calgary Laboratory Services, Calgary, AB

SP31 Multiple Cerebral Abscesses in an Immunocompromised Patient

M ELLIOTT1, D DIXIT1,2
1University of Saskatchewan, Saskatoon, SK, 2University of Alberta, Edmonton, AB
**POSTER PRESENTATIONS**

**SP32**
SMARTenAPP: The Development of a Web-Based Application as an Antimicrobial Stewardship Intervention: A Pilot Project

R MEDFORD1, S SRIVASTAVA2, GA EVANS3
1Division of Infectious Diseases - University of Ottawa, Ottawa, ON; 2Division of General Internal Medicine - Queen’s University, Kingston, ON; 3Division of Infectious Diseases - Queen’s University, Kingston, ON

**SP33**
Evaluation of the Matrix-Assisted Laser Desorption Ionization - Time of Flight Mass Spectrometry (MALDI-TOF MS) for the Identification of Cystic Fibrosis Pathogens

N NASHID, Y YAU
The Hospital for Sick Children, Toronto, ON

**Incubator Posters**

**IP01**
Verification of the RIDA®GENE Pertussis Real Time PCR Kit for the Detection of Bordetella pertussis and Other Bordetella Species from Nasopharyngeal Swabs Collected in Regan-Lowe Media

HY ZHOU1,2, S SHOKOPLES1, D ADACHI1, B DETWILER1, M HAY3, ADACHI1, B DETWILER1, M HAY3
1ProvLab Alberta, Edmonton, AB; 2Edmonton, AB; 3Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB

**IP02**
Enhancing a Caesarean Section Surgical Site Infection Surveillance System through Automated Texting and Email

V LEUNG1, M MCNAUGHTON1, C LOWE1,2, K LAPORTE1, E LLOYD-SMITH1
1Providence Health Care, Vancouver, BC; 2University of British Columbia, Vancouver, BC

**IP03**
Characterization of Novel γ-lactam Antibacterial Compounds Against Clostridium difficile and Drug Resistant Staphylococcus aureus

A FONG1,2, A DOUGLAS1,2, J KNOCKLEY1, VR SOLOMON1, H LEE1,2,3
1Laurentian University, Sudbury, ON; 2Advanced Medical Research Institute of Canada, Sudbury, ON; 3Northern Ontario School of Medicine, Sudbury, ON

**IP04**
Simultaneous Detection of Common Pathogens in Pediatric Empyema Using Loop-Mediated Isothermal Amplification (LAMP)

L JIAO1, Y YU1, B ALBARADI1, L DALLE VEDOVE1, J PERNICA1, P JAYARATNE1
1Medical Microbiology Residency Training Program, Pathology and Molecular Medicine, McMaster University, Hamilton, ON; 2Hamilton Regional Laboratory Medicine Program, Hamilton, ON; 3Microbiology Fellow, Medical Microbiology Residency Training Program, McMaster University, Hamilton, ON; 4the Division of Infectious Disease, Department of Pediatrics, McMaster University, Hamilton, ON; 5Project supervisor, the Division of Molecular Microbiology, St. Joseph Healthcare; McMaster University, Hamilton, ON

**IP05**
Piperacillin-Tazobactam in ESBL Escherichia coli: Should Reporting Be Revisited?

S DE L’ETOILE-MOREL1, M CHENG2, E MCDONALD1, A CHENG1, H ROBSON2, T LEE1,2
1McGill University Health Centre, department of Internal Medicine, Montréal, QC; 2McGill University Health Centre, Department of Infectious Diseases, Montréal, QC; 3Ecole Polytechnique de Montréal, Montréal, QC

**IP06**
Monitoring the Net Clinical Impact of Resistance: Composite Indices Show Improvement in our Ability to Cover Severe Device-Associated Infections in an Academic ICU since 2000

J HUGHES1, A HURFORD2, R FINLEY3, DM PATRICK4,5, J WU1, AM MORRIS6,7
1York University, Toronto, ON; 2Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, NL; 3Public Health Agency of Canada, Guelph, ON; 4British Columbia Centre for Disease Control, Vancouver, BC; 5University of British Columbia, Vancouver, BC; 6Mount Sinai Hospital and University Health Network, Toronto, ON; 7University of Toronto, Toronto, ON

**IP07**
A Potential Novel Treatment for Malaria Infections: Magnetic Extraction of Paramagnetic Particles from a Free Flowing System

A LAWANDI1, C SKINNER2
1McGill University Health Centre, Montréal, QC; 2Concordia University, Montréal, QC

**IP08**
Not your Usual Appendicitis

I ADEKANMBI1, D DIXIT1,2, J ZHU3
1Department of Medicine, Infectious Diseases, University of Alberta, AB; 2Department of Medicine, Infectious Diseases, University of Saskatchewan, SK; 3DynaLife, Edmonton, AB

**IP09**
PCR-Based Discrimination of Vaccine-Preventable Serotypes of Streptococcus pneumoniae

H GILLIS1, D GASTON1, I MARTIN2, M ELSherIF3, TF HATCHETTE1, S MCNEIL1, JJ LEBlANC1
1Canadian Center for Vaccinology (CCIV), Izaka Walton Killiam (IWK) Health Centre, Nova Scotia Health Authority (NSHA), and Dalhousie University, Halifax, NS; 2Streptococcus and STI Unit, National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, MB

**IP10**
Using Real-Time Computer-Generated Alerts to Identify Interventions and Optimize Antimicrobial Stewardship

P DOLCE1, L BERGERON, E LABRECQUE1, A BOVÎN1, H BERNATCHEZ
1CSSS Rimouski, Rimouski, Québec, QC; 2Université Québec Rimouski, Rimouski, QC
POSTER PRESENTATIONS

**IP13**
The Clinical Impact of a UTI Management Bundle in a Tertiary Care Teaching Hospital

**D SMYTH**1,2, **K IVerson**1,2, **C LE**1,2, **Z HUSSAIN**1, **T MACLAGGIN**1, **T WILCOX**1, **C ELLIS**1

1Moncton Hospital, Moncton, NB, 2Dalhousie University, Halifax, NS

**IP14**
Optimal Antimicrobial Prescribing – There’s an App for That!

**R MAJERE**1, **D GHAG**2, **T LAU**1,2, **W BOWIE**1,2, **S SHAJARI**1, **J GRANT**1,2

1University of British Columbia, Vancouver, BC, 2Vancouver Coastal Health, Vancouver, BC

**IP15**
Pharmacist Led Beta-lactam Allergy Skin Testing (BLAST) to Reduce Use of Alternate Second-Line Therapy Among Patients with Reported Beta-lactam Allergy

**JA LEIS**1,2, **L PALMAY**1, **J CAMPBELL**1, **S KOUJANIAN**1, **SA WALKER**1, **E WEBER**1

1Sunnybrook Health Sciences Centre, Toronto, ON, 2Department of Medicine and Centre for Quality Improvement and Patient Safety, University of Toronto, Toronto, ON

**IP16**
An Electronic Health System to Enhance Access and Delivery of Health Care to Urban Slum Dwellers and other Neglected Populations

**B BERENGER**, **B JAWHARI**, **H CHUNG**, **D JANZEN**, **P BACH**, **A ISAAC**, **A SALEH**

Innovative Canadians for Change, Edmonton, AB

**IP17**
Creation of a Novel Province-Wide Antimicrobial Stewardship Preceptorship Program – An Innovative Capacity Building Strategy for Stewardship Implementation

**D PASAY**1, **R CAPARINI**2, **J CONLY**2, **B DALTON**2, **M GURGUIS**3, **M GUNther**4, **D SABUDA**1, **J SLOBODAN**1, **D WERRY**2

1Alberta Health Services (Central Zone), Red Deer, AB, 2Alberta Health Services (Calgary Zone), Calgary, AB, 3Alberta Health Services (South Zone), Medicine Hat, AB, 4Alberta Health Services (Edmonton Zone), Edmonton, AB

**IP18** WITHDRAWN

**IP19**
Blastomycosis in Northwestern Ontario, 2004 to 2014

**D DALCIN**1, **SZ AHMED**2

1Northern Ontario School of Medicine, Thunder Bay, ON, 2Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON

**IP19** WITHDRAWN

**IP20** WITHDRAWN

**IP21**
Clinical Outcomes of Staphylococcus aureus Bacteremia Following Introduction of Mandatory Infectious Disease Specialist Consultation

**V VALBUENA**1, **A BAI**1, **A SHOWLER**1, **M STEINBERG**1, **AM MORRIS**1

1University of Toronto, Toronto, ON, 2University of Ottawa, Ottawa, ON, 3Mount Sinai Hospital, Toronto, ON, 4University Health Network, Toronto, ON

**IP22** WITHDRAWN
AUTHOR INDEX

A

Al-Rawahi G ............................................. P02, P17, P56, SP28
Adachi D ....................................................... IP01
Adhikari H .................................................. IP01
Adekannabi I ............................................... IP11
Adamković K ............................................... J02
Ahmed S ..................................................... IP19
Altair E ......................................................... G04
Alvarez M ................................................... O01
Andany N ................................................... P04
Andonov A ................................................... P28
Antonation K ............................................... P23
Aravind T ................................................... P70
Arroyave I ................................................... C08
Arthur J ....................................................... C04
Auk B ........................................................... P52
Avanes S ...................................................... J03
Avery L ...................................................... P63
Azana R ..................................................... I03, I04, P34

B

Bach P ......................................................... IP16
Badawi M ................................................... P02
Bai A .......................................................... P23
Balakumar S ............................................... O02
Barr E ........................................................ G04
Barth C ....................................................... P43
Barton M .................................................... L04, P65
Baticados W ............................................... D01, D02, SP12
Baxter M .................................................... B01, B04
Beaulieu MC ............................................... L03
Behati Y ...................................................... H03
Belouga L ................................................... P45
Bell C ........................................................ C02
Belzic N ...................................................... O04
Berenger B ................................................... IP16
Bergeron L ................................................... IP12
Bernard K ................................................... K04
Bernatko H ............................................... H01, H04, IP12
Berner A ..................................................... K04
Berr F ........................................................ B02
Bestman-Smith J ........................................... L03
Bilakova J .................................................... L03
Binkhamis K ............................................... P38
Blondel-Hill E ........................................... C01, P13, P29
Blouin K ..................................................... IP05
Bock D ........................................................ P65
Boyle-Le Rouge ........................................... G02
Boivin A .................................................... IP12
Boivin G ..................................................... L03, P31
Bonner C .................................................... K04
Bodhan S .................................................... L04
Book L ........................................................ P17
Boras V ...................................................... F03
Border S .................................................... P67
Berman MA ............................................... P49
Boudreau AA ........................................... H01, H04
Bowie W .................................................... IP14
Boyd DA ................................................... F01, F04, M02, M03, P61, P62
Bridgeau-Laughlin D .................................. P03
Bredikin E .................................................. I03, I04, P63, P73
Brooks A .................................................... P39
Brown K .................................................... J02
Brewe F ..................................................... P56
Bruce N ..................................................... P14
Brunetev P ................................................ P38
Bryce E .................................................... J05, P73
Burk D ........................................................ SP24
Bullard J ..................................................... N03, P03, P13
Burak KW .................................................. P01
Burde T ...................................................... K04
Burry L ...................................................... C02
Buseh K ..................................................... M04
Cabera A .................................................... F02, P60, SP26
Cally S ........................................................ J03
Campbell J ................................................ IP15
Camplano A ............................................... P36
Carparrini R ............................................... IP17
Carson I ..................................................... A01
Catt B ........................................................ J03
Chagla Z .................................................... G02
Chakroborty A ........................................... IP08
Chamberlain A .......................................... SP25
Champagne S ........................................... I03, J04, K02, P23
Chang Y .................................................... J03
Charlton CI ............................................... P01, P16
Chen C ...................................................... P07
Chen J ........................................................ SP16
Cheng A ................................................... IP05, P12
Cheng K .................................................... A03
Cheng M ................................................... IP05, P12
Cheng MP .................................................. L01, N04, P25
Chiang C ................................................... SP24
Choiette F .................................................. E04
Chong M .................................................. B02, C01, P02
Chow R ..................................................... P34
Chung E ..................................................... P35
Chung H .................................................... P16
Church D ................................................... SP30
Chung A ................................................... P67
Clément F .................................................. P06
Cloutier C .................................................. O04
Coffin CS .................................................. P01
Colin J ....................................................... J05
Coler H ...................................................... C02
Colin J ....................................................... J05
Comerford A ........................................... P09, SP02
Congly SE .................................................. P01
Conly J ..................................................... F03, IP17, P47, SP15
Constantinescu C ....................................... P01
Conway B ................................................ C03, G04, P49
Cook D ...................................................... O01
Cook J ........................................................ P58
Cook V ...................................................... P29
Coomeo MB ............................................... D01, D02, SP12
Corbett C .................................................. P23
Corpus C .................................................. J03
Courtelle F ................................................ E03
Crozet MA ................................................ I01, I03, I04, O03 (P54), P55
Cuche E ..................................................... P72, SP26
Cunningham I ........................................... P23
Cy R .......................................................... P07

D

Dalcin D .................................................... IP19
Daley P ..................................................... P09, P32, P37
Dalgaard O ................................................ G04
Dalle Vedove I ........................................... B03, IP04
Dalton B .................................................... IP17, P47
Daneman N ................................................ P04
Davies I .................................................... P01
De Etoile-Morel S ....................................... IP05, P12
Defalco K .................................................. L05
Degagne P ................................................ E01
Deekler R .................................................. P73
Delcorde K ............................................... P10
Delisle G .................................................. H01, H04
Dengelzampaz Z ........................................ F03, SP15
Dersch-Mills D .......................................... P01
Desilets J ................................................... SP09
Desjardins M ............................................ P14
Detweiler B ............................................... IP01
Devlin M ................................................... P04
Dewhurst NF ........................................... G03, P35
Dickson T ................................................... P73
Dididodato G ............................................. P58
Dimitrova K ............................................... D04, B02, P20
Dietz D ....................................................... IP11, SP31
Dolce P ..................................................... IP12
Domingo M ............................................... H01, H04
Dong C ..................................................... O03
Donovan T ................................................ J05
Dore G ...................................................... G04
Doualla-Bell F .......................................... P05, P06
Dow G ...................................................... P42
Drebot D .................................................... P20
Drebot M ................................................... D04, SP25
Dressler L .................................................. C02, G03, P35
Drews SJ ................................................... IP01, SP05
Droogers J ................................................ SP05
Dufresne P ................................................ SP09
Dunlop R ................................................... P29
Dunn K ..................................................... L05
Dust K ...................................................... N03, P19

E

Edge T ...................................................... M02
Elisier D ................................................... P52, P53
El-Helou P ................................................ SP13
Elliott M ................................................... SP31
Ellis C ...................................................... H02, IP13, P41, P42, SP10
Elsherif M ................................................ IP09
Esspen C ................................................... A01
Evans GE ................................................ P58, SP32

F

Faheem A ................................................ F02
Fakhruddin K ........................................... M02, M04
Fanella S ................................................... L04
Fattouh R ................................................ P36
AUTHOR INDEX

Fenton C ........................................ SP06
Fenton J ......................................... P16
Fera E ........................................... P08
Ferguson N .................................... C02
Fernando K .................................... K01
Ferris D ......................................... P67
Filitrailt B ...................................... P48
Finley R ......................................... IP07
Fong A .......................................... IP03
Fonseca K ...................................... D03
Forgie S .......................................... SP17
Forrester L ..................................... J05
Forsberg L ...................................... P43
Fortin C .......................................... P05,P06,P48
Fremes S ........................................ SP19
Fuller J .......................................... B01,B04,M04,N01

G
Gadsden G ...................................... SP12
Galama I ........................................ P57
Galanis E ....................................... B02,101
Ganges B ....................................... J05
Gane E .......................................... P56
Garber G ........................................ J02,P58
Gaskin M ....................................... A04
Gaston D ........................................ IP09
Gaudreault E .................................. P31
Geier S .......................................... P16
George D ........................................ C01,P02
German G ...................................... K04
Ghad D .......................................... IP14
Gilbert L ........................................ P28
Gillis H .......................................... IP09
Girard G ........................................ P39
Goggin P ........................................ E03
Gold W .......................................... P04,S01
Goldfarb D ..................................... P17
Goneau L ....................................... G03,P35,P36
Goossens H .................................... P47
Gorn L .......................................... P14
Gough K ........................................ SP01
Gould S ......................................... P48
Gourdeau M ................................... H01,H04
Graham M ...................................... G03,P35
Grant J .......................................... J02
Gravel Tropper D ......................... SP12

H
Hadwell V ..................................... P13
Hagtveld R .................................... SP17
Hakobyan S .................................... C03,P49
Haldane D ..................................... D04
Hamand B ...................................... G03,P35
Han G ........................................... J03
Harding M ..................................... SP15
Harrison RA ................................... D03
Hart G ........................................... J03
Hasan M ........................................ SP28
Hatchette TP .................................. D04,P09,P38,P40
Healy A ........................................ P19
Heggin K ...................................... P27
Henderson C .................................. P40
Henderson EA ................................ M04
Hiebert J ....................................... P38
Hillmer N ...................................... P04
Himsworth C ................................ D01,D02,S012
Hinshaw D .................................... D03
Hird T .......................................... P52
Hoang H ....................................... P04
Hoban D ........................................ B01,B04
Hoog A ......................................... P58
Holloway K ................................... P20
Hota S .......................................... G01
Hou C .......................................... SP07
Howe AY ...................................... G04
Hsiao W ........................................ D01,D02,N02,P44,S012
Hughes J ..................................... C02,P07
Hughes JM .................................... P32
Hurford A ..................................... J03,P29
Hussain Z ...................................... H02,P13,P41,P42
Huynh C ...................................... K04

I
Iaboni R ....................................... F01,F04,M01,M03
Irfan N ........................................ G02,P39
Isaac A ......................................... IP16
Iverson K ..................................... IP13

J
Jackson C ..................................... P40
Janardhanan M ................................ D07
Janes F ......................................... P37
Jang W ......................................... J04
Januja N ....................................... O01
Janz L .......................................... P53,P63
Jansen D ....................................... IP16
Jassim A ....................................... D01,D02,P34,P51,S12
Jawhari B ...................................... P16
Jayaratne P .................................... IP04,P37,S04
Jewsbury H ................................... P13
Jiao L .......................................... IP04
Jinnah F ....................................... J03
Joffe AM ....................................... D03
Joハンson C ................................... P58
Johnson D ..................................... A04,P21
Johnson G ..................................... P57
Johnson G ..................................... P57
Johnson BI .................................... D04
Johnston J ..................................... P33
Johnstone J ................................... F02,J02
Jones S ......................................... P04

K
Kadivar K ..................................... P22
Kadkhoda K ................................... A02
Kariravasam R ............................... A01,E01,P03
Karlsjofy J .................................... A01,E01,P03
Kasper K ....................................... SP08
Kassam A ...................................... P01
Kassam N ...................................... SP27
Kassim S ....................................... P27
Katz KC ....................................... F02,K01,P21
Keen J .......................................... P68,S22
Kerr E .......................................... J02
Keynan Y ...................................... SP08
Kiani G ......................................... C03,P49
Kirby P .......................................... I03,P29
Kim J ........................................... E04,P22,P47
Kind T .......................................... J01
Kissoom M ..................................... P60
Knockley J ..................................... A02
KoNo J .......................................... A03
Kohler P ....................................... F02
Kornherr P .................................... P10
Korver J ........................................ A04
Koufanian S .................................. IP15
Kraicer-Melamed H ....................... SP14
Kraiden M .................................... IP01,P34,P51
Kronfli N ...................................... IP08,S07
Kunimoto D ................................... SP16
Kuo M .......................................... A01,E01
Kus JY .......................................... P11
Kwok M ........................................ P30

L
Labbie A-C ................................... E03,P05,P06,P48
Labbreque E .................................. IP12
LaDefa A ....................................... P04
Lafriere JD ................................... P38
Lagace-Wiens P ............................. A01,E01
Lam F .......................................... J02
Laribert A ...................................... E03,P05,P06
Lapinsky S .................................... C02
Laporte K ...................................... IP02
Larios O ........................................ F03,P47
Lau T .......................................... IP14
Lavelle C ...................................... H01,H04
Lavoie M ...................................... D03
Lavoie S ........................................ E04,P22
Law I .......................................... SP26
Law M .......................................... SP26
Lawand A ...................................... IP10
Layne G ........................................ P28
Lazar N ........................................ C02
Le C ............................................. IP13
Leammon A ................................... J05
LeBlanc JJ ..................................... IP09,P38,P40
LeBlanc I ....................................... A04,P09
Lee H .......................................... IP03
Lee M-K ........................................ K01,P44,P46
Lee SS .......................................... P01
Lee T .......................................... IP05,P12,P51,P55
Lee TC .......................................... L01,S011
Ledell D ....................................... IP01,S05
Leen J .......................................... P04
Lefebvre B .................................... P05,P48
AUTHOR INDEX

Leis J A .................................................. IP15, J03, P04
Lemay M .................................................. P01
Leung A .................................................. P01
Leung V .................................................. P01, IP02, J01, P04
Levesque M ............................................. P03
Li L .................................................. J02, P18, SP29
Li Y .................................................. D03
Li Y-H .................................................. P07
Liang S .................................................. SP24
Libman M .................................................. P25
Lin AYC .................................................. G03, P35
Lindsay R .................................................. D04
Litwin AH .................................................. G04
Lloyd T .................................................. P45
Lloyd-Smith E ........................................ IP02, J01, J04, J05
Lo P .................................................. F01, F04, M01, M03, P61, P62
Lo T .................................................. P46
Lonerger A .............................................. O04
Longin J .................................................. L03, P05, P48, SP09
Loo VGY .................................................. L03, SP11
Low DE .................................................. G01
Lowe C .................................................. IP02, J01, J04
Lowe DO .................................................. G03, P35
Luethkemeyer A ....................................... P04
Lundeberg R ........................................... IP01, SP05

M
Mabon P .................................................. P23
Macdonald KA ......................................... I01, O03 (P54)
MacDougall L ........................................... B02
MacFadden D .......................................... P04
Mack B .................................................. P29
Mackay D ............................................... J03
MacSlaughter T ........................................ H02, P03, P41, P13
Magalang A ........................................... P04
Mahn A .................................................. L02
Mahn R .................................................. IP01
Mahesh V ............................................... P21
Mahoney J ............................................... SP24
Main C .................................................. SP21
Majerus R ............................................... IP14
Makowski K ........................................... P20
Maleczyk K ........................................... P27, P43
Man S .................................................. K01
Mandal K ............................................... IP22
Mangat CS ........................................... I03, J04
Manam K ............................................... P63
Mansour S ............................................... P64
Margach M ............................................ P56
Marha F .................................................. C01, P02
Marsh R .................................................. C01, P04
Martin J .................................................. C01, P05
Mask A .................................................. D04
Masud S ................................................. P67, SP23
Matasej L .............................................. M02, P61, P62
Mathieu S ............................................. E03
Matic N .................................................. SP18
Matukas LM .......................................... P36
Maurais E ............................................. E03
Mayo P .................................................. P64
Mazzuoli A ............................................ F04, M03
Mazzuoli T ............................................ F01, F04, M01, M03, P61, P62, P72, SP26
McCabe M ........................................... P44
McClure J ............................................ F03, SP15
McDonald E .......................................... IP05, P12
McGeer AJ ........................................... F02, G01, M02, P21, P72, SP26
McGill K ............................................... L02
McIntyre M ........................................... C02
Mckay R ............................................... L02
McNabb A ........................................... P34, P51, P52, P53
McNaughton M ...................................... IP02
McNeil S .............................................. IP09
McTaggart I .......................................... P11
Meatherall B ......................................... N01, P15, SP25
Medford R ............................................ SP32
Medjuck D ........................................... SP10
Mehta S ............................................... C02
Meier-Stephenson V ................................ N01, P15, SP25
Melano R ............................................. F02
Mellouk D ........................................... O04
Mendoza L ........................................... P38
Mertz D .............................................. P39, SP21
Michelin M .......................................... P10
Mihalco S ............................................ SP24
Minion J ............................................. P27, P43
Missaghi B .......................................... P47
Mistry MD .......................................... G03, P35
Moisan L ............................................. P68
Moore C ............................................. SP26
Morie J ............................................... J05
Morris AM ........................................... C02, IP07, IP21
Morshed M ......................................... K01, P29, P30, P44, P46, P67, B02
Mubareka S .......................................... SP18
Muller M ............................................. F02
Mulvey MR ......................................... F04, J03, J04, M02, M04, P61, P62
Murphy D ........................................... P48
Murray J ............................................... P03
Mwawasi K .......................................... SP24

N
Nadarajah J ........................................... P36
Nadon E ............................................... J02
Nadon C ............................................... J02
Nahass R ............................................. G04
Narendran A ......................................... SP25
Nashid N ............................................. SP33
Nathens A ........................................... J03
Needle R ............................................ P28, P37, P40
Nelson J .............................................. SP24
Ng C ................................................. I03, P04
Ng D .................................................. E04
Ng W .................................................. K03, P21
Nguyen B-Y ......................................... G04
Nguyen TT ........................................... L03, SP11
Nichol K .............................................. E01
Ninomiya A .......................................... SP26
Noskov S ............................................ SP25
Not C .................................................. P45

O
O'Donnell S .......................................... SP14
O'Neil CR ........................................... P01
Ogurerni T ........................................... L05
Olmstead A .......................................... P51
Onyeji C ............................................. P01
Oswijcki L ........................................... P02

P
Paccagnella A ....................................... I01, I03, J04, P34, P53, P63
Pacheco Al ........................................... K04
Palay M ............................................. IP15
Paramalingam S ................................... L05
Parkes LO ........................................... L03, N04, P25
Parkins M ........................................... SP20
Parsons S ........................................... P01
Pasay D ............................................. IP17
Patel S ............................................... F02
Patrick DM ......................................... C01, IP07, L02, P02
Patriquin G .......................................... D04
Payne M ............................................ K02, N02
Pelude L ............................................. L05
Peng C-Y ............................................. G04
Penney C ............................................ P09, P37
Perez AG ............................................ P04
Perpete C ........................................... P68
Peterson C .......................................... I02
Petkou A ........................................... J02
Petrescu D .......................................... P04
Petrich A ............................................ P59
Phillips P ........................................... A01, E01, H03, P50
Pillai D .............................................. P15
Pitre M .............................................. G03, P35
Plante M ........................................... SP22
Platt HL ............................................. G04
PNC Steering Committee ................................ I02
Pollicarpio M ....................................... J02
Poliquin G .......................................... P04
Poopalrajah R ...................................... P11
Porter V ............................................. M02
Poutanen SM ....................................... F01, F02, F04, G01, G03, M01, M03, P35, P60, P61, P62, SP26
Prentki A ........................................... SP07
Preedy G ........................................... D03
Prematunge C ...................................... J02
Priyantha R .......................................... SP30
Prystajecky N ...................................... D02, D01, P53, SP12
Purycz D ........................................... P63
Quach C ............................................. H01, H04, P18, P68, SP14, SP29

R
Rabin H ............................................. SP20
Rajadurai S .......................................... F01, M01
Rajapakse N ........................................... P47
Ramsamoo J ......................................... P03
Raybakhyan S ..................................... K03, P58
Raye T .............................................. C03, P49
Read S ............................................. L04
Rebastapragada A ................................ F02
Rehan M ........................................... SP21
Remus WE ......................................... P02
Reimer A ........................................... I01, I02
Reimer J ........................................... P33
Remington L ........................................ N01
Remulla S ........................................... P64
Rennie RP ........................................... B01, B04, F03
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ricci G</td>
<td>F01,F04,M01,M03,P61,P62</td>
</tr>
<tr>
<td>Richards D</td>
<td>J01</td>
</tr>
<tr>
<td>Richardson D</td>
<td>F02</td>
</tr>
<tr>
<td>Ritchie G</td>
<td>J04</td>
</tr>
<tr>
<td>Roberts C</td>
<td>P40</td>
</tr>
<tr>
<td>Robertson M</td>
<td>G04</td>
</tr>
<tr>
<td>Robson H</td>
<td>IP05</td>
</tr>
<tr>
<td>Roman S</td>
<td>P73</td>
</tr>
<tr>
<td>Romney M</td>
<td>J01,J04,P29</td>
</tr>
<tr>
<td>Roth V</td>
<td>P45</td>
</tr>
<tr>
<td>Roussy J-F</td>
<td>P31</td>
</tr>
<tr>
<td>Roy L</td>
<td>SP10</td>
</tr>
<tr>
<td>Rubin J</td>
<td>SP50</td>
</tr>
<tr>
<td>Rueda Z</td>
<td>SP98</td>
</tr>
<tr>
<td>Rumore J</td>
<td>J02</td>
</tr>
<tr>
<td>Rundle N</td>
<td>P10</td>
</tr>
<tr>
<td>Rusk A</td>
<td>M04</td>
</tr>
<tr>
<td>Sabuda D</td>
<td>IP17,P15,P47</td>
</tr>
<tr>
<td>Sadeghi M</td>
<td>J03</td>
</tr>
<tr>
<td>Safronetz D</td>
<td>P20</td>
</tr>
<tr>
<td>Saleh A</td>
<td>IP16</td>
</tr>
<tr>
<td>Sales V</td>
<td>SP1</td>
</tr>
<tr>
<td>Salim H</td>
<td>P07</td>
</tr>
<tr>
<td>Salmon J</td>
<td>P03</td>
</tr>
<tr>
<td>Salpeter MJ</td>
<td>G01</td>
</tr>
<tr>
<td>Saltzman I</td>
<td>P04</td>
</tr>
<tr>
<td>Salvador M</td>
<td>M05</td>
</tr>
<tr>
<td>Sant N</td>
<td>P14</td>
</tr>
<tr>
<td>Sarabia A</td>
<td>F02</td>
</tr>
<tr>
<td>Sauvé L</td>
<td>P02</td>
</tr>
<tr>
<td>Savithri V</td>
<td>P70</td>
</tr>
<tr>
<td>Sawatzky P</td>
<td>P05</td>
</tr>
<tr>
<td>Schlehauf D</td>
<td>D04</td>
</tr>
<tr>
<td>Science M</td>
<td>L04</td>
</tr>
<tr>
<td>Scinocca Z</td>
<td>SP24</td>
</tr>
<tr>
<td>Sekirov I</td>
<td>L04,P67,SP28</td>
</tr>
<tr>
<td>Sekhri B</td>
<td>P06</td>
</tr>
<tr>
<td>Shafman S</td>
<td>S12</td>
</tr>
<tr>
<td>Shajar S</td>
<td>IP14</td>
</tr>
<tr>
<td>Sharma A</td>
<td>J01,J04</td>
</tr>
<tr>
<td>Sharma S</td>
<td>C03,P49</td>
</tr>
<tr>
<td>Sheppard DC</td>
<td>SP22</td>
</tr>
<tr>
<td>Shi Y</td>
<td>SP19</td>
</tr>
<tr>
<td>Shibolet O</td>
<td>G04</td>
</tr>
<tr>
<td>Shkuratoff B</td>
<td>P56</td>
</tr>
<tr>
<td>Shokoples S</td>
<td>B01,B04,IP01,SP05</td>
</tr>
<tr>
<td>Showler A</td>
<td>P12</td>
</tr>
<tr>
<td>Shroff A</td>
<td>G02,P07</td>
</tr>
<tr>
<td>Siddhu B</td>
<td>J01,P04</td>
</tr>
<tr>
<td>Sieffert C</td>
<td>J102</td>
</tr>
<tr>
<td>Simmonds K</td>
<td>M04</td>
</tr>
<tr>
<td>Simont AE</td>
<td>F02,SP01,SP18,SP19</td>
</tr>
<tr>
<td>Simpson Y</td>
<td>P29,P30</td>
</tr>
<tr>
<td>Singh J</td>
<td>C02</td>
</tr>
<tr>
<td>Skinner C</td>
<td>IP10</td>
</tr>
<tr>
<td>Sloan A</td>
<td>A03</td>
</tr>
<tr>
<td>Slobodan J</td>
<td>IP17</td>
</tr>
<tr>
<td>Smith S</td>
<td>SP27</td>
</tr>
<tr>
<td>Smylie L</td>
<td>C04</td>
</tr>
<tr>
<td>Smyth D</td>
<td>H02,IP13,P41</td>
</tr>
<tr>
<td>So J</td>
<td>SP26</td>
</tr>
<tr>
<td>Solomon VR</td>
<td>IP03</td>
</tr>
<tr>
<td>Somayaji R</td>
<td>SP30</td>
</tr>
<tr>
<td>Sonpar A</td>
<td>SP27</td>
</tr>
<tr>
<td>Soon C</td>
<td>C04</td>
</tr>
<tr>
<td>Sparksman S</td>
<td>F03</td>
</tr>
<tr>
<td>Squires J</td>
<td>P45</td>
</tr>
<tr>
<td>Srivastava S</td>
<td>SP32</td>
</tr>
<tr>
<td>St Pierre J</td>
<td>SP09</td>
</tr>
<tr>
<td>Stefanovic A</td>
<td>I03,N02</td>
</tr>
<tr>
<td>Stein M</td>
<td>A01</td>
</tr>
<tr>
<td>Steiri B M</td>
<td></td>
</tr>
<tr>
<td>Stokes W</td>
<td>N01,SP06</td>
</tr>
<tr>
<td>Strong J</td>
<td>P04</td>
</tr>
<tr>
<td>Suh K</td>
<td>P14,P45</td>
</tr>
<tr>
<td>Swain MG</td>
<td>P01</td>
</tr>
<tr>
<td>Szabolcs N</td>
<td>P39</td>
</tr>
<tr>
<td>Tadros M</td>
<td>I03,J04,P63</td>
</tr>
<tr>
<td>Tan R</td>
<td>P17</td>
</tr>
<tr>
<td>Tang K</td>
<td>SP06</td>
</tr>
<tr>
<td>Tang P</td>
<td>D01,D02,P53,SP12</td>
</tr>
<tr>
<td>Tapardel A</td>
<td>SP27</td>
</tr>
<tr>
<td>Taylor G</td>
<td>M06</td>
</tr>
<tr>
<td>Taylor M</td>
<td>J01</td>
</tr>
<tr>
<td>Tellier R</td>
<td>SP25</td>
</tr>
<tr>
<td>Terenzi D</td>
<td>F04,M03</td>
</tr>
<tr>
<td>Terekhov A</td>
<td>A01</td>
</tr>
<tr>
<td>Tetrauld I</td>
<td>P48</td>
</tr>
<tr>
<td>Thomas E</td>
<td>SP28</td>
</tr>
<tr>
<td>Thompson D</td>
<td>B02</td>
</tr>
<tr>
<td>Tian X-I</td>
<td>P07</td>
</tr>
<tr>
<td>Tilley P</td>
<td>P17,P56,SP28</td>
</tr>
<tr>
<td>Timberlake</td>
<td>K04</td>
</tr>
<tr>
<td>Tippett G</td>
<td>D03</td>
</tr>
<tr>
<td>Todd J</td>
<td>B03</td>
</tr>
<tr>
<td>Tomassi J</td>
<td>K03</td>
</tr>
<tr>
<td>Tomlinson G</td>
<td>G01</td>
</tr>
<tr>
<td>Toye B</td>
<td>SP10</td>
</tr>
<tr>
<td>Trajkova-Adonova M</td>
<td>SP25,D04</td>
</tr>
<tr>
<td>Tremblay C</td>
<td>P06,P18,P48,P29</td>
</tr>
<tr>
<td>Trimi X</td>
<td>F01,F04,M01,M03</td>
</tr>
<tr>
<td>Trudelle A</td>
<td>P05,P06</td>
</tr>
<tr>
<td>Tsang C</td>
<td>P01</td>
</tr>
<tr>
<td>Tsang F</td>
<td>P52</td>
</tr>
<tr>
<td>Tsang R</td>
<td>N02</td>
</tr>
<tr>
<td>Tschetter L</td>
<td>J02</td>
</tr>
<tr>
<td>Tsekres S</td>
<td>D03</td>
</tr>
<tr>
<td>Turenne C</td>
<td>A01</td>
</tr>
<tr>
<td>Turnbull LA</td>
<td>B01,B04</td>
</tr>
<tr>
<td>Tyndall M</td>
<td>O01</td>
</tr>
<tr>
<td>Umalu J</td>
<td>P09,P37</td>
</tr>
<tr>
<td>Vaisman A</td>
<td>SP01</td>
</tr>
<tr>
<td>Valbuena V</td>
<td>IP21</td>
</tr>
<tr>
<td>Vafeas A</td>
<td>N03,P19</td>
</tr>
<tr>
<td>Vajdary S</td>
<td>C03,P49</td>
</tr>
<tr>
<td>Van Gaalen S</td>
<td>SP08</td>
</tr>
<tr>
<td>Vasanathamohan L</td>
<td>SP07</td>
</tr>
<tr>
<td>Vayalumkal J</td>
<td>P01,P47</td>
</tr>
<tr>
<td>Vearncombe M</td>
<td>J03,SP18</td>
</tr>
<tr>
<td>Vendranamelli R</td>
<td>A03</td>
</tr>
<tr>
<td>Venne S</td>
<td>P05</td>
</tr>
<tr>
<td>Versporten A</td>
<td>P47</td>
</tr>
<tr>
<td>Villena E</td>
<td>P61</td>
</tr>
<tr>
<td>Vind DC</td>
<td>L03,SP11</td>
</tr>
<tr>
<td>Wada R</td>
<td>P30</td>
</tr>
<tr>
<td>Wahl J</td>
<td>G04</td>
</tr>
<tr>
<td>Walker M</td>
<td>J03</td>
</tr>
<tr>
<td>Walker SA</td>
<td>IP15</td>
</tr>
<tr>
<td>Walkty A</td>
<td>P03</td>
</tr>
<tr>
<td>Wang B</td>
<td>P13,P67</td>
</tr>
<tr>
<td>Watamaniuk A</td>
<td>J03</td>
</tr>
<tr>
<td>Watson N</td>
<td>P17,P56</td>
</tr>
<tr>
<td>Webber D</td>
<td>P20</td>
</tr>
<tr>
<td>Welsh P</td>
<td>IP17,P47</td>
</tr>
<tr>
<td>Werry D</td>
<td>IP17,P47</td>
</tr>
<tr>
<td>Whelams D</td>
<td>SP13</td>
</tr>
<tr>
<td>Whitehead S</td>
<td>P13</td>
</tr>
<tr>
<td>Whiteside B</td>
<td>SP17</td>
</tr>
<tr>
<td>Wiebe D</td>
<td>K04</td>
</tr>
<tr>
<td>Wijesundera HC</td>
<td>SP19</td>
</tr>
<tr>
<td>Wilcox T</td>
<td>IP13</td>
</tr>
<tr>
<td>Wilcox-Carrier T</td>
<td>P41</td>
</tr>
<tr>
<td>Willey BM</td>
<td>F01,F04,M01,M02,M03,P60,P61,P62</td>
</tr>
<tr>
<td>Wilmers A</td>
<td>IP17,P47</td>
</tr>
<tr>
<td>Wong A</td>
<td>J04</td>
</tr>
<tr>
<td>Wong I</td>
<td>J04</td>
</tr>
<tr>
<td>Wong J</td>
<td>J04</td>
</tr>
<tr>
<td>Wong G</td>
<td>K01,P29,P30,P44,P46</td>
</tr>
<tr>
<td>Wright B</td>
<td>SP17</td>
</tr>
<tr>
<td>Wu J</td>
<td>P07</td>
</tr>
<tr>
<td>Wu K</td>
<td>SP15</td>
</tr>
<tr>
<td>Wu T</td>
<td>P01</td>
</tr>
<tr>
<td>Wylie J</td>
<td>P33</td>
</tr>
<tr>
<td>Yamamura D</td>
<td>A04,B03</td>
</tr>
<tr>
<td>Yau G</td>
<td>SP33</td>
</tr>
<tr>
<td>Young K</td>
<td>H02,P42</td>
</tr>
<tr>
<td>Young V</td>
<td>P17</td>
</tr>
<tr>
<td>Yu A</td>
<td>O01</td>
</tr>
<tr>
<td>Yu G</td>
<td>SP20</td>
</tr>
<tr>
<td>Yu Y</td>
<td>IP04</td>
</tr>
<tr>
<td>Zahiratos GJ</td>
<td>N04</td>
</tr>
<tr>
<td>Zelays N</td>
<td>SP05</td>
</tr>
<tr>
<td>Zhanel GG</td>
<td>B01,B04</td>
</tr>
<tr>
<td>Zhang J</td>
<td>SP15</td>
</tr>
<tr>
<td>Zhang K</td>
<td>F03,SP15</td>
</tr>
<tr>
<td>Zhang XM</td>
<td>P69</td>
</tr>
<tr>
<td>Zheng BJ</td>
<td>P69</td>
</tr>
<tr>
<td>Zhou H</td>
<td>IP01</td>
</tr>
<tr>
<td>Zhu J</td>
<td>IP11</td>
</tr>
<tr>
<td>Zurek K</td>
<td>P64</td>
</tr>
<tr>
<td>Zvonar R</td>
<td>P45,P58</td>
</tr>
</tbody>
</table>
## CONFLICT OF INTEREST

<table>
<thead>
<tr>
<th>Committee Member / Speaker</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam, Heather</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Allen, Vanessa</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Attara, Gail</td>
<td>Work with the Gastrointestinal Society receives support from Merck for educational materials, including a video on <em>C. difficile</em></td>
</tr>
<tr>
<td>Banaei, Niaz</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Behr, Marcel</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Blondel-Hill, Edith</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Botkin, Clayton</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Bowes, Victoria</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Buntain, Bonnie</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Chagla, Zain</td>
<td>Received speaking honoraria from Merck</td>
</tr>
<tr>
<td>Charlton, Carmen</td>
<td>Member of Roche Diagnostics Advisory Board; Received in-kind reagents for instrument comparison from Roche Diagnostics, Siemens, BioRad; Received an HPV grant from Merck</td>
</tr>
<tr>
<td>Chiu, Charles</td>
<td>Member of Scientific Advisory Board for both Karius, Inc. and Rubicon Genomics; Member of Merck Speakers Bureau (antibiotics); Received research support from Abbott Laboratories, Inc.; Holds a patent for a product referred to in the CME/CPD program or that is marketed by a commercial organization - UCSF related to SURPI+ (Sequence-Based Ultra-Rapid Pathogen Identification)</td>
</tr>
<tr>
<td>Chiu, Isabelle</td>
<td>Advisory Board Member for Janssen, Merck, Pfizer, Sunovion, Cubist; Member of a Speakers Bureau for Merck and Sunovion; Received payment from a commercial organization (Janssen, Merck, Pfizer, Sunovion, Cubist); Received a grant or honorarium from a commercial organization (Janssen, Merck, Pfizer, Sunovion, Cubist); within the past two years has participated in a clinical trial through the University of Alberta Division of ID Clinical Trials (no direct financial transactions)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Committee Member / Speaker</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Church, Deirdre</td>
<td>Received in-kind compensation for technology assessments from Cepheid Inc., Focus Diagnostics - Simplexa, R-Biopharm AG, Qiagen, Molzym GmbH+Co, Bio-Rad; Received grant funding from Abbott Molecular</td>
</tr>
<tr>
<td>Daley, Peter</td>
<td>Participated in INC research for Cubist (now Merck) (LCD-CDAD-11-06, completed July 2015)</td>
</tr>
<tr>
<td>Dey, Meghan</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Dien Bard, Jennifer</td>
<td>Member of Speakers Bureau for Meridian Bioscience; Received research grants and honorariums from Nanosphere Inc, BioFire Diagnostics and Meridian Bioscience; In the past two years has participated in clinical trials for Nanosphere Inc, BioFire Diagnostics and Great Basin</td>
</tr>
<tr>
<td>Drews, Steven J.</td>
<td>Received payment from Roche (2008-09) for consultations on antiviral resistance</td>
</tr>
<tr>
<td>Evans, Gerald</td>
<td>Is currently, or in the past two years has participated in a clinical trial with Merck (CDI study), with Astellas (Isavuconazole study), and with Biocryst (peramivir study)</td>
</tr>
<tr>
<td>Forgie, Sarah</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Fuller, Jeff</td>
<td>Member of an Advisory Board on antibiotic resistance for Merck; Received a grant or an honorarium from Astellas for antifungal resistance surveillance</td>
</tr>
<tr>
<td>Gantt, Soren</td>
<td>Within the past two years has been an investigator in a clinical trial with VBI of a CMV vaccine; May make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medications)</td>
</tr>
<tr>
<td>Garver, Kyle</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>German, Gregory</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Gilmour, Matthew W.</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Grant, Jennifer</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Gregson, Daniel B.</td>
<td>Has received industry grants for research purposes only; Within the past two years has participated in a clinical trial funded by Becton Dickinson for the detection of enteric and parasitic pathogens in stool</td>
</tr>
</tbody>
</table>
## Conflict of Interest

<table>
<thead>
<tr>
<th>Committee Member / Speaker</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grennan, Troy</td>
<td>Received honoraria for travel and presentations from ViiV, Merck and Gilead</td>
</tr>
<tr>
<td>Haider, Shariq</td>
<td>Member of advisory board for Merck, AbbVie and Sunovian; member of Merck Speakers Bureau for <em>C. difficile</em> and ceftolozane; within the past two years has participated in clinical trials with Merck, BMS and AbbVie (Antifungal and Hep C clinical trials)</td>
</tr>
<tr>
<td>Hatchette, Todd</td>
<td>Received honorarium from Abbvie for talk on latent TB and vaccination in patients receiving biological therapies; Received investigator initiated collaborative research agreement from GSK - anchor lab for the SOS network looking at vaccine effectiveness (S. McNeil PI)</td>
</tr>
<tr>
<td>Himsworth, Chelsea</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Imperial, Miguel</td>
<td>Received payment from Lifelabs as a contractor</td>
</tr>
<tr>
<td>Joffe, A. Mark</td>
<td>Participated in one-day two-way education sessions with Abbvie, Merck and Paladin Labs; Member of Speakers Bureau (Merck - has given lecture on vaccines and received honoraria for doing so)</td>
</tr>
<tr>
<td>Johnson, Stuart</td>
<td>Member of Advisory Board for Bio K+, Summit Therapeutics and Seres Therapeutics</td>
</tr>
<tr>
<td>Johnston, B. Lynn</td>
<td>Within the past two years has participated in a clinical trial with Pfizer (Local investigator for the POEM study (maraviro) now completed)</td>
</tr>
<tr>
<td>Kehler, Lindsay</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Krajden, Mel</td>
<td>Received research grants or contracts to member's institution from Roche, Merck, Siemens, Hologic, Boehringer Ingelheim</td>
</tr>
<tr>
<td>Leung, Victor</td>
<td>Member of Virtual Advisory Board for Sunovion and member of Advisory Board for Merck; within the past two years has participated in a clinical trial with Cubit (Cubist CDI Study - RCT)</td>
</tr>
<tr>
<td>Levett, Paul N.</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Loeb, Mark</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Martin, Philippe</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Masud, Shazia</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Minion, Jessica</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Murray, Melanie</td>
<td>Member of Gilead Sciences Speakers Bureau (Genvoya); Received payment from Gilead Sciences, Merck and Bristol-Myers-Squibb for speaker-chosen speaking arrangements; Received WeTel BC1 pilot study support from Bristol-Myers-Squibb, WeTelOAKTREE study support from Gilead Sciences, in-kind phone support from Telus and in-kind platform support from WeTel; within the past two years has participated in a clinical trial with Bristol-Myers-Squibb (BMS AI438-017) and with ViiV (Triumeq switch study)</td>
</tr>
<tr>
<td>Murray, Melanie</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Naidu, Prenilla</td>
<td>Received an honorarium for a webinar delivered to BD Diagnostics; Research and Development Director of Morphology.ca (skin care company); in the past two years has participated in a clinical trial for Hologic (study on T.vag &amp; M.gen NATTs) and for Alere (study evaluating CPO chromogenic media)</td>
</tr>
<tr>
<td>Oughton, Matthew</td>
<td>Received payment from bioMérieux for a presentation on carbapenemase detection in Montreal (2014); within the past two years has participated in clinical trials with Merck (MK3415A - vaccine for <em>C. difficile</em>) and with Summit (SMT 19969 - antibiotic for <em>C. difficile</em>)</td>
</tr>
<tr>
<td>Patrick, David</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Poole, Doris</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Poutanen, Susan</td>
<td>Advisory Board Meeting Participant for Merck/Optimer/Cubist and Paladin Labs; Received honorarium for speaking at educational events supported by Merck</td>
</tr>
<tr>
<td>Quach, Caroline</td>
<td>Received investigator-initiated grant research support, paid to institution, from Pfizer (surveillance CLABSI), GSK (rotavirus surveillance), AbbVie (validation RSV surveillance) and Sage (risk factors CLABSI)</td>
</tr>
<tr>
<td>Radke, Brian</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Rebbapragada, Anu</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Ritchie, Stewart</td>
<td>No Conflict Declared</td>
</tr>
</tbody>
</table>
## CONFLICT OF INTEREST

<table>
<thead>
<tr>
<th>Committee Member / Speaker</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sakoulas, George</td>
<td>Member of Advisory Board for Arsanis; Member of Speakers Bureau for Merck, Allergan and The Medicines Company; Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medication)</td>
</tr>
<tr>
<td>Simor, Andrew</td>
<td>Member of Advisory Board for Merck Canada</td>
</tr>
<tr>
<td>Singh, Ameeta</td>
<td>No Conflict Declared; Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medication)</td>
</tr>
<tr>
<td>Steiner, Ted</td>
<td>Member of Advisory Board for Merck and Pendopharm; Member of Speakers Bureau for Merck and BMS; Received payment from Merck and Pendopharm for speeches; Received a research grant from Merck; In the past two years has participated in clinical trials for Merck, Sanofi Pasteur and Rebiotix; Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medications)</td>
</tr>
<tr>
<td>Thirion, Daniel</td>
<td>Member of Advisory Board for both Pendopharm and Merck Frosst; Member of Speakers Bureau for both Merck Frosst and Accelerate Diagnostics</td>
</tr>
<tr>
<td>Turenne, Christine</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Vearncombe, Mary</td>
<td>No Conflict Declared</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Committee Member / Speaker</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vinh, Donald</td>
<td>Member of ad hoc advisory board for CSL Behring Canada and ad hoc advisory board for Sunovion; received honoraria for presentations from CSL Behring Canada, Merck Canada and Sunovion; received unrestricted educational grants from CSL Behring Canada and a research grant from Astellas Canada; Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e., “off-label” use of medication)</td>
</tr>
<tr>
<td>Webster, Duncan</td>
<td>Member of AbbVie HCV Advisory Board Rothesay, New Brunswick February 1 2014; Received seed funds from AbbVie for HCV clinic focusing on marginalized at-risk populations; within the past two years has participated in a clinical trial for AbbVie (TOPAZ-1)</td>
</tr>
<tr>
<td>Wong, Titus</td>
<td>Received speaker honorarium from Merck/Cubist</td>
</tr>
<tr>
<td>Wright, Alissa</td>
<td>Member of Merck-organized single meeting on May 22, 2015 entitled &quot;Infectious Disease Specialists Regional Consultation Meeting” regarding use of ceftolozane/tazobactam; Received grant money from Pfizer and Sunovion for UBC to create UBC Transplant ID training grant; Within the past two years has attempted to participate in a clinical trial with Gilead (attempt to open study NCT02254408 for 2015-2016 RSV season - closed prior to initiation)</td>
</tr>
</tbody>
</table>
Attara, Gail
Gail Attara is the President and CEO of the Gastrointestinal Society (www.badgut.org), serving for twenty years. Gail’s motto, ‘the patient comes first’, directs her resolve for patient-focused health care and commitment to increasing awareness about the seriousness of gastrointestinal and liver illnesses.

Gail is now serving her sixth year as Chair of the Best Medicines Coalition and is a member of the Consensus Framework for Ethical Collaboration, the Innovative Medicines Canada Stakeholder and Partnerships Advisory Group, and is on the CADTH Patient Liaison Forum. Gail is co-founder of Advocacy Boot Camp Inc., where she fulfils her goal of expanding the network of knowledgeable patient advocates working in health.

Banaei, Niaz
Niaz Banaei received his medical education from Stanford University and completed residency training in laboratory medicine at the University of California, San Francisco. He then completed a postdoctoral fellowship in infectious diseases at the New York University. He is currently an Associate Professor of Pathology and Medicine at Stanford University and is the Medical Director of the Clinical Microbiology Laboratory at Stanford Medical Center. In addition, he is the Director of Stanford Pathology Fellowship in Global Health Diagnostics. He serves on the board of advisors for the Center for Disease Control Tuberculosis Epidemiologic Studies Consortium II (TBESC). His research interests include development, assessment, and improvement of novel infectious diseases diagnostics. He was the recipient of Kenneth L.

Behr, Marcel
Dr. Marcel Behr is Professor of Medicine at McGill University where he is Director of the McGill International TB Centre and Microbiologist-in-Chief of the McGill University Health Centre. His training included BSc (Biochemistry) from the University of Toronto, MD from Queen’s University, Residency training in Infectious Diseases and Medical Microbiology at McGill, an MSc (Epidemiology) from McGill and then post-doctoral studies of Molecular Epidemiology and Bacterial Genomics at Stanford.

Dr. Behr's research interest is the application of bacterial genetics to study the epidemiology and pathogenesis of mycobacterial diseases, specifically, M. tuberculosis, the cause of TB, BCG, the vaccine used against TB, and non-tuberculous mycobacteria, including members of the M. avium-intracellular complex. This work has been recognized by numerous awards, in Quebec (Chercheur National of the Fonds de la Recherche en Sante du Quebec) and beyond (election to the American Society for Clinical Investigation, 2010). The work of Dr. Behr is funded by operating grants from the Canadian Institute for Health Research, Genome Quebec and the National Institutes of Health.

Chagla, Zain
Dr. Zain Chagla is a Tutor in the Master of Science in Global Health program at McMaster University. An M.D. specializing in internal medicine, tropical medicine, and infectious diseases, he is a Consultant Physician at St. Joseph’s Hospital and Hamilton Health Sciences, Assistant Professor of Medicine at McMaster University, and adjunct faculty at the University of Namibia in the Department of Medicine.

He also received his M.Sc from the London School of Hygiene and Tropical Medicine, and a Diploma in Tropical Medicine completed in Tanzania and Uganda through the London School of Hygiene and Tropical Medicine. Research and clinical interests include antimicrobial stewardship, web/mobile technology and medical education, diagnostic ultrasound in resource poor settings, travel and tropical medicine, and transplant derived infections.

Chiu, Charles
Charles Chiu, M.D./Ph.D. is Associate Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. He is a board-certified consulting infectious diseases physician at UCSF, and his practice is in both infectious diseases and clinical microbiology. Dr. Chiu received an MD and PhD in biophysics from UCLA and subsequently completed an internal medicine residency, infectious diseases fellowship, and postdoctoral research at UCSF. He heads a translational research laboratory focused on clinical diagnostic next-generation sequencing, assay development for infectious diseases and genomic analyses of emerging pathogens, including Borrelia burgdorferi, Ebola virus, and enterovirus D68. His work is supported by research grants from the NIH, Bay Area Lyme Disease Foundation, Global Lyme Alliance, USAID PREDICT program, UC Center for Accelerated Innovation, Sandler / Bowes Foundation, and the California Initiative to Advance Precision Medicine. Dr. Chiu has authored more than 50 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory board for Karius Dx and Rubicon Genomics.

Church, Deirdre
Dr. Church has spent 30 years in clinical adult Infectious Diseases, and Medical Microbiology practice, both in hospital, private and regional laboratory settings. She was involved from inception in 1996 in regional restructure of microbiology services in Calgary, and completed two consecutive 5-year terms as the Clinical Section Chief. Microbiology in 2007, a position she recently re-acquired in 2015. The management experience gained during this time allowed her to be comfortable dealing with constant system challenges and practice change. Dr. Church has extensive experience in technology assessment, including the development and implementation of new procedures, particularly molecular tests. Throughout her career, Dr. Church has also held an academic appointment with the University of Calgary, and is a Professor, Departments of Pathology & Laboratory Medicine and Medicine, Faculty of Medicine, University of Calgary. She has also published more than 350 peer-reviewed publications.

Dien Bard, Jennifer
Jennifer Dien Bard, Ph.D., D(ABMM), FCCM is the Director of Clinical Microbiology and Virology at Children’s Hospital Los Angeles and an Assistant Professor of Clinical Pathology at University of Southern California.

After receiving her Bachelor of Science degree in Medical Laboratory Science from the
University of Alberta, Canada, Jennifer Dien Bard earned her Doctor of Philosophy degree in Medical Sciences studying the aberrant activation of Signal Transducer and Activator of Transcription-3 in the pathogenesis of Cancer in the laboratory of Dr. Raymond Lai, MD, PhD, at the University of Alberta, Canada. She completed a Medical Microbiology and Public Health Fellowship at UBC/BC Children’s Hospital in 2013. Currently, she is a Professor in the Division of Infectious Diseases. For almost a decade, Sarah coordinated and taught in the undergraduate infectious diseases block. Sarah has also served as the Chair of the Education and Continuous Professional Development Committee for the Association of Medical Microbiology and Infectious Diseases Canada. She has been awarded 25 teaching awards including the 3M National Teaching Fellowship in 2012, and she recently completed a Master’s in Education in Health Sciences Education (MED in HSE) from the University of Alberta in 2014. Sarah’s research focuses on innovative medical education interventions and infection prevention. She has published over 40 peer-reviewed manuscripts, 8 book chapters and 6 peer reviewed online learning resources. For the past two years, Sarah has co-chaired the Provost’s Digital Learning Committee, and in 2015, she served as a Provost Fellow, conducting a qualitative analysis of faculty development through centres for teaching and learning at research-intensive universities. In the fall of 2015, she was appointed Vice-Provost (Learning Initiatives) at the University of Alberta.

Dr. Gerald Evans is the Chair of the Division of Infectious Diseases and a Professor in the Departments of Medicine, Biomedical & Molecular Sciences, and Pathology & Molecular Medicine at Queen’s University and an Infectious Diseases physician at Kingston General Hospital in Kingston, Ontario. Dr. Evans is Past President of AMMI Canada and Past Chair of the Committee to Evaluate Drugs of the Ontario Ministry of Health and Long-Term Care, the Ministry’s expert advisory committee on optimal drug utilization. He is currently a co-investigator with the Ontario Drug Policy Research Network, the Chair of the AMMI Canada Guidelines Committee, and the provincial lead for Antibiotic Stewardship with Public Health Ontario.

Sarah received a BSc in Microbiology and Immunology from the University of Toronto, and completed her MD and specialty training at the University of Manitoba. She joined the University of Alberta in the Department of Pediatrics in 2003 where she is currently a Professor in the Division of Infectious Diseases. For almost a decade, Sarah coordinated and taught in the undergraduate infectious diseases block. Sarah has also served as the Chair of the Education and Continuous Professional Development Committee for the Association of Medical Microbiology and Infectious Diseases Canada. She has been awarded 25 teaching awards including the 3M National Teaching Fellowship in 2012, and she recently completed a Master’s in Education in Health Sciences Education (MED in HSE) from the University of Alberta in 2014. Sarah’s research focuses on innovative medical education interventions and infection prevention. She has published over 40 peer-reviewed manuscripts, 8 book chapters and 6 peer reviewed online learning resources. For the past two years, Sarah has co-chaired the Provost’s Digital Learning Committee, and in 2015, she served as a Provost Fellow, conducting a qualitative analysis of faculty development through centres for teaching and learning at research-intensive universities. In the fall of 2015, she was appointed Vice-Provost (Learning Initiatives) at the University of Alberta.

Jennifer Grant has practiced Microbiology and Infectious Diseases in Vancouver since 2007. In the past, she has served on the CHICA (now IPAC) Canada board as director of standards and guidelines. More recently she served as a member of the ASR committee at AMMI Canada and an advising member of Do Bugs Need Drugs. Her current concentration is on Antimicrobial Stewardship as the Medical Director of Vancouver Coastal Health’s ASPIRES programme – providing stewardship support for the Coastal Region of British Columbia. Research projects include quality improvement initiatives in antimicrobial utilization, C. difficile vaccination and treatment, and recently completed an AMMI Canada recommendation document on surveillance of antibiotic resistance and utilization for Canada.

Dr. Matthew Gilmour is the Scientific Director General of Canada’s National Microbiology Laboratory (based in Winnipeg, MB, Guelph, ON, Lethbridge, AB, St. Hyacinthe, PQ and other satellite locations in Ontario.). These laboratories lead the national outbreak response and surveillance activities for infectious diseases, including those caused by respiratory and foodborne pathogens. The national programs for diagnostic and reference testing services and research reside at these laboratories, including for high-priority pathogens such as viral hemorrhagic fevers, arboviruses, tick-borne pathogens, sexually-transmitted infections and vaccine-preventable diseases. Dr. Gilmour and his team innovated a whole genome sequencing approach that brings the power of whole genome sequencing to outbreak response activities. The first demonstration of the power of genomics came during the 2008 nationwide listeriosis outbreak, as this team is recognized as completing one of the first applications of whole-genome sequencing of a bacterial pathogen during the scope of a public health investigation. The transformative nature of genomics and other high-resolution technologies continue to be explored and implemented to improve diagnostic testing and epidemiological investigations.
SPEAKER BIOGRAPHIES

Grennan, Troy
Dr. Troy Grennan is currently the Physician Lead of the HIV/STI Program in Clinical Prevention Services at the BC Centre for Disease Control, as well as Clinical Assistant Professor in the Division of Infectious Diseases at the University of British Columbia. He graduated from McMaster University Medical School in 2005, followed by Internal Medicine training at the University of Toronto, and Infectious Diseases and Medical Microbiology training at McMaster University. This was followed by a post-doctoral fellowship from the CIHR Canadian HIV Trials Network, where his research project focused on HPV in HIV-positive MSM. Prior to his arrival in BC in January 2015, he was Assistant Professor in the Department of Medicine and the Division of Infectious Diseases at McMaster University in Hamilton, Ontario. His primary clinical activities centered around general infectious diseases, HIV care through clinics at McMaster University Medical Centre and Maple Leaf Medical Clinic in Toronto, as well as anal cancer screening at the Toronto General Hospital’s Anal Dysplasia Clinic. He continues his engagement in research, and is currently a principal investigator on a large CIHR team grant developing a program of research for HPV care in HIV-positive MSM.

Imperial, Miguel
Dr. Miguel Imperial completed his medical training and residency at UBC. He has had a varied career including medical microbiologist locums at Vancouver General Hospital and BCCDC. He currently still practices in a variety of settings, including as a medical microbiologist at a large community lab (Lifelabs), a hospitalist doing general medicine in Fraser Health and in clinical consultation in microbiology/infectious diseases/tropical medicine at BC Women’s Hospital Complex Chronic Diseases Clinic and in a private community clinic setting. He also has 4 sons and most importantly a wonderful, understanding and supportive wife.

Johnson, Stuart
Dr. Johnson is an Infectious Disease Clinician and Researcher at the Hines VA Hospital and a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center in Maywood, Illinois. Dr. Johnson received his MD degree from the University of Minnesota Medical School and completed his internal medicine residency and infectious disease fellowship training at the University of Minnesota Hospital and the Minneapolis VA Medical Center. He received a Diploma in Tropical Medicine and Hygiene at Mahidol University in Bangkok, Thailand and a Career Development Ward from the Department of Veterans Affairs. He is the past President of the Anaerobe Society of the Americas.

His main research interest and focus has involved the epidemiology, pathogenesis, and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early recurrences of CDI. He is also a member of the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/ SHEA) CDI Guidelines Committee. In addition, he has been involved in clinical research on the parasite, Angiostrongylus cantonensis, responsible for most cases of eosinophilic meningitis, world-wide.

Johnston, B. Lynn
Dr. Johnston received her MD from Dalhousie University in Halifax, NS in 1979 and then went on to residencies in internal medicine (Dalhousie University), infectious disease (University of California, Los Angeles), and hospital epidemiology (University of Virginia, Charlottesville). In 2011 she finally completed her MSc in Epidemiology at the University of Toronto! She has been on Faculty with Dalhousie University Department of Medicine since 1987 and is currently a Professor of Medicine. She was Division Chief for Infectious Diseases at the former Capital District Health Authority in Halifax from January 2003 until August 2015 and Hospital Epidemiologist from 1991-2013. Dr. Johnston has held several positions with AMMI Canada, including President from 2010-2012. She is a founding member of the Canadian Hospital Epidemiology Committee (CHEC) and Co-chair of the Public Health Agency of Canada’s Infection Prevention and Control Expert Working Group (IPC-EWG), a committee she has served on since 1996. More recently, she has been a member of the Society for Healthcare Epidemiology of America’s Guidelines Committee. In 2015 she served as an Infection Prevention and Control consultant to the World Health Organization as part of the Ebola response and was deployed to Sierra Leone for 3 months.

Leung, Victor
Victor Leung is the Medical Director for Infection Prevention and Control at Providence Health Care. He is also the Medical Lead for the PHC Antimicrobial Stewardship Program. He has been practicing clinical infectious diseases and medical microbiology at St. Paul’s Hospital since completing his fellowships in Infectious Diseases and Medical Microbiology at McGill University.

Loeb, Mark
Dr. Mark Loeb is an Infectious Diseases physician and Medical Microbiologist. He completed medical training at McGill University followed by a residency in Internal Medicine at the University of Toronto. This was followed by training in Medical Microbiology and Infectious Diseases at McMaster University, where he completed training in clinical epidemiology. He is a Professor in the Departments of Pathology and Molecular Medicine and Clinical Epidemiology and Biostatistics at McMaster University. He is Division Director for Infectious Diseases and holds the Michael G DeGroot Chair in Infectious Diseases. Previous honours include the SHEA Investigator of the year award, the Royal College Gold Medal Award for Medicine, and the Jonas Salk Award. He has conducted clinical trials and cohort studies in the area of Infection Control and Prevention. He is currently conducting two clinical trials involving sites in Asia, Africa, and the Middle East. Funding sources include CIHR, NIH, WHO, and MRC UK. Dr. Loeb has 250 publications and 10 book chapters.
**SPEAKER BIOGRAPHIES**

**Martin, Philippe**
Dr. Philippe Martin completed his training in internal medicine, infectious diseases and medical microbiology in 2015 at the University of Sherbrooke, Quebec. He is currently pursuing a research fellowship at the Sunnybrook Health Sciences Centre in Toronto. His research interests include antimicrobial resistance, clinical laboratory management and innovative diagnostic technologies.

**Murray, Melanie**
Melanie Murray (MD, PhD, FRCPC) is an Assistant Professor in the Division of Infectious Diseases, Department of Medicine, at the University of British Columbia (UBC). She completed her medical degree and PhD at the University of Manitoba where she studied viral characteristcs involved in the transmission of HIV from mother to child. She came to Vancouver for her Internal Medicine Residency, then stayed to complete her Infectious Disease training. She is currently a clinician scientist at the University of Alberta and the supervision of postgraduate students.

**Poutanen, Susan**
Dr. Poutanen received her Medical Degree from the University of Toronto in 1996 and completed Internal Medicine and Medical Microbiology Residencies at the University of Toronto and an Infectious Diseases Fellowship at Stanford University, California. She received her Masters of Public Health with a focus on Epidemiology from the University of California, Berkeley in 2002.

Dr. Poutanen is a Medical Microbiologist and Infectious Diseases Physician at Mount Sinai Hospital & University Health Network in Toronto, Canada and an associate professor in the Department of Laboratory Medicine and Pathobiology and Department of Medicine at the University of Toronto.

Her broad research interests include: the epidemiology and detection of antimicrobial resistance; the diagnosis of and preparedness for emerging and re-emerging infectious diseases; the optimization of microbiology laboratory practices to support antimicrobial stewardship and patient care; and the assessment of fecal microbiota transplantation as an investigational intervention for a variety of conditions.

**Rebbapragada, Anu**
Dr. Anu Rebbapragada is an American board Certified Clinical Microbiologist (Diplomate American Board of Medical Microbiology; D(ABMM), FCCM) and Certified Infection Control specialist (CIC) whose professional experience spans academic, public and private sectors. Her training includes microbial molecular genetics, cell signaling pathways, mucosal immunology, diagnostic test development and, clinical epidemiology. Her research aims to leverage diagnostic testing to examine epidemiological associations of disease.

**Naidu, Prenila**
Prenilla Naidu, MD, FRCPC, is the STI Lead at the Provincial Laboratory for Public Health in Edmonton and a Clinical Associate at the University of British Columbia.

She received her MD from Natal University Medical School, in South Africa and subsequently trained and worked in Paediatrics in South Africa and the United Kingdom. After arrival in Canada in 1999 she worked in general practice, as a consultant at the STI Clinic and at the inner-city Boyle McCauley Health Centre in Edmonton.

Her research interests in STIs started in 1998 during her first medical microbiology residency in South Africa when she managed an STI clinic in a rural village and conducted research studies to direct the National STI Treatment Guidelines. She continues her research in this area with ongoing projects on chlamydia, gonorrhea, mycoplasma and trichomonas infections. She is also integrally involved in the Medical Microbiology Residency Training Program at the University of Alberta and the supervision of postgraduate students.

**Sakoulas, George**
George Sakoulas, MD, earned his medical degree from Harvard Medical School, Boston, Massachusetts, and completed his postgraduate
training in internal medicine at Beth Israel Deaconess Medical Center in 1998. From 1998-1999 he served as chief medical resident in the Department of Medicine at Beth Israel Deaconess Medical Center. From 1999 to 2002, he was a fellow in infectious diseases at Beth Israel Deaconess Medical Center where he developed interests in Gram positive infections while working under the guidance of Robert C. Moellering, Jr.

Currently, he is an Associate Professor in the Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection and Inflammation at the University of California San Diego School of Medicine. He is also an active inpatient and outpatient infectious diseases clinician at Sharp Rees-Stealy Medical Group and Sharp Memorial Medical Campus in San Diego.

Dr. Sakoulas is the author or coauthor of more than 120 scientific publications and has written several book chapters and scientific abstracts in the areas of infectious diseases. He lectures extensively on topics such as treatment options and resistance mechanisms of S. aureus, MRSA, vancomycin-resistant Enterococcus spp, and other multidrug-resistant pathogens. His research interests include investigating the relationships between antimicrobial resistance and virulence mechanisms in S. aureus, host response characteristics that may potentially be used as prognostic markers, as well as novel future therapeutic strategies against invasive S. aureus infections. In addition, he is actively studying the vastly under-appreciated interactions between innate host defense and administered antimicrobial drugs.

**Simor, Andrew**

Dr. Simor graduated with a medical degree from the University of Toronto in 1976, and completed Royal College fellowship training in internal medicine, infectious diseases, and medical microbiology. He has worked at Sunnybrook Health Sciences Centre since 1993. Dr. Simor’s research focus is on the development of novel diagnostics and effective therapies for infectious diseases. He has received research funding from peer-reviewed and industry-based granting agencies. He has published a large number of papers in scientific journals, and he is on the editorial board of several journals, and is an Associate Editor for the Canadian Journal of Infectious Diseases and Medical Microbiology. His primary research interests include antimicrobial resistance, hospital-acquired infections, and the application of molecular technologies to the diagnosis and management of infectious diseases.

Dr. Simor has received several teaching awards from the university, and in 2005 he was selected to receive the Distinguished Service Award from the university’s Department of Laboratory Medicine & Pathobiology. He has also received a Canadian Hospital Infection Control Association Award of Merit for service in the advancement of infection prevention and control.

**Singh, Ameeta**

Dr. Ameeta Singh completed her undergraduate medical degree at Nottingham University in the United Kingdom in 1989. This was followed by an internal medicine residency and infectious diseases fellowship at the University of Alberta, which were completed in 1996. In 2002, she completed a Masters of Science in Epidemiology at Harvard University. She was the Alberta provincial consultant for sexually transmitted and blood borne infections from 1998 to 2008, and the Medical Director of the Edmonton STI Clinic from 1998 to 2014. Provincially and nationally, Dr. Singh has contributed to the development of a wide range of guidelines, programs, and policies for HIV, sexually transmitted infections (STI) and viral hepatitis, and has published extensively in these areas. She maintains a general infectious diseases practice at the Royal Alexandra Hospital in Edmonton and an HIV/STI outpatient practice at the Edmonton STI Clinic and the Edmonton Institution for Women.

**Steiner, Ted**

Dr. Steiner trained in Internal Medicine at Duke University and Infectious Diseases at the University of Virginia. He joined the faculty at UBC in 2000 and is currently Professor of Medicine and Associate Head of the UBC Division of Infectious Diseases. His clinical and research interests focus on intestinal immunology and enteric infections. He has helped lead provincial programs on C. difficile infection and participated in several clinical trials on C. difficile prevention and management.

**Thirion, Daniel**

Dr. Daniel Thirion is currently Clinical Full Professor of Pharmacy at the Université de Montréal where his teaching responsibilities are focused on infectious diseases pharmacotherapy. As pharmacist, he is co-chair of the antimicrobial stewardship program at the McGill University Health Center.

He earned his Doctor of Pharmacy degree from the College of Pharmacy at Wayne State University, Detroit, Michigan (1999), his Bachelor of Pharmacy (1996) and Masters of Science (1997) from Université de Montréal, Montreal, Quebec. He completed post-doctoral training in infectious diseases at University of California, San Francisco. He is recognized as Fellow of the Canadian Society of Hospital Pharmacists. Prior to coming to Montreal in 2001, he was adjunct faculty at the School of Pharmacy, Auburn University in Alabama and clinical pharmacist at Columbus Regional Healthcare System in Georgia. His research focuses on the impact of antimicrobial use on emerging diseases and development of resistance, and appropriate use of antimicrobials in clinical practice. He has published over 100 articles and book chapters, served as invited speaker for over 300 conferences, and trained numerous pharmacy graduate students. He is also editor, publisher, and author of the “Snippets for Snappy Antimicrobial Therapy” an award winning reference for ID pharmacotherapy. His clinical practice is focused on providing pharmaceutical care in infectious diseases for the tertiary care hospital. His teaching responsibilities include ID pharmacotherapy for the undergraduate and graduate programs and development of the Pharm.D. program. He has also assumed the role of President of the AFPC (Association of Faculties of Pharmacy in Canada) over the past year. As a recognized expert, he devotes time and effort in his field of interest for committees, juries, and advisory boards up to the international level.
**SPEAKER BIOGRAPHIES**

**Vearncombe, Mary**

Dr. Vearncombe is a Medical Microbiologist and is Medical Director, Infection Prevention and Control, for Sunnybrook Health Sciences Centre and an IPAC Physician for Public Health Ontario. She is an Associate Professor in the Faculty of Medicine, University of Toronto. She is:

- Past-Chair of the Ontario Provincial Infectious Diseases Advisory Committee on Infection Prevention and Control
- Chair of the Expert Panel on Infection Control for the Faculty of Medicine, University of Toronto
- Member of the Steering Committee on Infection Control Guidelines of the Public Health Agency of Canada

She has over 30 years experience in Infection Prevention and Control. She is a previous president of the Canadian Association of Medical Microbiologists and a previous Chair of the Royal College of Physicians and Surgeons of Canada Specialty Committee in Medical Microbiology.

She is the recipient of the Award for Excellence in Teaching, Faculty of Medicine, University of Toronto, 1994, the Association of Medical Microbiologists and Infectious Diseases Canada (AMMI Canada) Distinguished Service Award, 2005, the College of Physicians and Surgeons Council Award, 2007 and the CHICA-Canada Champion Award 2010.

**Vinh, Donald**

Dr. Vinh obtained his medical degree in 2001 from McGill University. He then completed a residency in Internal medicine at McGill University, followed by a combined fellowship in clinical Infectious Diseases at the University of Manitoba and in Medical Microbiology at McGill. He subsequently completed a CIHR-funded, post-doctoral translational research fellowship at the National Institutes of Health (NIH), in the laboratory of Dr. Steve Holland, to understand inborn errors of immunity that render humans susceptible to infections, particularly fungal diseases. This work focused on understanding chronic granulomatous disease, autosomal-dominant hyper-IgE (Job's) syndrome, and defects in the interleukin (IL)-12/interferon (IFN)-gamma axis. It culminated in the discovery of a new genetic immunodeficiency, MonoMac syndrome, due to mutations in GATA2. His work earned him the Canadian Foundation for Infectious Disease Research Award in 2010 and the 2013-2014 NIAID Merit Group Award as a member of the GATA2 Discovery Group.

Dr. Vinh is Assistant Professor and Clinician-Scientist in the Division of Infectious Diseases and the Division of Allergy & Clinical Immunology, at the MUHC. He is also Assistant Professor in the Department of Medical Microbiology and Affiliate in the Department of Human Genetics. He has established the Infectious Disease Susceptibility Program at the MUHC, a translational research program on Genetic Immune Deficiencies.

**Wright, Alissa**

Dr. Alissa Wright is a Clinical Assistant Professor at the University of British Columbia (UBC) within the Division of Infectious Disease. She received her medical degree from the University of Toronto. She completed her training in Infectious Disease at UBC before going on to complete a two year fellowship in Transplant Infectious Disease at Massachusetts General Hospital in Boston. Her priority is to establishing a comprehensive Transplant Infectious Disease program for the province of British Columbia for both solid organ and hematopoietic stem cell transplant recipients. Her clinical responsibilities include the care of pre- and post-transplant patients at Vancouver General Hospital and St Paul’s Hospital in Vancouver. She is a consultant for BC Transplant on infectious disease issues in organ donors.
EXHIBITOR OVERVIEW

<table>
<thead>
<tr>
<th>EXHIBITOR</th>
<th>BOOTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td>44</td>
</tr>
<tr>
<td>Accelerate Diagnostics</td>
<td>38</td>
</tr>
<tr>
<td>AFFINITY Diagnostics Corp.</td>
<td>26</td>
</tr>
<tr>
<td>Alere Canada</td>
<td>20</td>
</tr>
<tr>
<td>Alpha-Tec Systems</td>
<td>18</td>
</tr>
<tr>
<td>Anaerobe Systems</td>
<td>2</td>
</tr>
<tr>
<td>Applied Maths, Inc.</td>
<td>40</td>
</tr>
<tr>
<td>BD Diagnostic Systems</td>
<td>31</td>
</tr>
<tr>
<td>Bio Nuclear Diagnostics Inc.</td>
<td>12</td>
</tr>
<tr>
<td>bioMérieux Canada, Inc.</td>
<td>41</td>
</tr>
<tr>
<td>Bio-Rad Laboratories Canada</td>
<td>10</td>
</tr>
<tr>
<td>Bruker Corporation</td>
<td>35</td>
</tr>
<tr>
<td>Canadian Foundation for Infectious Diseases (CFID)</td>
<td>Registration Area</td>
</tr>
<tr>
<td>CEDARLANE</td>
<td>5</td>
</tr>
<tr>
<td>CIHR – Institute of Infection and Immunity (III)</td>
<td>9</td>
</tr>
<tr>
<td>COPAN Diagnostics, Inc.</td>
<td>19</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>1</td>
</tr>
<tr>
<td>DiaSorin Canada Inc.</td>
<td>24</td>
</tr>
<tr>
<td>Hologic Canada Limited</td>
<td>22</td>
</tr>
<tr>
<td>Infectious Diseases Society of America / IDWeek</td>
<td>15</td>
</tr>
<tr>
<td>Innovatek Medical</td>
<td>17</td>
</tr>
<tr>
<td>Inter Medico</td>
<td>45</td>
</tr>
<tr>
<td>LabWare Inc.</td>
<td>36</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXHIBITOR</th>
<th>BOOTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck Canada</td>
<td>27</td>
</tr>
<tr>
<td>Nanosphere</td>
<td>42</td>
</tr>
<tr>
<td>Nosotech</td>
<td>49</td>
</tr>
<tr>
<td>NovaTec Immundiagnostica GmbH</td>
<td>3</td>
</tr>
<tr>
<td>Paladin Labs Inc.</td>
<td>50</td>
</tr>
<tr>
<td>PENDOPHARM, a division of Pharmascience Inc.</td>
<td>14</td>
</tr>
<tr>
<td>Pfizer Canada Inc.</td>
<td>37</td>
</tr>
<tr>
<td>Phoenix AirMid Biomedical Corp.</td>
<td>4</td>
</tr>
<tr>
<td>Pro-Lab Diagnostics</td>
<td>30</td>
</tr>
<tr>
<td>Promega Corporation</td>
<td>13</td>
</tr>
<tr>
<td>Quidel Corporation</td>
<td>48</td>
</tr>
<tr>
<td>Roche Diagnostics</td>
<td>43</td>
</tr>
<tr>
<td>Royal College of Physicians and Surgeons of Canada</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Seegene Canada Inc.</td>
<td>16</td>
</tr>
<tr>
<td>Somagen Diagnostics Inc.</td>
<td>11</td>
</tr>
<tr>
<td>Starplex Scientific Inc.</td>
<td>51</td>
</tr>
<tr>
<td>Sunovion Pharmaceuticals Canada Inc.</td>
<td>29</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>47</td>
</tr>
<tr>
<td>Thermo Fisher Scientific - Oxoid, Remel and TREK Products</td>
<td>8</td>
</tr>
<tr>
<td>Trinity Biotech - Nova Century Scientific, Inc.</td>
<td>46</td>
</tr>
</tbody>
</table>
Abbott Laboratories
BOOTH # 44
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. We are displaying products from our Molecular and Diagnostic Divisions.
Brad Thomas
Molecular Account Executive
7115 Millcreek Drive
Mississauga, Ontario L5N 3R3
Phone: 800-387-8378, ext. 4603
Email: bradley.thomas@abbott.com
Website: www.abbottmolecular.com

Accelerate Diagnostics
BOOTH # 26
Accelerate Diagnostics, Inc., is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic-resistant organisms and hospital-acquired infections.
Laura Katterhenry
Marketing Coordinator
470 - 3950 S. Country Club Road
Tucson, Arizona 85714 USA
Phone: 520-618-3277
Fax: 520-269-6580
Email: L.Katterhenry@axdx.com
Website: www.axdx.com

Alere Canada
BOOTH # 20
Alere Canada is a foremost leader in laboratory diagnostics that delivers reliable and actionable information through rapid diagnostic tests resulting in better clinical outcomes. Alere has well respected brands specializing in the areas of cardiovascular and infectious disease. Alere has recently launched Alere i, the first point-of-care rapid molecular diagnostic assay for influenza A & B.
Kim Orr
Marketing Coordinator
1 - 57 Iber Road
Ottawa, Ontario K2S 1E7
Phone: 613-271-1144
Fax: 613-271-1148
Email: kim.orr@alere.com
Website: www.alere.ca

Applied Maths, Inc.
BOOTH # 40
BioNumerics: the one universal bioinformatics solution to store and analyze all of your biological data. BioNumerics offers unparalleled options for gel analysis, sequence analysis, metagenomics and more.
Heather Balderach
Accounts Manager
11940 Jollyville Road, Suite 115N
Austin, Texas 78759 USA
Phone: 512-482-9700
Fax: 512-482-9708
Email: heather_balderach@applied-maths.com
Website: www.applied-maths.com

Alpha-Tec Systems
BOOTH # 18
Our cost-conscious Mycobacteriology reagent systems are an affordable way for labs to reduce contamination, maximize recovery and standardize laboratory diagnostic processes.
Laurie Williams
Vice President Operations & Sales
12019 NE 99th Street, Building 17
Vancouver, Washington 98682 USA
Phone: 360-260-2779
Fax: 360-260-3277
Email: l.williams@alphatecsystems.com
Website: www.alphatecsystems.com

Anaerobe Systems
BOOTH # 2
Manufacturer of PRAS culture and transport media. Manufacturer and distributor of ergonomic and maintenance free anaerobe chambers. Educational workshops. Anaerobe educator software.
Steve Cox
Product Manager, Anaerobe Chambers
15906 Concord Circle
Morgan Hill, California 95037 USA
Phone: 408-782-7557
Fax: 408-782-3031
Email: stevecox@anaerobesystems.com
Website: www.anaerobesystems.com
**Bio Nuclear Diagnostics Inc.**  
**BOOTH # 12**  
BND is a leading supplier of infection control, diagnostic, medical disposable and laboratory products. We are the sole distributor of Focus Diagnostics’ molecular detection platform and ELAs. Our own medical disposable and laboratory product brand is “Technologists’ Choice”.

**Franklin Chan**  
**Molecular Accounts Manager**  
1791 Albion Road  
Toronto, Ontario M9W 5S7  
Phone: 647-291-1558  
Fax: 416-674-7280  
Email: franklin.chan@bndinc.com  
Website: www.bndinc.com

**Bio-Rad Laboratories Canada**  
**BOOTH # 10**  
Bio-Rad Laboratories is one of the biggest leading diagnostics companies worldwide. It is recognized for its leadership position in quality control, diabetes monitoring, autoimmune diseases and microbiology.

**Louis Beaudoin**  
**National Sales Manager**  
2403 Guénette  
Montréal, Québec H4R 2E9  
Phone: 514-334-4372  
Fax: 514-334-4415  
Email: louis_beaudoin@bio-rad.com  
Website: www.bio-rad.com

**Bruker Corporation**  
**BOOTH # 35**  
Bruker Corporation supplies analytical mass spectrometry for diagnostic applications. The industry leading MALDI Biotyper System produces identifications in minutes with minimal reagents from primary culture.

**Angela Abraham**  
**Customer Support Specialist**  
555 Steeles Avenue East  
Milton, Ontario L9T 1Y6  
Direct: 905-876-4641, ext. 107  
Office: 978-663-3660  
Fax: 978-667-5993  
Email: ms.sales.bdal@bruker.com  
Website: www.bruker.com

**Bio-Mérieux Canada, Inc.**  
**BOOTH # 41**  
bioMérieux is a worldwide group specialized in the field of in vitro diagnostics. We design, develop, manufacture and market systems used in infectious diseases.

**François Turgeon**  
**Clinical Marketing Manager**  
7815 Henri-Bourassa West  
Saint-Laurent, Québec H4S 1P7  
Phone: 514-336-7321  
Fax: 514-334-4415  
Email: francois.turgeon@biomerieux.com  
Website: www.biomerieux.com

**Canadian Foundation for Infectious Diseases (CFID)**  
**REGISTRATION AREA**  
CFID is a charitable organization committed to improving the health of Canadians through the support of research and dissemination of knowledge pertaining to infectious diseases. CFID’s vision is to achieve effective research outcomes, strong and extensive stakeholder connections, successful advocacy and a positive impact on public policy.

**Dr. Susan Richardson**  
**President, CFID**  
c/o The Hospital for Sick Children Microbiology, Room 3654 Atrium  
555 University Avenue East  
Toronto, Ontario M5G 1X8  
Phone: 416-813-5992  
Fax: 416-813-5992  
Email: cfid@researchid.com  
Website: www.cfid.ca

**CEDARLANE**  
**BOOTH # 5**  
CEDARLANE® provides ATCC bacterial/viral controls, Millipore’s DFA kits, SSI’s Strep Pneumo kit, Altona Diagnostics’ PCR kits, Biomed Diagnostics’ media system and AdvanDx’s rapid pathogen detection platform.

**Eddie Johnson**  
**General Manager**  
4410 Paletta Court  
Burlington, Ontario L7L 5R2  
Phone: 289-288-0000  
Toll-free: 800-268-5058  
Fax: 289-288-0020  
Email: eddie.johnson@cedarlanelabs.com  
Website: www.cedarlanelabs.com

**CIHR – Institute of Infection and Immunity (III)**  
**BOOTH # 9**  
CIHR is the federal agency responsible for funding health research in Canada, and III supports research and builds capacity in the areas of infectious diseases and the immune system.

**Élisabeth Pagé**  
**Associate, Strategic Initiatives**  
2705 Laurier Boulevard, TR62  
Québec City, Québec G1V 4G2  
Phone: 418-577-4688  
Fax: 418-577-4689  
Email: elisabeth.page@crchudequebec.ulaval.ca  
Website: www.cihr-irsc.gc.ca/e/13533.html

**COPAN Diagnostics, Inc.**  
**BOOTH # 19**  
With a reputation for innovation in preanalytics, Copan is the leading manufacturer of collection and transport systems. Copan’s collaborative approach has resulted in Flocked Swabs, ESwab, Universal Transport Medium and laboratory automation, WASP® and WASPLab.

**Jane Lukashevsky**  
**Business Development Manager, Canada**  
26055 Jefferson Avenue  
Murrieta, California 92562 USA  
Phone: 800-216-4016  
Fax: 800-600-1832  
Email: marketing@copanusa.net  
Website: www.copanusa.com
CSL Behring
BOOTH # 1
We are passionate about improving the quality of life for people with rare diseases such as immune deficiencies, hemophilia and von Willebrand disease.

Brian McMaster  
Senior Product Manager, Immunoglobulin Portfolio
CSL Canada Inc.  
1460 - 55 Metcalfe Street  
Ottawa, Ontario K1P 6L5
Phone: 613-232-5142  
Mobile: 613-769-5142  
Fax: 613-232-2398
Email: brian.mcmaster@cslbehring.com

DiaSorin Canada Inc.  
BOOTH # 24
DiaSorin, the Diagnostic Specialist, provides specialized reagents and automated diagnostic instrumentation for laboratories. DiaSorin offers immunodiagnostic assays for infectious diseases, autoimmune, bone and endocrine diseases, as well as automated nucleic acid purification from clinical samples.

Jeff Kormos  
Senior Director Commercial Operations, Canada
Units 3 & 4, 2nd Floor, 205 Export Boulevard  
Mississauga, Ontario L5S 1Y4
Phone: 905-677-1600  
Toll-free: 855-677-0600  
Fax: 905-677-1630
Email: jeff.kormos@diasorin.com
Website: www.diasorin.com

Hologic Canada Limited  
BOOTH # 22
As a leader in molecular diagnostic solutions, Hologic thoughtfully blends engineering and science. Our innovative Aptima assays and advanced automation platforms work together to give laboratories the power to quickly and accurately detect and monitor infectious diseases. Our proven solutions help promote early detection, appropriate treatment and better outcomes—both clinical and financial.

Kayla Shea  
Regional Business Manager
401 - 130 Spadina Avenue  
Toronto, Ontario M5V 2L4
Phone: 647-449-8261
Email: kayla.shea@hologic.com
Website: www.hologic.com

Infectious Diseases Society of America / IDWeek  
BOOTH # 15
IDWeek is the premier international meeting in infectious diseases – October 26 to 30, 2016, in New Orleans. Now accepting abstracts, travel awards available, visit www.idweek.org.

John Buckley  
Director, Meeting Services
300 - 1300 Wilson Boulevard  
Arlington, Virginia 22209 USA
Phone: 703-740-4961  
Fax: 866-579-0939
Email: info@idweek.org
Website: www.idweek.org

Innovatek Medical  
BOOTH # 17
A Canadian company selling rapid diagnostic kits in the areas of drugs of abuse, women’s health and infectious diseases. Our primary focus is on innovation for clinical laboratory technology.

Marcus Tiitian Parsad  
National Sales Manager
3 - 1600 Derwent Way  
Delta, British Columbia V3M 6M5
Phone: 604-522-8303
Fax: 604-522-8318
Email: marcus@innovatekmed.com
Website: www.innovatekmed.com

Inter Medico  
BOOTH # 45
Inter Medico provides automated technology solutions for rapid PCR molecular testing such as MRSA, VRE, C. difficile, MTB and Flu, plus other general microbiology reagents.

Carli Garnett  
Marketing Manager
50 Valleywood Drive  
Markham, Ontario L3R 6E9
Phone: 800-387-9643
Fax: 905-470-2381
Email: cgarnett@inter-medico.com
Website: www.inter-medico.com

LabWare Inc.  
BOOTH # 36
LabWare provides proven software solutions for public health, biobanking clinical research, clinical trials and reference laboratories.

David Trottier  
Business Development Manager
102 - 3 Mill Road  
Wilmington, Delaware 19806 USA
Direct: 302-830-9153  
Office: 302-658-8444  
Fax: 302-658-7894
Email: trottier@labware.com
Website: www.labware.com

Merck Canada  
BOOTH # 27
Today’s Merck is a global healthcare leader working to help the world be well. For information on Merck Canada, visit www.merck.ca.

Debra Manning  
Exhibits and Conventions Manager
16750 Trans-Canada Highway  
Kirkland, Québec H9H 4M7
Phone: 514-428-3477  
Cell: 514-795-5127
Email: debra.manning@merck.com
Website: www.merck.ca
**EXHIBITOR DIRECTORY**

**Nanosphere**
**BOOTH # 42**
Nanosphere’s versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low-cost and simple-to-use multiplexed diagnostic test.

Phone: 847-400-9194
Website: www.nanosphere.us

**Nosotech**
**BOOTH # 49**
Nosotech provides the most complete and efficient software solutions for antimicrobial stewardship and infection control combining user-friendly solutions, top clinical expertise and best-in-class customer support.

Laurent Bellavance
**General Manager**
215 - 133 Julien-Réhel
Rimouski, Québec G5L 9B1
Phone: 418-723-0862
Email: laurent.bellavance@nosotech.com
Website: www.nosotech.com

**NovaTec Immundiagnostica GmbH**
**BOOTH # 3**
NovaTec Immundiagnostica GmbH is a manufacturer and research and development company of diagnostic test kits. We are expert in infectious diseases, hormones, tumour markers, autoimmune diseases and allergies. Our products include ELISA, qPCR and Blots.

Rodrigo Berlie  
**Director of Marketing and New Business Development**
Waldstrasse 23A6
Dietzenbach 63128 GERMANY
Phone: +49 6074 4876 0
Fax: +49 6074 4876 29
Email: r.berlie@novatec-id.com
Website: www.novatec-id.com

**Paladin Labs Inc.**
**BOOTH # 50**
Paladin Labs, headquartered in Montreal, Quebec, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

Patrick Lacasse  
**Associate Product Manager**
600 - 100, boulevard Alexis-Nihon
St-Laurent, Québec H4M 2P2
Phone: 514-215-8461
Fax: 514-344-4675
Email: Placasse@paladinlabs.com
Website: www.paladinlabs.com

**PENDOPHARM, a division of Pharmascience Inc.**
**BOOTH # 14**
PENDOPHARM, a division of Pharmascience Inc., is engaged in licensing, partnering, developing and marketing late-stage specialty prescription medicines and consumer brands.

Dora Philippou  
**Director of Business Development**
6111, avenue Royalmount
Montréal, Québec H4P 2T4
Phone: 514-340-9800
Fax: 514-733-9684
Email: dphilippou@pendopharm.com
Website: www.pendopharm.com

**Pfizer Canada Inc.**
**BOOTH # 37**
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world’s leading biopharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines and vaccines for humans.

Nathalie Labonté  
**CHE Manager**
17300 Trans-Canada Highway
Kirkland, Québec H9J 2M5
Phone: 418-580-1073
Fax: 418-877-6174
Email: nathalie.labonte@pfizer.com
Website: www.pfizer.com

**Phoenix AirMid Biomedical Corp.**
**BOOTH # 4**
PAB provides Canadian laboratories with high performance results and flexibility across multiple automated platforms through our comprehensive menu of molecular diagnostic kits and controls for infectious diseases, gastroenteritis and transplant monitoring.

Amir Memon  
**National Sales Manager**
1166 South Service Road West
Oakville, Ontario L6L 5T7
Phone: 905-469-4253
Fax: 905-825-9795
Email: info@phoenixairmid.com
Website: www.phoenixairmid.com

**Pro-Lab Diagnostics**
**BOOTH # 30**
Pro-Lab Diagnostics is an industry leader in the development of diagnostic test kits. A new division called Canadian Molecular Diagnostics is developing new molecular technologies and primer sets for use with the Genie Instrument.

Martin Skulnick  
**Clinical Specialist**
4 - 20 Mural Street
Richmond Hill, Ontario L4B 1K3
Phone: 647-290-8591
Email: martin.skulnick@pro-lab.com
Website: www.pro-lab.com
**EXHIBITOR DIRECTORY**

**Promega Corporation**
**BOOTH # 13**
Promega has over 35 years of expertise delivering instruments and reagents to life science and clinical laboratories. Our portfolio includes IVD and RUO products.

**Ron Kolojek**
**CLINICAL ACCOUNT MANAGER**
2800 Woods Hollow Road
Madison, Wisconsin  53711  USA
Phone:  608-274-4330
Fax:  608-277-2601
Email:  ron.kolojek@promega.com
Website:  www.promega.com

**Quidel Corporation**
**BOOTH # 48**
Quidel is a leading brand in molecular, immunoassay and point-of-care diagnostic technologies such as QuickVue®, AmpliVue®, D3 Direct Detection™, Thyretain®, Sofia®, Solana® and Lyra®.

**Kevin Orr**
**SENIOR SALES MANAGER - CANADA**
200 - 12544 High Bluff Drive
San Diego, California  92130  USA
Phone:  647-289-3717
Email:  kevin.orr@quidel.com
Website:  www.quidel.com

**Royal College of Physicians and Surgeons of Canada**
**REGISTRATION AREA**
Our booth is an excellent opportunity to get the latest information about what's happening at the Royal College, including CanMEDS 2015, CBD, certification and the MOC Program. Drop by to pick up a CPD activity framework, receive personal assistance with the MAINPORT ePortfolio, or ask a question.

**Jennifer Gordon**
**ASSOCIATE DIRECTOR, CONTINUING PROFESSIONAL DEVELOPMENT**
774 Echo Drive
Ottawa, Ontario  K1S 5N8
Phone:  800-461-9598
Email:  cpd@royalcollege.ca
Website:  www.royalcollege.ca

**Seegene Canada Inc.**
**BOOTH # 16**
Seegene is the world’s leading developer of multiplex molecular technologies and multiplexed clinical molecular diagnostics. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labour and cost.

**James Yantzi**
**PRESIDENT**
800 - 661 University Avenue
Toronto, Ontario  M5G 1M1
Phone:  416-995-9849
Fax:  888-950-9004
Email:  jyantzi@seegene.com
Website:  www.seegene.com

**Somagen Diagnostics Inc.**
**BOOTH # 11**
As Canada's leading laboratory diagnostics distribution company, we represent an expanding portfolio of innovative products and technologies for microbiology and infectious disease testing.

**Jaylene Lavoie**
**DIRECTOR OF BUSINESS DEVELOPMENT**
9220 - 25 Avenue
Edmonton, Alberta  T6N 1E1
Phone:  800-661-9993
Fax:  780-438-6595
Email:  info@somagen.com
Website:  www.somagen.com

**Sunovion Pharmaceuticals Canada Inc.**
**BOOTH # 29**
Sunovion Pharmaceuticals Canada Inc. is focused on the commercialization of prescription products in Canada. Our strategy is to license pharmaceuticals products that meet the needs of patients and the Canadian health care system. We are focused in the areas of cardiology, central nervous system and infectious disease.

**Paul Peters**
**BUSINESS UNIT MANAGER, CUBICIN**
100 - 6790 Century Avenue
Mississauga, Ontario  L5N 2V8
Phone:  905-814-9145
Fax:  905-363-0162
Email:  paul.peters@sunovion.com
Website:  www.sunovion.ca

**Starplex Scientific Inc.**
**BOOTH # 51**
Starplex Scientific Inc. specializes in premium quality collection and transportation devices including Leakbuster™ containers and Starswab™ transport swabs.

**Fred Turco**
Phone:  800-665-0954
Email:  info@starplexscientific.com
Website:  www.starplexscientific.com
EXHIBITOR DIRECTORY

**Thermo Fisher Scientific**
**BOOTH # 47**
Thermo Fisher Scientific is the world leader in serving science. Our Applied Biosystems and Invitrogen brands help customers accelerate innovation and enhance productivity.

**Kila K. Wells**
**Senior Manager, Meetings & Events**
Events Channel, Americas Marketing
5791 Van Allen Way
Carlsbad, California  92008  USA
Phone:  858-335-8187
Email:  kila.wells@thermofisher.com

**Thermo Fisher Scientific - Oxoid, Remel and TREK Products**
**BOOTH # 8**
The industry-leading Thermo Scientific product portfolio features Oxoid prepared media, VersaTREK™ automated blood culture and Sensititre™ AST/MIC solutions. Our products are renowned for quality, accuracy and reliability.

100 - 1926 Merivale Road
Nepean, Ontario  K2G 1E8
Phone:  800-267-6391
Email:  ooxid.ca.webinfo@thermofisher.com
Website:  www.thermoscientific.com/microbiology

**Trinity Biotech - Nova Century Scientific, Inc.**
**BOOTH # 46**
Trinity Biotech / NCS offers an extensive line of diagnostic kits for the following: Enterics, ToRCH, Measles, Mumps, VZV, EBV, STD, Lyme, Sepsis and Respiratory Identification.

**Walter Schmidt**
**VP Sales**
5022 South Service Road
Burlington, Ontario  L7L 5Y7
Toll-free:  800-615-5072
Fax:  800-639-9006
Email:  walter@novacentury.com
Website:  www.trinitybiotech.com